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ABSTRACT 
Author: Jett, Rachel MS 
Institution: Purdue University 
Degree Received: August 2017 
Title: Paper Spray Mass Spectrometry for Rapid Drug Screening 
Major Professor: Nick Manicke 
Paper spray mass spectrometry is an alternative technique for toxicological screening that 
is able to quickly and adequately screen for compounds encountered in postmortem 
investigations with little sample handling and no sample preparation.  For analysis of 
dried blood spots using a triple quadrupole mass spectrometer, detection criteria were 
defined to align with relevant regulatory guidelines while considering how fragment ion 
selection, method sensitivity, and fragment ion ratio tolerances are best utilized in paper 
spray mass spectrometry.  For analysis, drugs and drug metabolites relevant to 
postmortem investigations were spiked into drug-free blood, and by monitoring two 
fragment ion channels in selected reaction monitoring mode, as well as the ratio between 
the two fragment ions, a method was developed capable of detecting over 120 drug and 
drug metabolites at concentrations relevant to postmortem drug screening.  Total analysis 
time for the developed method is less than 8 minutes, and less than 50µL of sample and 
5mL of solvent are consumed during analysis. 
1 BACKGROUND 
The following project was undertaken with the goal of developing a multi-target 
toxicological screening process that would be applicable for use in forensic postmortem 
investigation cases.  While the same method may be applied in different areas of 
forensics or even in different fields within toxicology, it was postmortem investigation 
that provided the context that shaped this project.  As such, a brief overview of how 
postmortem toxicology relates to other disciplines and how analysis is typically carried 
out within this context will provide a basis for understanding how this project advances 
the field of forensic toxicology and why certain decisions were made along the way. 
1.1 Toxicology 
The word, “toxicology” is derived from the Greek root toxicos, meaning 
“poisonous.”  At its core, toxicology is simply the study of poisons.  Hundreds of years 
ago, however, one of the fathers of toxicology, Paracelsus, famously stated that any 
physical or chemical agent can be defined as a poison, and that, “Solely the dose 
determines that a thing is not a poison.”4  Toxicology then, is actually a very broad field 
that draws from organic and analytical chemistry, genetics, biochemistry, ecology, 
pharmacology, pathology, physiology, and other areas of study in order to identify what 
physical agents and chemical substances cause toxic effects in living organisms, at what 
dose those effects arise, the mechanisms through which those effects take place, and how 
to limit or treat exposure to these poisons.  The diverse background necessary to 
understand the complexities of toxicology also allow for its application into a wide 
variety of situations.  From determining how many aspirin we take for headache relief to 
what chemicals OSHA allows us to handle at work, the impact of toxicology is woven 
throughout our daily lives.   
Although there are a wide range of applications for toxicology, a few sub-
disciplines represent much of the prominent work in the field.  Clinical and medicinal 
toxicology are concerned with the development and safe use of medicines and
pharmaceuticals that are used to treat, manage, or prevent disease.  Environmental 
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toxicology looks at how industrial waste and byproducts can adversely affect humans and 
other living creatures in the environment. Food toxicology promotes food safety by 
monitoring and setting limitations on what pesticides and/or veterinary medicines are
safe for human consumption. Forensic toxicology is used when toxicological effects may 
have legal ramifications, and can include anything from determining a person’s cause of 
death to detecting the use of illegal performance-enhancing drugs in racehorses.
1.2 Forensic Toxicology 
While other branches of toxicology are concerned with why a compound is toxic 
or the mechanisms by which it affects an organism, forensic toxicology is used mostly in 
situations where the presence or absence of a substance has legal implications.  While 
forensic toxicologists must still understand the hows and whys of toxicology, their 
primary focus is on the detection, identification, and quantification of toxic agents in the 
body.  There are four essential disciplines within forensic toxicology: human 
performance investigation, doping control, workplace drug testing, and postmortem 
investigations.9 
1.2.1 Human Performance Toxicology 
Human performance toxicology is concerned with identifying the presence and 
concentration of drugs and chemicals which are known to affect the way a person reasons 
and behaves.  Identifying the presence of these chemicals can aid in different types of 
investigations ranging from collision investigations where a driver is suspected to have 
been impaired, to drug facilitated crimes such sexual assault cases, and even to child 
welfare cases.  The primary analytical targets of these investigations tend to be alcohol 
and drugs of abuse. 
1.2.2 Doping Control 
  In competitive sports, using certain performance enhancing substances is illegal 
and is regulated and monitored by organizations like the World Anti-Doping Agency 
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(WADA).  While most of these drugs have legitimate medical application, banning their 
use provides a level playing field for athletes and protects their health.  These substances, 
which include steroids, diuretics, and stimulants, are generally not illegal for the general 
public, but because of the rules and regulations of the professional sports associations, 
detecting them in athletes can have legal consequences.9   
1.2.3 Workplace Drug Testing 
In 1988, Congress passed the Drug-Free Workplace Act that mandates that federal 
employees or employees of a company operating on federal money are prohibited from 
using recreational drugs.  Many other companies and organizations, especially those 
where workers preform potentially dangerous tasks, have chosen to comply with these 
standards in order to promote workplace safety.  Before being hired and during random 
screenings, employees will give a urine sample which is typically screened for five major 
classes of abused drugs.9  If a toxicologist identifies the presence of one of these drugs, 
there can be occupational and legal consequences for the parties involved.  
1.2.4 Postmortem Investigations 
The toxicity of a chemical can produce adverse effects ranging anywhere from a 
headache or a rash to loss of fine motor skills or blindness.  In the most severe cases, 
however, the toxicity of a substance or the dose administered is so extreme that it results 
in coma or death.  In death investigation cases, also known as postmortem investigations, 
toxicologists work with medical examiners and coroners to help determine cause and 
manner of death.  Unlike in other areas of toxicology, toxicologists investigating 
postmortem cases must consider a wide range of compounds instead of a small, targeted 
list.  In these cases, toxicologists are presented with a sample that is truly unknown and is 
presented with the difficult job of detecting, identifying, and quantifying any and all 
possible toxicants present within any given sample. 
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1.3 Analytical Strategy 
The analytical strategies employed by a forensic toxicologist are often dictated by 
practicality rather than ideology.  Legal goals, limitations within the laboratory, and the 
circumstances surrounding a case all shape how each sample is processed.  Individual 
labs determine an analytical strategy that is fit for the purpose of each case and is an 
effective use of the time, money, and resources available to it.  In theory, there are two 
basic analytical strategies: targeted analysis and general unknown screening.  In practice, 
however, many laboratories operate on a hybrid of these methods and use a two-fold 
method of screening and confirmatory testing. 
1.3.1 Targeted Analysis 
In cases where there are a finite number of compounds of interest, such as in doping 
control or workplace drug testing, a targeted, or directed analytical approach may be 
used.   The result of this type of analysis is a list of compounds whose presence in a 
sample is either confirmed or excluded at certain concentrations.  The list of targets 
analyzed can range from a handful of compounds to several hundred compounds.   
Targeted analysis is widely employed in forensic laboratories for a number of 
reasons.  First, forensic toxicology is not an isolated science; it occurs in context.  There 
is often non-analytical information that can serve as a jumping off point for the 
toxicological examination.  If a known drug abuser’s body is found surrounded by 
paraphernalia, a lot of time and money can be saved by first testing for the abused drugs 
suggested by the investigation.  Another reason that targeted analysis is widely used is 
that a very small number of compounds are typically responsible for death in the majority
of postmortem cases.  One laboratory reported that 70% of fatal drug poisoning cases in 
their lab were the result of the less than 30 individual drugs.10   
Even though only a few dozen compounds are commonly encountered in typical 
forensic toxicology cases, the list of potential toxic substances is practically limitless.  
Additionally, new designer drugs are continually developing, and toxicology laboratories 
are responsible for detecting them, even if it is a new drug that has never been seen 
before.  Because of this, toxicology laboratories cannot solely rely on targeted analytical 
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techniques, and must incorporate methods to detect a broad range of compounds that are 
either new or not commonly encountered in typical case work.  
1.3.2 General Unknown Screening 
The alternative analytical approach to targeted analysis is untargeted analysis, also 
known as general unknown screening (GUS).  The daunting task of untargeted analysis is 
to identify any and all potentially harmful substances, even when their identity is 
unknown and their presence is uncertain11.  In order to provide a framework for 
untargeted analysis, toxicologists utilize what is known as systematic toxicological 
analysis (STA), as a guide through the analytical process.  
The International Association of Forensic Toxicologists’ Committee of Systematic 
Toxicological Analysis defines systematic toxicological analysis as, “the application of 
an adequate analytical strategy for the detection and identification of as many as possible 
potentially toxic compounds and their metabolites in biological samples.”12  The goal of 
STA is to use a panel of analytical techniques to detect, identify, and if necessary, 
quantify a very broad range of targets.  A few decades ago, this approach meant throwing 
a sample through every test the lab was capable of because techniques were not as 
selective or sensitive as they are today.13   
Modern advances in instrumentation and computational software are opening doors 
to make general unknown screening a much more viable option.  In mass spectrometry, 
data-dependent, or information-dependent acquisition modes allow for adaptive data 
acquisition.  Developments in high-resolution mass spectrometry are also advancing the 
field by opening the door for a posteriori data analysis to detect compounds that were not 
originally targeted.  The downside of GUS is that it is often labor intensive and requires 
extensive sample preparation.  In its truest form, STA means running a prescribed panel 
of tests independently.  In practice, toxicologists can save time and money by allowing 
the results of each test to help direct further testing instead of running everything 
independently.   
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1.3.3 Practical Toxicology 
In an effort to use their resources efficiently, most forensic toxicology laboratories 
use a two-step process to detect toxicants in biological samples.  The first step is 
screening, and is analogous to STA in that a variety of analytical procedures are 
employed to detect a broad range of targets.  The best screening tests require little sample 
manipulation, are fast, inexpensive, sensitive, selective, and cover a broad range of 
targets.  Historically, analysis using immunoassays, liquid chromatography coupled to 
ultra-violet detection, and gas chromatography mass spectrometry have been used for 
screening purposes, but liquid chromatography mass spectrometry has become a more 
common screening technique in recent years.14   Screening tests may be based on multi-
target screening (MTS) or may screen for a certain classification of drugs or toxins, and 
are generally qualitative in nature. 
After qualitative identification is achieved in the screening process, the second 
step a toxicology laboratory will take is confirmatory analysis.  This step is analogous to 
targeted screening because only those compounds detected in the initial screen are 
intentionally analyzed.  While screening tests are used to detect toxins, confirmatory 
analysis focuses on identifying and quantifying them.  According to the guidelines 
published by the Society of Forensic Toxicologists in conjunction with the American 
Academy of Forensic Science, a confirmatory test should be more specific than the 
screening test and based upon a different chemical principal.15   
1.4 The Need for Something New 
Traditionally, toxicology laboratories performing postmortem analyses use 
immunoassays, gas chromatography either alone or coupled with mass spectrometry, or 
liquid chromatography with ultra-violet detection to perform their screening tests.  Each 
of these techniques suffer from various limitations including lack of specificity, difficulty 
of incorporating new targets, and labor intensive sample preparation and instrument 
maintenance.   
Immunoassays are commonly used for presumptive screening in forensic 
toxicology because they are inexpensive, simple, fast, and automatable.  Several types of 
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immunoassays are utilized in casework, including: fluorescence polarization 
immunoassays (FPIA), radioimmunoassays (RIA), enzyme-multiplied immunoassay 
technique (EMIT), kinetic interaction of microparticles in solution (KIMS), and 
enzyme-linked immunosorbent assays (ELISA).16  Immunoassays are good at detecting a 
class of compounds, but have poor specificity due to the cross reactivity of the binding 
sites of the antibodies, which prohibits immunoassays from being used to identify 
specific compounds.  In order for immunoassays to provide a broad range of coverage, 
several analyses have to be run, and it is difficult to add new targets into these analyses. 
Even in multiplex systems, the coverage provided by immunoassays is far from 
comprehensive and they have a problematic false positive rate which can waste a 
laboratory’s time and resources by unnecessarily routing truly negative samples to 
confirmatory testing.   
Gas chromatography, typically coupled with mass spectrometry (GC-MS) has 
typically been considered the so-called “gold standard” for toxicological analysis.  Gas 
chromatography is able to separate compounds well, and when it is coupled with mass 
spectrometry, the technique gains a high level of specificity.  GC-MS also benefits from 
being able to compare laboratory generated results to externally generated libraries and 
databases due to the reproducible ion fragmentation that is produced when using a hard 
ionization technique like electron impact.  While GC-MS is an excellent analytical 
process for confirmatory testing, its use as a screening test is less than ideal because of 
the labor and time involved in sample preparation.  Because only volatile, thermally-
stable compounds can be analyzed via GC-MS, sample clean up, extraction, and 
derivatization is often necessary.  Sample preparation in GC-MS will vary depending on 
the analytes of interest, making it necessary to use several different derivatizations to 
provide adequate coverage, making GC-MS a labor and time intensive option for 
postmortem toxicological screening.14  
Liquid chromatography with ultra violet detection (LC-UV) has historically been 
used as a screening technique, but has recently been fading in popularity due to its 
limitations.  LC-UV can require long run times for peak resolution and does not have 
good specificity.  Instead of LC-UV, more toxicology laboratories are currently opting to 
run high performance liquid chromatography coupled with mass spectrometry (HPLC-
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MS).  HPLC-MS has good sensitivity and specificity, especially when high resolution or 
tandem mass spectrometry is used.  It is also able to screen for a broad spectrum of 
analytes, and is not limited to volatile or thermally stable compounds like GC-MS.  
Because of this, HPLC-MS is rapidly gaining prominence in toxicology laboratories for 
confirmatory testing.14  Its use as a screening technique, however, is less ideal for several 
reasons.  First, HPLCs are comparatively expensive, which limits their use in public 
laboratories where funding is tight.  This problem is compounded by the fact that HPLCs 
require much more oversite than most instruments in order to keep them functioning 
properly. When using an HPLC system, a lot of time and expertise is spent 
troubleshooting leaks and fluctuating backpressure, monitoring retention shifts, and 
preventing carryover and column degradation.  The oversight and money necessary to 
implement HPLC-MS into routine screening testing is often beyond the capabilities of 
small laboratories, and even when using HPLC-MS is a viable option, the time spent in 
sample preparation makes HPLC-MS much better suited for confirmatory analysis rather 
than for initial screening. 
The use of immunoassays, GC-MS, LC-UV, and HPLC-MS in conjunction with 
one another is an effective way for toxicology laboratories to detect a broad range of 
compounds commonly encountered in postmortem cases, however, they represent a 
significant investment of both time and money in a system that is notoriously strained by 
tight budgets and substantial backlogs.  It would be advantageous then, if new techniques
could be developed that provided a simpler, faster, and cheaper screening method that 
would allow toxicology laboratories to operate more efficiently. 
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2 INTRODUCTION 
Paper spray mass spectrometry (PS-MS) is an ambient ionization technique that 
drastically simplifies traditional sample preparation, allowing for the rapid analysis of 
samples.   This technique was first published in 2010 as a new method for detecting drugs 
and other small molecules in biofluids.17  Originally, paper spray research was directed 
towards dried blood spot analysis,18 but it has since been utilized in areas including: 
pharmacokinetic studies,19 food safety,20-23 tissue analysis,24 and the profiling of algae 
and bacteria.25,26  The ability of PS-MS to detect drugs and pharmaceuticals has been 
widely investigated,27-34 routinely allowing for low to sub-ng/mL limits of 
quantitation.16,18,35-38 While the focus of paper spray’s application has historically been 
the quantitative analysis of a small panel of targets,16 it may be well suited as an 
alternative for toxicological drug screening procedures as well.   
2.1 Project Overview 
The goal of this project was to develop a PS-MS based method to use as a screening 
procedure in postmortem toxicology.  In order to narrow down the nearly infinite list of 
possible toxic substances that forensic toxicologists may encounter, the original scope for 
this project was defined based on consultations with the Axis Forensic Toxicology 
(AFT).  AFT is a national toxicology lab that processes over 100 postmortem samples a 
day, and is accredited by the American Board of Forensic Toxicologists.  AFT provided 
the project with a list of targets that represent their mid-grade, extended screening panel, 
which covers 99.5% of targets they encounter in postmortem investigations.39  They also 
provided screening cutoff values for the project that generally fall at the low-end of what 
a therapeutic dose of the drug would be.  These detection levels have since been raised at 
AFT, but will serve as a guide for this project.  The compiled list consisted of 154 target 
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compounds (Appendix A) that represent a variety of drugs, 
pharmaceuticals, and metabolites.  The staked column graph in 
Figure 1 describes the relative representation of different 
classes of compounds within the list of analytical targets.  
Classes of targets represented in the “other” category include: 
amphetamines, cannabinoids, cocaine, fentanyl, 
gastrointestinal, methadone, neurologicals, stimulants, and 
urologicals.  The screening cutoff levels for these targets set by 
AFT range from 1 to 30,000 ng/mL and are summarized in 
Table 1. 
2.2 Paper Spray-Mass Spectrometry 
Using paper spray (PS) as a new approach to drug 
screening may allow toxicology laboratories to operate more 
efficiently for several reasons.  First, paper spray would allow 
for faster data turnaround by eliminating the time spent in 
sample cleanup and pretreatment, and by shortening analytical 
run times.  Being a direct analysis technique, there is no sample 
preparation for PS analysis, and run times are typically less 
than two minutes.  Comparatively, the currently employed 
methods of GC-MS, IA’s, or LC-MS have analytical run times 
of 10 minutes to upwards of an hour,40-42 without considering 
the time spent in sample clean up and derivatization.  The 
disposable paper substrate used in PS-MS analysis would also 
allow laboratories to recover the time that is currently spent 
troubleshooting by eliminating problems caused by carryover, 
clogs, and leaks. 
Another reason that developing a PS-MS method for 
toxicological screening would be advantageous is that it 
provides a cheaper alternative to current techniques by 
Other 
Antidepressants 
Analgesics 
Benzodiazepines 
Anticonvulsants 
Cardiovascular 
Antipsychotics 
Barbiturates 
Sedatives 
Opiates 
Anesthetics 
Narcotics 
Antihistamines 
Barbiturates 
Figure 1 Drug classes 
represented in this 
project. The size of 
each block is 
proportional to the 
number of targets in 
that class 
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reducing cost in several different areas.  First, the amount of solvent used in PS-MS 
analysis is typically only around 100 microliters and is completely consumed during 
analysis, leaving behind absolutely no solvent waste.  This reduces the amount of money 
laboratories have to spend on reagents, as well as eliminates the costs associated with 
waste management and removal.  Using PS-MS can also reduce the cost associated with 
properly storing and shipping biological samples since the dried blood spots used do not 
have to be carefully refrigerated like liquid whole blood or plasma samples.  Another 
added advantage to paper spray’s use of dried blood spots for sampling is that samples 
stored as dried blood spots are more stable than liquid samples.43,44  The potential to 
lower cost, limit sample preparation, and increase sample throughput make paper spray a 
valuable option for toxicological screening, but there are a few things that must be 
considered if PS-MS is to be implemented into routine toxicology work.  To understand 
these issues, it is important to understand the principals of paper spray-mass 
spectrometry. 
Paper spray mass spectrometry belongs to a family of ambient ionization techniques 
that simplify analysis by removing the chromatography that is typically carried out prior 
to mass spectrometry.  To accomplish this using paper spray, a sample is dried onto a 
piece of paper that has been cut to a point at one end.  Typical sample matrices used in 
Table 1 Screening cutoff values for the target anlaytes in the project ranged from less than 
5 ng/mL to over 1000 ng/mL. 
Cutoff (ng/mL) 
Number of 
Targets 
Percentage of 
Total Targets 
≤5 4 3% 
10 17 11% 
20 26 17% 
25 13 8% 
50 43 28% 
100 14 9% 
500 13 8% 
1000+ 24 16% 
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PS-MS analysis include whole blood, plasma, and urine.   The sample is typically 
allowed to dry prior to analysis, although analysis of wet samples has been reported.38  
Once the sample is dried, solvent is applied to the back of the paper, which is positioned 
a few millimeters away from the inlet of the mass spectrometer at atmospheric pressure.  
As the solvent wicks through the paper and permeates the sample, it extracts the soluble 
components from the matrix, and they travel with the solvent front to the sharp tip of the 
paper.  Once the paper is completely saturated, a high voltage is applied, which generates 
ions through electrospray ionization by inducing a Taylor cone at the sharp tip of the 
paper.  A schematic of this experimental set up illustrated in Figure 2 is depicted visually 
by the images in Figure 3.   
Inlet to mass spectrometer 
Charged droplets containing analyte 
Paper 
4.0 
kV
Extraction/spray solvent 
Figure 2 Schematic of paper spray
Figure 3  (A) During paper spray, a piece of paper cut into a sharp tip is positioned 5 mm away 
from the inlet of a mass spectrometer. (B) Solvent is added and allowed to saturate the paper 
while the voltage remains off. (C) When high voltage is applied, a Taylor cone forms at the 
paper’s tip, emitting a plume of charged droplets that quickly evaporate, leaving behind 
gaseous ions that enter the inlet of the mass spectrometer. 
B C A 
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The data that is generated though PS-MS analysis looks different than typical front-
end chromatography techniques, although it is processed similarly.  Because there is no 
intentional chromatography performed during PS-MS analysis, the term “chromatogram” 
is a misnomer in this application.  Instead, the word “chronogram” is used to describe the 
ion signal over time.  In typical chromatography based methods, ion signals appear as 
more or less Gaussian peaks.  As shown in the chronogram in Figure 4, the “peaks” 
produced by PS-MS do not follow this trend.  As soon as a high voltage is applied, the 
analytes extracted by the spray solvent are ionized and are detected by the mass 
spectrometer.  As long as the paper remains wet enough to produce an electrospray, the 
signal will continue until the voltage is turned off.  Much like typical chromatograms, 
chronograms are analyzed by quantifying the area under the curve of extracted ion 
chronograms (XIC) or selected reaction monitoring (SRM) channels.  
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Time (min) 
Voltage On Voltage Off 
Figure 4.  Unlike typical chromatograms produced in LC-MS, the “peaks” produced 
in PS-MS are boxy rather than Gaussian and are called “chronograms”.  This is 
because essentially no chromatography occurs during PS-MS.  When the voltage is 
turned on, all extracted ions enter the mass spectrometer at the same time, leading to 
an almost instantaneous rise in ion intensity.  When the voltage is turned off, the 
Taylor cone collapses and ionization stops. An example chronogram of the transition 
from m/z 172 -> 119 for gabapentin in blank blood and at 500 ng/mL is depicted. 
Voltage On Voltage Off 
Blank Gabapentin at 
500 ng/mL
172 -> 119
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2.3 Selectivity 
Because no chromatography is performed in paper spray, there is a burden of 
specificity that is placed on the mass spectrometer.  During PS-MS, all compounds that 
are extracted by the solvent co-elute, therefore the mass spectrometer must be able to 
differentiate compounds with the same nominal mass in order to discriminate between a 
target analyte and any of similar mass/charge that could interfere with the signal 
produced by the analyte of interest.  In PS-MS, this is accomplished by high resolution 
mass spectrometry (HR-MS) and/or tandem mass spectrometry.  Typical mass 
spectrometers that have been used for PS-MS analysis include: ion trap, orbitrap, time-of-
flight, and triple quadrupole mass spectrometers.16   
2.3.1 Mass Spectrometer Selection 
While a variety of types of mass spectrometers have been used to perform PS-MS 
experiments, they are not all suitable for use in forensic toxicology laboratories.  Ion trap 
mass spectrometers are able to achieve adequate specificity for PS-MS by using their 
MSn feature.  Because they are tandem in time, however, they are too slow to be used for 
screening procedures because of the need to quickly acquire data for a large list of 
targets.  High resolution mass spectrometry is able to distinguish between co-eluting 
compounds based on exact mass measurements.  Their high mass resolution reduces the 
possibility of interference from non-isomeric compounds, and they also have the unique 
feature of being able to retrospectively interrogate data for targets that were not originally 
specified.  The detection limits on a HRMS are generally higher than on other mass 
spectrometers, however, and they are much more expensive to purchase and require daily 
calibration.  Triple quadrupole (QqQ) mass spectrometers achieve specificity much like 
ion traps, in that they are able to discriminate targets by monitoring characteristic 
fragment ions.  Triple quadrupoles are low resolution instruments and can only measure 
mass to about +/- 0.5 m/z units.  However, because QqQ’s are tandem in space rather 
than time, they are able to quickly scan a large list of targets by using selected reaction 
monitoring mode.  QqQ’s can also attain adequately low detection limits for toxicological 
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purposes and are more accessible to forensic laboratories due to their lower price.  
Because of these reasons, a triple quadrupole mass spectrometer was chosen as the mass 
spectrometer to be used during method development in this project.
2.3.2 Fragmentation 
When used in selected reaction monitoring (SRM) mode, triple quadrupole 
instruments are able to enhance selectivity by using two sets of quadrupoles as mass 
filters.  The first set of quadrupoles is set to only allow ions within a certain window of 
mass-to-charge ratio (m/z) to pass through.  This window, normally 0.7 m/z units wide, 
filters out all other ions that have been generated by the ionization source.  The ions 
produced by electrospray ionization and typically selected to pass through the first 
quadrupole are the protonated or deprotonated molecular ions ([M + H]+ or [M - H]-) or 
small adduct ions, such as potassium, sodium, or ammonium.  The ions with the selected 
m/z, known as either parent or precursor ions, enter the second set of quadrupoles where 
they are bombarded with argon gas.  When the ions collide with the gas molecules, they 
fragment via Collision Induced Dissociation (CID).  The ions produced by this 
fragmentation process are known as daughter or product ions.  The product ions then 
enter the third set of quadrupoles which is used to as a mass filter.  In SRM mode, a 
characteristic fragment at a specific m/z is specified, and only that fragment is allowed to 
pass through the third quadrupole and reach the detector. 
A decade ago, the detection of one unique fragment ion was generally seen as 
sufficient grounds for quantitative analysis.45  It is more common nowadays, however, to 
enhance selectivity even further by monitoring more than one fragment ion per parent 
ion.  If full specificity is required, the third quadrupole can be operated in full scan mode, 
in which case all of the fragments produced in the second quadrupole would be detected.  
For most HPLC-MS/MS applications, adequate specificity is generally achieved by 
monitoring two fragments for each parent ion.  The most abundant of these fragment ions 
is referred to as the quantifier ion, while the lesser abundant is termed the qualifier ion.  
Typically the two most abundant ions are monitored, however, due to interfering 
compounds or matrix effects, other fragments can be monitored instead.  Oftentimes, 
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however, the specificity of the chosen fragment ions is not considered due to the 
perceived specificity that can be gained by monitoring the ratio between different 
fragment ions.  The idea behind using fragmentation ratios is that under specified 
conditions, a parent ion should fragment reproducibly, and the abundance of the fragment 
ions produced under those conditions should be relatively consistent from run to run for a 
specific target analyte.   
Fragmentation ratios can be established by either taking the ratio of the intensities 
of the SRM transitions for each product ion or by taking the ratio of the area under the 
curves.  There are several conditions under which fragmentation ratios may be obtained.  
A common method is to optimize instrumental conditions for each fragment ion 
separately and use the resulting ion intensities to calculate the fragmentation ratio.  This 
method is advantageous when signal to blank response is poor or when interferences are 
present, as it provides an optimized signal for each product ion.  Another method is to 
monitor two fragments under identical conditions.  Other methods used include 
monitoring the same fragment ion under varying conditions and monitoring fragments 
from different precursor ions.45  The use of the later, though, has been discouraged 
recently because of indications that asymmetrical signal suppression can interfere with 
fragmentation ratios.46 When ionization suppression is present, competitive ionization 
within the matrix can hinder analytes from completely ionizing, leading to a less intense 
signal.
2.3.3 Selectivity in Paper Spray 
By using a triple quadrupole instrument and monitoring a parent ion, two 
fragment ions, and the fragment ion ratio, good selectivity is achievable for paper spray 
even without the advantage of chromatography.  Using this method should allow for 
differentiation between structural isomers that fragment differently.   For example, 
although the isomers methamphetamine and 4-methylamphetamine have the same exact 
mass, they fragment uniquely.  Methamphetamine undergoes transitions from m/z 150 to 
m/z 119 and 91, while 4-methylamphetamine fragments from m/z 150 to ions with m/z 
133, 105, 103, 77, and 79.16  While both compounds would produce a parent ion with m/z 
150 that would pass through the first set of quadrupoles, the unique fragments generated
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in the collision cell would allow one compound to be detected without interference from 
the other.  Even in cases where no unique fragments exist, fragmentation ratios have been 
able to distinguish between two isomers.45   Because of this, fragmentation ratios not only 
add a level of confidence to compound identification, but can also help differentiate 
between otherwise interfering compounds.     However, in the case where isomers with 
the same nominal mass share the same fragment ions, unique fragments should be used if 
possible.   
There are several established organizations that use fragments and fragmentation 
ratios as the basis for identification.  The requirements these organizations have set for 
analytical identification using these ratios vary depending on application and have 
evolved over time.  Some relevant identification criteria for LC-MS based assays are 
summarized in Table 2.  One thing to consider when looking at these requirements is that 
all of these are based on the assumption that chromatography is being performed.  With 
this, there is the assumption that co-eluting compounds will be somewhat limited, but this 
is not the case in paper spray.  Some of these organizations acknowledge and sometimes 
discourage the use of commonly produced fragment ions, but none of them ban them from 
being used for identification purposes.  Another variable to note is the tendency to base 
the acceptable deviation of the fragment ion ratio on the relative abundance of the two 
ions.  The precedence for this decision is based on the European Union decision that was
made by a panel of experts in the 90’s.49  Since that time, however, instrumentation has 
evolved and fragmentations ratios have been found to be analyte and instrument specific 
and vary widely based on concentration and matrix.15,47,50,51  The variability of fragment 
ion ratios in some instances has caused some to suggest recently that it is better to simply 
rely on the presence or absence of fragment ions for compound identification.52  Many 
other authors have suggested a “fitness of purpose” approach that tailors criteria to fit the 
analytical specificity needs of each particular project.  Using fragmentation ratios in PS-
MS analysis has historically been done to add a level of specificity lost by not preforming 
chromatography.  During the method development phase of this project, setting the 
acceptable tolerances for these ratios will be an area of interest.  
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2.4 Special Considerations 
There are several areas that require special consideration if paper spray mass 
spectrometry is to be applied to toxicological postmortem screening.  Two of these are 
the characteristics of postmortem blood as compared to healthy blood and the matrix 
effects that can arise during PS-MS analysis.  
Table 2 MS-MS based identification criteria for various applications 
Organization/Code Applies To 
Ion 
Requirements 
Fragment Ion Ratio 
Tolerance 
EU:  
2002/657/EC1 
Live animals and 
animal products 
≥2 product ions 
Ratio tolerance is 
dependent relative 
abundance of ion to base 
peak; ranges from ±20% 
to ±50% 
EU: 
SANCO/12571/20133 
Pesticides in food 
products and animal 
feed 
≥2 product ions Ratio tolerance is ±30% 
WADA  
TD2010DCR5 
Sports doping 
1 product if 
unique; if not 
unique, ≥2 
product ions 
Ratio tolerance is 
dependent on relative 
abundance of ion to base 
peak; ranges from ±10% 
to ±50% 
EWDTS6 
Workplace drug 
testing 
≥3 ions Ratio tolerance is ±20% 
UNODC7 Illegal drugs ≥3 ions Ratio tolerance is ±20% 
SOFT/AAFS8 Forensic Toxicology ≥2 product ions 
Ratio is tolerance is 
±25% to ±30% 
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2.4.1 Postmortem blood 
While this project used single-donor drug free blood, there are several unique 
aspects of postmortem blood that will affect this project as it undergoes method
validation.  One important, well-recognized phenomenon that continues to be the subject 
of current research is the process by which drug concentrations change after death, 
known as post-mortem redistribution (PMR).  During PMR tissue-bound drugs diffuse 
into adjacent blood vessels, increasing the drug concentrations in blood, especially for 
basic and lipophilic drugs.  The extent of PMR varies with each drug, with some drugs 
showing highly time-dependent concentration, while other drug concentrations remain 
more or less stable over time.53  Understanding the effects of PMR is one of the most 
important considerations for medical examiners in selecting blood sampling sites that are 
the truest representation of drug concentrations in the blood at the time of death.  If any, 
the most likely effect that PRM will have on this project is an increase in basic drug 
concentration levels.  While exact concentrations are not important for screening 
methods, increased concentrations could improve performance for drugs near the limit of 
detection when real postmortem blood is used.    
Another aspect for consideration is the difference in matrix effects between ante-
mortem and post-mortem blood caused by the decomposition process.  Saar et al. studied 
the differences in matrix effects and liquid-liquid extraction (LLE) efficiency for 
antipsychotic drugs in ante-mortem and post-mortem blood.   They found considerable 
differences in both extraction efficiency and matrix effects between the different types of 
blood and suggested that post-mortem methods be validated using drug-free postmortem 
blood as opposed to pooled blood bank ante-mortem blood.54  They also found that while 
the matrix effects for decomposed post-mortem blood were similar to ante-mortem blood, 
they were much more variable.  Similarly, Rosano et al found that both the variability of 
matrix effects and the ion suppression in post-mortem blood was higher than in bank 
blood.55  Because of these differences, Peters et al. echoed Saar’s proposition to use post-
mortem blood in method validation and additionally suggested that non-decomposed 
post-mortem blood and decomposed blood be separately evaluated.56 
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In this project, higher variability in drug recovery in post-mortem blood could lead 
to a “hit-or-miss” scenario that could require multiple samples to be run in certain cases 
where the concentrations are near the limit of identification.  Higher ion suppression 
could also be problematic for targets that either do not ionize well or exist at low 
concentrations.  Both of these could potentially be somewhat counteracted by pre-
concentration techniques, such as integrating SPE, as described by Zhang et al.57
2.4.2 Matrix Effects 
Matrix effects are a common phenomenon which cause instrumental response to be 
altered due to components within the matrix in which the analyte is contained.  Both the
ionization technique and the analytical separation technique can affect which matrix
effects are observed.  For example, electrospray ionization is more affected by matrix 
effects than atmospheric-pressure chemical ionization.56  In chromatography-based 
techniques like GC and LC, matrix effects commonly arise from co-eluting compounds 
and can cause either ion suppression or ion enhancement.  This issue is compounded 
even further for non-chromatography based techniques like paper spray due to the fact 
that all compounds elute simultaneously.   
There are two principal forms of matrix effects that affect the performance of paper 
spray mass spectrometry: recovery and ion suppression.  Recovery refers to the 
percentage of the analyte that is extracted from the matrix.  Ion suppression occurs when 
ionization efficiency for an analyte is lowered due to competitive ionization between the 
analyte and other co-extracted matrix components.  Factors that influence competitive 
ionization include: access to a droplet’s surface during electrospray, surface tension of 
the solvent, sample pH, and compound polarity.58  Both of these affect the amount of ions 
that reach the mass spectrometer and are therefore available for detection.  As such, they 
have a direct effect on the limits of detection. 
Ion suppression and recovery depend on both the specific analyte of interest and the 
matrix from which the analyte is extracted.  The spray solvent used will also play a role 
in ion suppression and recovery based on how soluble the analyte and potentially co-
extracted matrix components are in the solvent system.  Out of the typical biofluids 
20
analyzed in PS-MS (urine, plasma, and whole blood), blood has been reported to 
typically have the lowest recovery.  This is offset, however, by the fact that ion 
suppression is generally lowest in blood.18,59  One study investigated the donor-
dependency of ion suppression and recovery in blood using PS-MS and found that neither 
were significantly different in the 33 patient samples that were tested.60  This suggests 
that within whole blood samples, the variability of matrix effects will be due mostly to 
compound-specific qualities. 
Compounds that are known to ionize well in paper spray are hydrophobic 
molecules with basic aliphatic amine groups.18   These compounds do not suffer from ion 
suppression nearly as much as poor ionizers.59  Poor ionizers are hydrophilic (logP >~2) 
and lack basic aliphatic amine groups.  Out of the 154 targets in this project, 48 do not 
have aliphatic amines and 97 have logP values that are greater than two.  That means that 
64% of the targets have the potential to ionize poorly.  However, only 15% of the targets 
are both hydrophobic and lack a basic aliphatic amine.   
The challenge to drug recovery in this project will be in maintaining the simplicity 
of the process.  Recovery may be improved by optimizing the solvent system, but using 
multiple solvent systems would add time to the analytical process.  However, even if 
multiple solvents must be run for full target coverage, the time required for PS-MS would 
still be competitive with current screening techniques.  One of the challenges for the 
project, then, is to find a solvent system that efficiently extracts as many targets as 
possible at relevant concentrations while minimizing the possibility of extracting 
interfering compounds from the matrix.  Ion suppression is also a potential problem, 
especially for poor ionizers with low target cutoff concentrations.  Incorporating a pre-
concentration technique with PS-MS has been shown to improve signal in some of these 
cases and is an option to help improve detection in future method development.57 
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While recovery and ion suppression are the primary matrix effects of concern in 
paper spray, other minor effects could play a role in this project, one of which is the 
formation of protomers.  Protomers are ions that differ only by the site at which they are 
protonated.  Where the proton is attached to the molecule is determined by the chemical 
environment, and solvent composition has been suggested as a contributing factor.61  
Solvent characteristics that have been found to influence the formation of protomers 
include: pH, aqueous-organic ratio, and ionic strength.62   
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3 MATERIALS AND METHODS
3.1 Chemicals and Reagents 
Analytical grade methanol, acetic acid, and water were purchased from Fisher 
Scientific (Hampton, NH, USA).  All targets (Appendix A) were purchased as standards 
from Cerilliant (Reston, VA, USA) with the exception of: acetaminophen, metaxalone, 
salicylic acid, etomidate, carbamazepine, valproic acid, fluvoxamine, hydroxyzine, 
aripiprazole, secobarbital, amlodipine, papaverine, metoclopramide, benztropine, 
donepezil, ropinirole, methocarbamol, bupivacaine, levetiracetam, and labetalol, which 
were purchased from Sigma–Aldrich (St. Louis, MO, USA).  Drug-free human blood was 
collected in K2EDTA blood collection tubes from a single donor.  Both analytes and 
blood were stored at -20°C. 
3.2 Mass Spectrometer and Materials 
Experiments for this project were carried out on a triple quadrupole, TSQ Vantage 
mass spectrometer (Thermo Scientific, San Jose, CA, USA) operated in MS/MS mode.  
Manually run experiments were performed using an in-house designed cartridge (Figure 
5-A) and Whatman grade 31ET chromatography paper purchased from Whatman
(Piscataway, NJ, USA). A TM-200 miniature CCD camera was purchased from JAI 
PULNiX (San Jose, CA, USA) and used to visually monitor paper and electrospray 
quality during manual experiments. Automated experiments were run using a Velox 360 
sample handling and ionization source and Velox sample cartridges (Figure 5-B) from
Prosolia, Inc. (Indianapolis, IN, USA).  
3.3 Method 
Two sets of methods were used during this project.  Method development and initial 
testing were done using the manual method outlined below.  After a functional method 
was developed using the manual method, the parameters were used to inform a method 
that used an automated ionization source and disposable cartridges. 
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 For both the manual and automated experiments, analytical targets were combined 
together from their original stocks into 13 different cocktail solutions according to 
Appendix D.  Each cocktail contained anywhere from 8 to 14 target analytes at 20x each 
analyte’s target detection concentration.  While the analytes were grouped according to 
their target detection concentrations, care was taken to ensure isomers were separated 
into different cocktails to avoid introducing interferences.  The diluent used to bring each 
cocktail to the appropriate concentration was 95:5:0.01 methanol:water:formic acid, and 
the cocktails were stored at -20° C.  
For both the manual and automated methods, 300 µL of drug-free blood was 
aliquoted into plastic microcentrifuge tubes and put through two freeze-thaw cycles to try 
to mimic the matrix decomposition that may occur in postmortem blood samples.  15 µL 
of one of the cocktail solutions was then added to the thawed blood so that the total 
organic content was less than or equal to 5%.  This helped prevent the blood from 
congealing and limited protein precipitation which caused the blood to become 
heterogeneous and difficult to pipette.  For blanks, 15 µL of 95:5:0.01 
methanol:water:acetic acid was added to blank blood to keep organic content consistent 
between blank and spiked samples.  The samples were then inverted 30 times, and 
Figure 5:  (A) An in-house designed reusable cartridge was used for manual experiments.  Using
this set up 3 µL blood spots were dried onto pentagon-shaped papers hand-cut from Whatman 
31ET chromatography paper and inserted into a slot at the front of the cartridge.  In this design, 
solvent is applied through a well directly over blood spot.  (B) Commercial Velox cartridges from 
Prosolia were used for automated experiments.  In this set up, 12 µL blood spots are dried onto 
precut paper stored inside individual disposable cartridges.  Solvent is applied into well behind 
blood spot and wicks through the paper and blood spot.  
A B 
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allowed to incubate for 45 minutes at room temperature before being aliquoted onto 
paper. 
3.3.1 Manual Method
During manually run experiments, pentagonal papers (Figure 6-B) were razor-cut 
from Whatman 31ET chromatography paper to fit into an in-house designed cartridge 
(Figure 5-A).  After the analytes were incubated in the blood for 45 minutes, the samples 
were mixed and 3 µL of blood was used to saturate 3.5mm paper punches 
(Figure 6-A) and allowed to dry at room temperature for two hours.
For analysis, the pentagonal papers were loaded though the side slot in the cartridge 
and then the dried blood spots were placed on top of the paper via the well on the top of 
the cartridge.  The solvent system 95:5:0.01 methanol:water:formic acid was delivered in 
three 15µL aliquots to saturate the paper and then 4000 V was applied through a metal 
contact to induce electrospray.  Data was collected for 60 s for each sample, and four 
replicate dried blood spots were run for each target cocktail.  Between each sample, the 
voltage was turned off, and the cartridge was rinsed with methanol and air dried before 
loading the next sample.  Replicate samples were run in succession followed by replicate 
blanks. 
10 mm 
5 mm 
5 mm 
B
3.5 mm 
3 µL 
A 
12 µL 
C 
Figure 6 (A) Using the manual method, 3 µL of whole blood was used to saturate a 3.5 mm 
round paper punch (B) Pentagonal paper was hand-cut with razor blades and the dried blood 
spot was placed on top of the paper. (C) The automated method utilized a larger, different 
shaped paper design than the manual method. This precut paper was housed in single-use 
Prosolia cartridges and 12 µL of whole blood was directly applied to the paper for analysis. 
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4.3.2 Automated Method 
During experiments run using the automated ionization source, blood samples were 
prepared following the same procedure as the manual experiments.  Instead of applying 
the spiked blood to a paper disk and setting the disk on top of the paper tip, the spiked 
blood was applied directly to the paper housed inside  each disposable cartridge.  Two 
types of paper were investigated in the automated experiments, laser-cut and die-cut.  
Prosolia typically cuts their paper tips with lasers, but a slight brown discoloration was 
observed on the edges of the paper of the laser-cut tips, so die-cut tips were provided as 
well in order to investigate whether the laser-cutting process affected results.  
Because the paper size was larger, 12 µL aliquot volumes were used in the 
automated experiments, and instead of a spot of blood, a band of blood was created 
across the width of the paper (Figure 6-C).  Creating a “band” of blood instead of a spot 
was necessary because the automated source delivers the solvent behind the dried sample 
rather than on top of it.  Forming a band of blood ensures that solvent must flow through 
the blood and will not flow around it, bypassing the sample.  The larger size of the paper 
also led to using 120 µL of solvent rather than 45 µL, but like the manual method, the 
solvent was delivered in several aliquots to allow the solvent time to soak through the 
paper. Like the manual method, the solvent system used was 95:5:0.01 
methanol:water:formic acid, and 4000 V were applied to induce electrospray.  Due to the 
automatic ionization source, however, the spray was not able to be monitored visually for 
samples run in the disposable cartridges. 
Unlike in the manual method, no clean up was necessary between samples while 
using the automatic method.  Sample were allowed to dry on the papers contained within 
each cartridge and then the cartridges were loaded into a magazine.  This magazine 
attached into the automated ionization source so that the samples could be queued up and 
left to run automatically. 
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4 METHOD DEVELOPMENT
Several preliminary sets of experiments were run for method development.  
These included a series of experiments to optimize the solvent system, paper layout, and 
sample loading.  Experiments were also run to select appropriate SRM channels for each 
target analyte, establish the amount of data needed to reliably represent results, and to 
establish acceptable fragment ion ratio tolerances. 
4.1 Solvent Selection 
Solvent selection is the primary means though which both selectivity and sensitivity 
are manipulated during paper spray experiments.  One of the challenges in this project 
was to find one solvent mixture that could effectively extract and spray the entire panel of 
analytical targets.  Typically, paper spray solvents are mostly organic in composition, 
which allows hydrophobic small molecules like drugs to be extracted while the 
hydrophilic matrix components remain trapped on the paper.  Examples of commonly 
used extraction/spray solvents include 90:10 methanol:water and 90:10 
acetonitrile:water.18  Oftentimes, acetic acid or formic acid is added as a solvent modifier 
at approximately 0.01% to help encourage the formation positively charged ions and to 
increase spray stability.  In negative mode, ammonium hydroxide can be used to 
encourage the formation of deprotonated ions. 
In order to choose a spray solvent for this project, a subset of 16 targets was chosen 
to represent a range of target cutoff levels, hydrophobicities, and ionizabilities.  A set of 
two-solvent systems made by combining either methanol, acetonitrile, ethanol, 
isopropanol, water, dichloromethane, or tetrahydrofuran were made in proportions of 
35:65, 40:60, 50:50, 65:35, and 95:5 and included 100 ppm acetic acid as a solvent 
modifier to encourage positive ion formation.  This yielded 47 different solvent 
combinations that were tested on the subset of 16 targets that were spiked at their cutoff 
concentrations into blood.  Observations for some of these solvent systems can be found 
in Table 3. 
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Table 3. 47 different solvent systems were tested for use with PS-MS in an effort to identify a 
solvent that would produce a steady Taylor cone at 4000 V, prevent electrical discharge, and
effectively extract target analytes. 
Solvent Observations 
60:40 Ethanol:Water Didn't produce cone 
75:25 Ethanol:Water Unstable cone, discharge at higher voltages 
95:5 Ethanol:Water Discharge that isn't solved by lowering voltage 
60:40 Isopropanol:Water Cone wasn't visualized, but spray was; wicked slowly 
75:25 Isopropanol:Water 
Cone wasn't visualized, but spray was; both blank and 
target signals elevated 
95:5 Isopropanol:Water Cone wasn't visualized, but spray was 
60:40 Acetonitrile:Water Cone wasn't visualized 
75:25 Acetonitrile:Water Cone only formed in some trials 
95:5 Acetonitrile:Water Taylor cone stable until 30s 
60:40 Methanol:Water Stable cone 
75:25 Methanol:Water Stable cone 
60:40 Methanol:Acetonitrile Cone only formed in some trials 
75:25 Methanol:Acetonitrile Produced good cone, failed after 30s 
95:5 Methanol:Acetonitrile Cone failure after 20-30 seconds; Tendency to discharge 
60:40 Ethanol: Acetonitrile 
Cone failure after 15 seconds, but spray still visualized for 
up to a minute 
75:25 Ethanol: Acetonitrile Sometimes spray was seen without a cone forming 
95:5 Ethanol: Acetonitrile Sprayed for up to a minute, even without cone formation 
60:40 Isopropanol:Acetonitrile Cone failure quickly and tendency to discharge 
75:25 Isopropanol:Acetonitrile Cone wasn't visualized, but spray was 
95:5 Isopropanol:Acetonitrile Discharges badly 
40:60 Methanol:Dicholormethane Neither cone nor spray consistently 
65:35 Methanol:Dicholormethane Unstable spray 
95:5 Methanol:Dicholormethane Cone failure after 30s and discharge 
40:60 Ethanol:Dicholormethane Neither cone nor spray consistently 
65:35 Ethanol:Dicholormethane Sputtering discharge throughout 
95:5 Ethanol:Dicholormethane Sprayed at times, but discharged 
40:60 Isopropanol:Dicholormethane Cone wasn't visualized but spray was at times 
65:35 Isopropanol:Dicholormethane Cone wasn't visualized, tendency to discharge 
95:5 Isopropanol:Dicholormethane Cone wasn't visualized but spray was 
35:65 Methanol:Tetrahydrofuran 
Cone wasn't visualized but spray was; Solvent depleted 
quickly 
50:50 Methanol:Tetrahydrofuran 
Cone wasn't visualized but spray was; Solvent depleted 
quickly 
65:35 Methanol:Tetrahydrofuran Spray dries up quickly 
35:65 Ethanol:Tetrahydrofuran Cone wasn't visualized but spray was 
50:50 Ethanol:Tetrahydrofuran Cone failure after 35s; tendency to discharge 
35:65 Isopropanol:Tetrahydrofuran Cone wasn't visualized but spray was 
50:50 Isopropanol:Tetrahydrofuran 
Cone wasn't visualized but spray was; tendency to 
discharge 
65:35 Isopropanol:Tetrahydrofuran 
Cone wasn't visualized but spray was; tendency to 
discharge 
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Some of these solvent systems did not produce a stable 
Taylor cone and had a tendency to produce an electrical 
discharge, which was indicated by the presence of a glowing 
point at the tip of the paper, a spike in the spray current, and at 
times an audible clicking.  Other solvent systems produced 
unreasonably high blank signals which would not allow for 
adequate sensitivity.  In the end, the solvent system that 
produced a stable electrospray and yielded the best extraction 
results for the panel of drugs tested was 95:5:0.01 
methanol:water:acetic acid.  This solvent was used for all 
subsequent experiments. 
4.2 Paper Shape and Sample Loading 
Historically, paper spay experiments have been 
performed on paper that is shaped more or less like an 
equilateral triangle on top of a square (Figure 7-A).  However, 
during method development, elongating the paper was 
investigated because Vega et al. found that as the distance 
between the sample and the tip of the paper increased, both 
ionization suppression and recovery decreased.59  This could 
potentially benefit targets that are bad ionizers by reducing 
ionization suppression, at the expense, however, of decreasing 
recovery.  The published experiments increased the distance 
between the sample and the paper tip by stacking blank 
“spacer” discs of paper between the sample and the paper that 
was cut into a point.  Rather than taking this approach during 
method development, a strip of paper 30 mm long, as depicted 
in Figure 7-B, was used to increase the distance from the 
sample to the paper tip. 
Figure 7: Paper shape and 
sample loading capacity were 
tested on two different paper 
designs. (A) Traditional 
pentagonal-shaped papers 
provided a base-line 
reference while (B) 30 mm 
long pointed paper strips 
were used to test the effects of 
higher loading capacities  
5 mm 
10 mm 
5 mm 
30 mm 
A 
B 
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4.2.1 Placement of Sample
The first set of experiments run using the long paper studied the effect of the 
position of the blood on the paper.  To do this, 20 µL of whole blood was loaded at 13, 
17, and 22 mm from the tip of the paper.  All of the blood was loaded onto the paper at a 
single point, resulting in a sample front that was rounded due to the way that the blood 
wicked though the paper, but always resulting in bands of blood 11 mm wide.  Five 
targets (morphine, zolpidem, clonazepam, fentanyl, and buprenorphine) were monitored 
during these experiments. The area under the curve for several fragment ions from these 
targets was recorded and normalized using the lowest area in order to easily compare 
which position produced the strongest signal.  The results presented in Table 4 show that 
for most of the fragments, the central position at 17 mm produced the highest signal by a 
factor of approximately 1.5-2.  During these experiments, it was observed that the 
cartridge design allowed some of the solvent to wick around the sides of the paper rather 
than through the sample, so a new cartridge was designed for future experiments.  The 
new cartridge supported the length of the paper on small pegs rather than on channeled 
grooves on the sides, so that the solvent would be forced though the sample.  
4.2.2 Loading Capacity and Blood Dilution
Using the small paper punches, a set of experiments were run to find the effect of 
diluting blood, which could improve ion suppression and/or analyte recovery.  To this 
end, triplicate samples were run at blood:water ratios of 1:0.5, 1:1, 1:5, and 1:10.  The 
results of the five drugs investigated (morphine, zolpidem, clonazepam, fentanyl, and 
buprenorphine) shown in Table 5 indicate that a dilution factor of 1:1 could increase 
signal to blank.   
Another set of experiments were run using both diluted blood and whole blood on 
30mm long paper.  The longer paper allows for a larger volume of blood to be loaded 
onto the paper, which increases the absolute amount of drug available to be recovered 
during paper spray.  Therefore, while using the elongated paper, the amount of sample 
loaded onto the paper was also investigated.   The larger volumes used in these 
experiments meant that it was not feasible to position the samples at 17mm from the tip 
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Table 4 Relative AUC of fragment ions at different positions on the long paper strip.  The
lowest AUC was normalized to 1.00 for comparative purposes and the position on the paper 
strip with the largest AUC is denoted in green. 
Position Relative Area Under the Curve 
m/z of fragments 152 165 201 
Morphine at 40 
ng/mL
13 mm 1.00 1.00 1.09 
17 mm 1.58 1.48 1.00 
21 mm 1.40 1.33 1.02 
m/z of fragments 235 92 
Zolpidem at 10 
ng/mL 
13 mm 1.07 1.00 
17 mm 1.00 1.12 
21 mm 1.37 1.27 
m/z of fragments 270 214 241 151 205 206 207 190 
Clonazepam 20 
ng/mL 
13 mm 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
17 mm 1.84 2.19 1.68 1.71 1.92 2.94 2.19 2.64 
21 mm 1.29 1.74 1.28 1.07 1.38 1.56 1.53 1.68 
m/z of fragments 188 105 79 
Fentanyl at 10 
ng/mL 
13 mm 1.00 1.00 1.00 
17 mm 1.07 1.53 1.79 
21 mm 1.23 1.30 1.15 
m/z of fragments 396 414 101 187 55 211 225 
Buprenorphine at 
ng/mL 
13 mm 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
17 mm 2.08 1.92 2.47 1.65 1.81 1.59 2.17 
21 mm 1.79 1.55 1.49 1.22 1.23 1.44 1.88 
as in previous experiments, since this would cause the sample to wick all the way to the 
tip of the paper and inhibit the solvent from spraying. Instead, the front edge of the blood 
spot was positioned so that it was always 6mm from the tip of the paper.  
When 5µL of whole blood was used, the band of blood produced on the strip of 
paper was 6mm long. The same sized blood band was produced when diluted blood was 
used as well.  The amount of blood used was increased incrementally up to 40µL, which 
was found to be the maximum volume of blood that the long paper strips could 
accommodate and maintain a good spray.  The length of the blood band formed on the 
paper increased as the loading volume increased, with the final volume of 40µL 
producing a blood band 20mm long.  The results of these experiments are presented in 
Appendix B and summarized in Figure 8 and Figure 9.  The results indicate that the 
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optimal loading capacity using the 30mm long paper is 20µL and that using a dilution 
factor of 1:1 can increase a target’s signal to noise ratio by lowering the blank signal.  
In order to test the effects of the optimized method of using 20µL of blood diluted 
1:1 with water and placed in the center of a 30mm long paper, an experiment was run that 
tested this method against the original method (loading 3.5µL of whole blood onto a 
3mm punch placed on top of a 10mm long paper).  A panel of 13 targets was split into 
two groups and tested using both the original method and the optimized method.  The 
targets from each group were cocktailed together and tested at each analyte’s target cutoff 
concentration.  Two cocktails of targets were necessary in this case to avoid introducing 
intra-target interferences from targets who share parent ions in the same sample, i.e. 
morphine and 7-aminoclonazepam.   
The results of these experiments, shown in Table 6 indicate that long paper with 
diluted blood generally gives lower blank signals and higher response to target SRM 
channels, resulting in better signal to noise ratios.  While in some cases, this improved 
S:B enough to make a target be considered “detected” due to raising the S:B ratio above 
3:1, the improvements are not drastic enough to warrant adapting the entire experimental 
set up in favor of the simpler original method.  Since the end goal of this project is to be 
able to run a fully automated process using the automated ionization source, the results of 
Table 5 Four dilutions schemes used to test the effect of diluting blood on the signal to 
blank ratio of five analytical targets.  The results indicate an optimal dilution factor of 1:1
Dilution 
Factor 
1:10 1:5 1:1 1:0.5 
Fragment S:B S:B S:B S:B 
Morphine 
286-> 152 1.7 1.7 3.5 3.0 
286-> 165 1.5 1.5 2.3 2.3 
Zolpidem 
308 -> 92 1.8 2.2 5.2 3.7 
308 -> 235 9.4 18 39 6.8 
Clonazepam 
316 -> 214 1.6 1.8 1.5 2.0 
316 -> 241 2.4 2.6 4.0 4.0 
Fentanyl 
337 -> 105 1.3 1.6 2.5 2.1 
337 -> 188 2.7 4.7 15 13 
Buprenorphine 
468-> 396 1.2 1.2 2.1 1.5 
468-> 414 1.1 1.1 2.7 1.7 
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Figure 8: Plots of signal to
blank ratio using blood diluted 
1:1 on 30mm long paper for 
(A) Zolpidem
(B) Morphine (C) Clonazepam
(D) Fentanyl (E)
Buprenorphine indicate an 
optimal loading capacity of 
20µL for diluted blood 
A. B. 
C. D. 
E. 
the dilution and placement survey will serve to inform future work, but in this project, 
undiluted blood and commercially available cartridges will be tested. 
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Figure 9: Plots of signal to blank ratio
using whole blood on long paper for (A) 
Zolpidem (B) Morphine 
(C) Clonazepam (D) Fentanyl
(E) Buprenorphine.  Although the
analytes do not  follow the same trend, 
they generally show an optimal loading 
capacity of ~20µL of whole blood 
E. 
D. C. 
B. A. 
34
T
a
b
le
 6
 R
es
u
lt
s 
fr
o
m
 t
h
ir
te
en
 a
n
a
ly
te
s 
sh
o
w
 t
h
a
t 
u
si
n
g
 l
o
n
g
 p
a
p
er
 w
it
h
 d
il
u
te
d
 b
lo
o
d
 g
en
er
a
ll
y 
g
iv
es
 l
o
w
er
 b
la
n
k 
si
g
n
a
ls
 a
n
d
 h
ig
h
er
 a
n
a
ly
te
 r
es
p
o
n
se
 t
h
a
n
 
u
si
n
g
 w
h
o
le
 b
lo
o
d
 a
n
d
 3
m
m
 p
u
n
ch
es
. 
 T
h
e 
fi
rs
t 
se
ve
n
 a
n
a
ly
te
s 
(i
n
 b
lu
e)
 w
er
e 
ru
n
 i
n
 o
n
e 
se
t 
o
f 
sa
m
p
le
s 
a
n
d
 t
h
e
 l
a
st
 6
 (
in
 r
ed
) 
w
er
e 
ru
n
 i
n
 a
 s
ec
o
n
d
 s
et
 o
f 
sa
m
p
le
s.
 
F
ra
g
m
en
t 
m
/z
 
L
o
n
g
 
B
la
n
k
 
A
v
g
 
A
U
C
 
L
o
n
g
 
B
la
n
k
 
E
rr
o
r 
P
u
n
ch
 
B
la
n
k
 
A
v
g
 
A
U
C
 
P
u
n
ch
 
B
la
n
k
 
E
rr
o
r 
L
o
n
g
 
D
ru
g
 A
v
g
 
A
U
C
 
L
o
n
g
 
D
ru
g
 
E
rr
o
r 
P
u
n
ch
 
D
ru
g
 A
g
v
 
A
U
C
 
P
u
n
ch
 
D
ru
g
 
E
rr
o
r 
L
o
n
g
 
S
:B
 
P
u
n
ch
 
S
:B
 
G
ab
ap
en
ti
n
 
1
1
9
 
1
.5
E
+
0
4
 
1
4
0
0
 
3
.2
E
+
0
4
 
1
0
0
0
 
2
.0
E
+
0
5
 
2
3
0
0
0
 
1
.6
E
+
0
5
 
1
1
0
0
0
 
1
3
 
4
.9
 
1
3
7
 
3
.9
E
+
0
4
 
3
8
0
0
 
9
.1
E
+
0
4
 
2
8
0
0
 
6
.0
E
+
0
5
 
6
9
0
0
0
 
4
.8
E
+
0
5
 
3
7
0
0
0
 
1
5
 
5
.2
 
N
o
rm
ep
er
d
in
e
 
4
2
 
2
.2
E
+
0
3
 
1
6
0
 
2
.4
E
+
0
3
 
2
9
0
 
2
.2
E
+
0
4
 
2
3
0
0
 
1
.9
E
+
0
4
 
8
7
0
 
1
0
 
8
.1
 
5
6
 
4
.4
E
+
0
3
 
2
8
0
 
6
.6
E
+
0
3
 
4
5
0
 
4
.5
E
+
0
4
 
5
3
0
0
 
4
.2
E
+
0
4
 
1
8
0
0
 
1
0
 
6
.3
 
K
et
a
m
in
e
 
1
2
5
 
4
.1
E
+
0
3
 
3
3
0
 
8
.0
E
+
0
3
 
2
7
0
0
 
9
.7
E
+
0
5
 
1
.3
E
+
0
5
 
8
.5
E
+
0
5
 
2
8
0
0
0
 
2
4
0
 
1
1
0
 
8
9
 
3
.6
E
+
0
3
 
4
0
0
 
5
.2
E
+
0
3
 
1
4
0
0
 
2
.6
E
+
0
5
 
3
4
0
0
0
 
2
.3
E
+
0
5
 
8
2
0
0
 
7
2
 
4
4
 
M
ep
ro
b
am
at
e 
1
5
8
 
7
.5
E
+
0
3
 
2
8
0
 
5
.3
E
+
0
3
 
6
2
0
 
1
.3
E
+
0
4
 
9
6
0
 
1
.2
E
+
0
4
 
5
2
0
 
1
.7
 
2
.2
 
1
8
0
 
8
.0
E
+
0
3
 
5
1
0
 
3
.9
E
+
0
4
 
1
8
0
0
0
 
6
.6
E
+
0
4
 
8
3
0
0
 
9
.1
E
+
0
4
 
2
4
0
0
 
8
.2
 
2
.3
 
M
o
rp
h
in
e
 
1
5
2
 
1
.4
E
+
0
4
 
1
2
0
0
 
1
.5
E
+
0
4
 
2
4
0
0
 
2
.4
E
+
0
4
 
3
3
0
0
 
1
.7
E
+
0
4
 
2
3
0
0
 
1
.7
 
1
.2
 
1
6
5
 
5
.8
E
+
0
3
 
4
2
0
 
5
.6
E
+
0
3
 
1
1
0
0
 
1
.2
E
+
0
4
 
8
9
0
 
8
.2
E
+
0
3
 
4
9
0
 
2
.0
 
1
.5
 
Z
o
lp
id
e
m
 
9
2
 
6
.6
E
+
0
3
 
4
6
0
 
7
.1
E
+
0
3
 
8
5
0
 
9
.8
E
+
0
4
 
1
2
0
0
0
 
1
.1
E
+
0
5
 
7
9
0
0
 
1
5
 
1
6
 
2
3
5
 
1
.0
E
+
0
3
 
8
4
 
4
.0
E
+
0
3
 
1
5
4
0
 
4
.9
E
+
0
5
 
7
9
0
0
0
 
5
.8
E
+
0
5
 
4
5
0
0
0
 
4
7
0
 
1
5
0
 
T
o
p
ir
am
at
e
 
2
0
7
 
3
.3
E
+
0
3
 
2
2
0
 
8
.2
E
+
0
3
 
2
6
0
0
 
6
.7
E
+
0
5
 
1
.1
E
+
0
5
 
9
.6
E
+
0
5
 
3
4
0
0
0
 
2
0
0
 
1
2
0
 
2
6
5
 
8
.4
E
+
0
3
 
7
6
0
 
1
.6
E
+
0
4
 
5
2
0
0
 
1
.2
E
+
0
6
 
2
.1
E
+
0
5
 
1
.7
E
+
0
6
 
5
8
0
0
0
 
1
5
0
 
1
0
0
 
A
lp
ra
zo
la
m
 
2
8
1
 
8
.6
E
+
0
3
 
2
2
0
0
 
6
.3
E
+
0
3
 
1
0
0
0
 
5
.7
E
+
0
4
 
6
9
0
0
 
1
.5
E
+
0
4
 
1
5
0
0
 
6
.6
 
2
.3
 
2
0
5
 
8
.3
E
+
0
3
 
2
0
0
0
 
6
.8
E
+
0
3
 
8
6
0
 
5
.1
E
+
0
4
 
6
3
0
0
 
1
.3
E
+
0
4
 
1
7
0
0
 
6
.2
 
2
.0
 
7
-A
m
in
o
cl
o
n
az
ep
a
m
9
4
 
9
.8
E
+
0
3
 
9
8
0
 
7
.2
E
+
0
3
 
8
0
0
 
2
.0
E
+
0
4
 
1
0
0
0
 
9
.4
E
+
0
3
 
1
1
0
0
 
2
.1
 
1
.3
 
1
2
1
 
6
.8
E
+
0
3
 
9
8
0
 
5
.7
E
+
0
3
 
6
7
0
 
3
.0
E
+
0
4
 
2
1
0
0
 
1
.5
E
+
0
4
 
1
6
0
0
 
4
.4
 
2
.7
 
B
u
p
re
n
o
rp
h
in
e
 
3
9
6
 
2
.0
E
+
0
3
 
3
4
0
 
2
.3
E
+
0
3
 
2
5
0
 
2
.2
E
+
0
3
 
2
6
0
 
1
.9
E
+
0
3
 
2
7
3
 
1
.1
 
0
.8
 
C
lo
n
az
ep
a
m
 
2
1
4
 
6
.0
E
+
0
3
 
1
1
0
0
 
5
.8
E
+
0
3
 
9
4
0
 
1
.2
E
+
0
4
 
1
0
0
0
 
5
.9
E
+
0
3
 
1
1
0
0
 
2
.0
 
1
.0
 
2
4
1
 
3
.6
E
+
0
3
 
7
0
0
 
3
.2
E
+
0
3
 
5
0
0
 
8
.7
E
+
0
3
 
7
8
0
 
3
.7
E
+
0
3
 
6
0
0
 
2
.4
 
1
.2
 
C
o
ca
et
h
y
le
n
e
 
1
9
6
 
5
.3
E
+
0
4
 
2
5
0
0
0
 
1
.8
E
+
0
4
 
2
6
0
0
 
1
.9
E
+
0
6
 
2
.8
E
+
0
5
 
1
.1
E
+
0
6
 
9
1
0
0
0
 
3
5
 
6
1
 
8
2
 
2
.4
E
+
0
4
 
8
8
0
0
 
1
.2
E
+
0
4
 
1
0
0
0
 
5
.8
E
+
0
5
 
8
2
0
0
0
 
3
.5
E
+
0
5
 
2
9
0
0
0
 
2
4
 
2
8
 
F
en
ta
n
y
l 
1
0
5
 
7
.3
E
+
0
4
 
1
1
0
0
0
 
7
.5
E
+
0
4
 
6
9
0
0
 
7
.9
E
+
0
4
 
5
9
0
0
 
8
.7
E
+
0
4
 
1
6
0
0
0
 
1
.1
 
1
.2
 
1
8
8
 
9
.3
E
+
0
3
 
8
6
0
 
1
.4
E
+
0
4
 
4
5
0
 
1
.9
E
+
0
4
 
1
0
0
0
 
2
.0
E
+
0
4
 
8
3
0
 
2
.0
 
1
.4
 
35
4.3 Tuning 
Thermo TSQ Tune Master was used to automatically identify the prominent 
fragment ions produced for each analytical target and to optimize instrumental 
parameters for those fragments.  During tuning, the voltage was set to 4000 V, the 
collision gas pressure was held at 1.5 mTorr, and the software was set to exclude 
fragments resulting from loss of water and ammonium.  From there, the software 
optimized instrumental conditions for the parent ion, identified the 4 most intense 
fragment ions, and found optimal collision energies (CE) for each fragment ion (Figure 
10).  For each analyte, it also optimized the S-lens, which focuses the initial gas plume
that enters the inlet of the mass spectrometer into a concentrated beam of ions that enter 
the high-vacuum region of the mass 
spec.  
Initial tuning was 
performed using targets 
cocktailed in 95:5:0.01 
methanol:water:acetic acid at 
1ppm and an H-ESI source.  
The results generated were the 
basis of selecting appropriate 
fragment ions and establishing 
fragmentation ratios and 
instrument parameters for each 
analyte.  After several 
experiments were done, each 
analyte was re-tuned by 
spraying it in a neat solvent 
over blank paper at each 
analyte’s respective target 
cutoff concentration.  This was 
Figure 10: An example of some of the data generated from 
the tuning software.  In the curves produced for 
Flunitrazepam above, the 4 most intense fragment ions are 
plotted against collision energy.  Some fragments, like m/z 
268 are more sensitive to changes in collision energy, as 
is evident in the narrow peak in the curve, while other 
fragments with broad peaks, like m/z 183, are less effected 
by changes in collision energy. 
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done in part because using a 1ppm solution in some cases saturated the detector, but also 
because of experiments performed after the initial tuning where fragmentation ratios were 
found to be somewhat concentration dependent. This resulted in a few minor adjustments 
of the fragment ions selected and the established fragment ion ratios. 
In most cases, the protonated molecular ion was selected as the precursor ion, 
although for some targets, like topiramate, a sodiated precursor ion was used.  An effort 
was made to encourage all targets to ionize positively due to complications that arise 
when paper spray is used in negative ionization mode, however, the following targets 
were only found at suitable intensities as deprotonated ions: all barbiturates (amobarbital, 
butabarbital, butalbital, pentobarbital, phentobarbital, and secobarbital), as well as 
furosemide, hydrochlorothiazide, warfarin, ibuprofen, salicylic acid, valproic acid, and 
tadalafil. 
Although not typically required because of chromatography, in this project the 
specificity of the product ions used for identification was considered.  In general, the two 
most abundant fragments from the automated tuning were selected, as they provide 
greatest sensitivity near the limit of detection.  However, to enhance selectivity, larger, 
more complex fragments were chosen over smaller fragments when possible.  Commonly 
produced fragments were avoided for compounds with amino side chains including m/z 
58, 86, and 100.47  Similarly, the isopropyl side chains present in many cardiovascular 
drugs produce common fragments at m/z 43, 60, 116, 98, 74, and 56, which were avoided 
if possible.48   
In some cases, the most abundant fragment found during tuning was not used 
because it caused unacceptably low signal to blank ratios.  This is expected in instances 
where the most abundant fragment is a commonly produced fragment like those outlined 
in Section 2.3.3.  In a few instances, the most abundant fragment was not used because it 
caused the fragmentation ratios to behave disproportionately over a range of 
concentrations.  While this was not observed in most cases, an example of this behavior 
was seen in the fragmentation of norbuprenorphine and depicted in Figure 10.  
Circumstances such as this have lead some to suggest that ratios should be established 
near the intended analytical concentration.46  A list of the final parent/fragment ions 
chosen, instrumental conditions, and the fragmentation ratios used for each target analyte 
in this project can be found in Appendix C.
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4.4 Acquisition Parameter 
In tandem-in-time mass spectrometers, there are inevitable small variations in the 
signal intensity of fragment ions between scans.  Averaging a large number of scans for 
each SRM channel will produce a more consistent, representative response, but at the 
expense of increasing run time.  The variability of individual SRM channel responses 
becomes a compounded concern when two SRM’s are used to calculate a fragmentation 
ratio.  In order to reach an accurate ratio and to minimize the time required for sample 
analysis, it is necessary to determine the minimum number of scans needed in order to 
provide a consistent fragmentation ratio. 
To this end, data from 26 different targets that had shown moderate to severe ratio 
deviations were analyzed.  The targets were analyzed in cocktails in solution using
95:5:0.01 methonol:water:acetic acid as a solvent.  The number of scans over which 
Figure 11:  When selecting appropriate fragment ions to monitor, fragmentation ratio
stability over a range of concentrations was considered.  For example, while m/z 83 was 
found to be the most abundant fragment for norbuprenorphine during tuning, ratios that use 
fragment m/z 83 do not behave proportionally, especially near the target detection level 
(1 ng/mL).  In cases like this, a lesser abundant fragment is used to provide fragmentation 
ratios that are more consistent over a range of concentrations 
35
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data was recorded ranged from 32 to 60, and each scan lasted 0.1 seconds. The data was 
analyzed by monitoring the running average of the ratio of the intensities of two fragment 
ions per target analyte.  The ratio produced after all scans were collected was considered 
the “true” ratio, and this ratio was compared to the ratio obtained for each target after 10, 
15, 20, 25, and 30 scans. The running averages are shown for the first 50 scans in Figure 
12 and Figure 13.  62% of targets showed no significant difference between their “true”
fragmentation ratio and the ratio acquired after 15 scans (1.5 seconds/channel).  92% of 
targets showed less than ±5% variation between their true ratio and the ratio obtained 
after 15 scans. Doubling the number of scans to 30 only increases that percentage to 96%.  
As such, 15 was chosen as the minimum number of 0.1 second scans needed to provide a 
reproducible fragmentation ratio. 
 Defining the minimum number of scans needed per SRM channel has direct 
implications on the analysis time for paper spray.  If there are 154 target analytes that 
each have two fragment ion channels and if each of these channels needs to be scanned 
for 1.5 seconds, total analysis time to screen the entire panel of targets is set at a 
minimum of 7.7 minutes.  If run times are capped at two minutes to eliminate the need to 
replenish solvent mid-run, at least four samples will need to be run to provide full 
coverage for the purposed targets. 
4.5 Screening Identification Criteria 
One of the final tasks during method development for this project was to establish 
screening identification criteria by which the targets would be classified as “detected” or 
“not detected”.  These criteria need to be stringent enough that they support specificity 
and low false positive rates, but liberal enough that they allow for the detection of targets 
with possible interferes from co-eluting matrix components or similarly structured 
targets.  Because paper spray cannot rely on chromatographic retention times, specificity 
when using a triple quadrupole instrument is obtained from identifying the presence of 
two known fragment ions for each target, as well as the fragmentation ratio between these 
ions.  Confirmative results are obtained when both fragments are present in a sample and 
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Figure 12: Running average plot of fragmentation ratios for targets with ratios > 50 show ratios
generally stabilize after 15 scans on each fragment ion channel 
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Figure 13: Running average plot of fragmentation ratios for targets with ratios < 50 show
ratios generally stabilize after 15 scans on each fragment ion channel  
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when their fragmentation ratio is within some permitted tolerance of the expected ratio 
for the analyte.  A signal to blank threshold of 3:1 is commonly used to define the limit of 
detection, and will be adopted in this project.  Detecting two fragment ions with a signal 
to blank ratio of greater than 3, will be the first criteria that must be met to establish the 
detection of an analyte, although a higher threshold may be needed depending on future 
method validation experiments. 
It is also necessary to establish an appropriate tolerance for fragmentation ratio 
variance.  Establishing a fragmentation ratio tolerance that is fit for paper spray was 
informed by both past paper spray research and published guidelines from various 
organizations (Table 2).  The first major guideline to be published on this topic and which 
many others are based off of was the European Union decision of 2002, which allowed 
for tolerances as high as ±50% for fragmentation ratios3.  While these guidelines were 
used as a basis for establishing suitable tolerance levels for PS-MS, they are based on 
assumptions that do not apply to paper spray, namely the assumption that 
chromatography is being performed for quantitative analysis.  Paper spray does not enjoy 
the selectivity that comes from chromatography, so the possibilities of interferences 
arising is higher, which suggests the need for a broader ion ratio tolerance to decrease the 
chances of false negatives. 
A broad tolerance is also supported by the findings of Mol et al. who investigated 
ion ratio deviations in 120 pesticides in 21 food matrices in five different laboratories. 
The authors found that fragment ion ratio deviations are dependent upon detector 
response, and that near the limit of detection it is typical for ion ratios to diverge as much 
as ±45%.49  Historically a ratio tolerance of ±20% has been used for paper spray analysis, 
however, qualitative screening on a large group of targets has not been done before.  
During quantitative analysis of eight drugs using paper spray, Espy et al. saw ratio 
variations as high as 19%, in the case of morphine.  This variation occurred at a 
concentration of 38 ng/mL34 (double this project’s target LOD).  Deviations at lower 
concentrations would be expected to be even greater because of lower detector response 
and would deviate even further if the ratios were derived from solvent standards and were 
not matrix-matched.  The problem of variable ratios near LOD is illustrated by the data 
compiled in Figure 13.  While it is possible a higher tolerance range may prove suitable 
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after method validation, a range of ±30% for fragment ion ratios was used in this project, 
as it allows more variability than previous paper spray experiments, yet still falls within 
the guidelines published by the society of forensic toxicologists and the academy of 
forensic scientists.  
Figure 14: Deviation between solvent-established fragmentation ratios and fragmentations
ratios in whole blood at cutoff concentrations for target analytes where both fragments were 
detected with a S:B ≥3 
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5 RESULTS 
At the beginning of this project, 154 different analytical targets were proposed to 
investigate the feasibility of paper-spray mass spectrometry as an effective means of 
rapid drug screening.  After method development, 14 of the originally proposed targets 
were shown to only ionize well in negative mode and will be studied in future 
experiments optimized for negative ionization.  The 14 negatively ionizing targets 
included all of the barbiturates (amobarbital, butabarbital, butalbital, pentobarbital, 
phentobarbital, secobarbital), as well as: furosemide, hydrochlorothiazide, ibuprofen, 
salicylic acid, thiopental, tadalafil, valproic acid, and warfarin. In addition to the 
negatively ionizing targets, delta-9-THC and its secondary metabolite 11-nor-9-carboxy-
THC, as well as buprenorphine and its metabolite norbuprenorphine were also not 
analyzed in these experiments because they failed to be detected in preliminary 
optimization experiments, even at 250 times higher than their proposed cutoff levels.  
Previously published paper spray studies have shown that delta-9-THC and 11-nor-9-
carboxy-THC require a specialized solvent system for detection.34  In addition to these 
targets, hydroxychloroquine and 10-monohydroxyoxcarbazepine have been excluded 
from this data set due to the availability of the compounds during the time frame in 
which the experiments were conducted.  Excluding all of these compounds from the 
panel of analytical targets originally proposed by AFT left 134 targets that were analyzed 
to determine if PS-MS could be an effective alternative method for drug screening in 
forensic toxicology.  
Experiments were run on paper cut manually with razors and reusable cartridges,  
as well as on laser-cut and die-cut paper in disposable cartridges.  Only 69 of the targets, 
however, were run using the die-cut paper because there were only a limited number of 
die-cut cartridges available.  Although 134 target analytes were included in the cocktails 
that were analyzed, results will only be reported for 133 targets using the manual method 
and 131 targets using the laser-cut cartridges due to an error in transposing the correct 
SRM channels to the mass spec acquisition program for topiramate, papaverine, and 
etomidate.   
Out of the 134 targets included in the cocktails, 28 had to be run at concentrations 
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other than the cutoffs specified by AFT during project development.  Six out of these 28 
targets (acetaminophen, benzylpiperazine, naproxen, phenytoin, topiramate, and 
zonisamide) were run at concentrations lower than those originally proposed by AFT in 
order to avoid swamping the detector at the upper end of the calibration curve.  The other 
22 targets were found to have limits of detection higher than the proposed cutoff 
concentrations from AFT.  These differences in the experimental LOD and proposed 
cutoffs from AFT are outlined in Table 7.  Only four targets of the 23 targets whose 
limits of detection were found to be higher than AFT’s, however, were run at 
concentrations outside of the expected normal therapeutic concentration range as defined 
by data compiled by Schultz et al. (See Table 7).  The four targets were: amphetamine, 
buspirone, tramadol, and demoxepam. 
5.1 Results 
A summary of the results for all 154 proposed targets is found in Table 8 and more 
detailed results sorted by cocktail are found in Table 9 – Table 21.  For full results, see 
Appendix E. 
Out of the 133 targets run using the manual method, 114 met the detection 
requirements when spiked into drug free whole blood at the targeted cut-off 
concentration; the detection criteria were having a signal to blank ratio of greater than 
three and deviated less than 30% in their established fragmentation ratio.  Nineteen of the 
targets failed to meet these criteria, half of the time because of low signal to blank and 
half of the time due to ratio variability. When the same targets (minus papaverine and 
etomidate whose SRM channels were wrongly transcribed) were run using the automated 
source and the laser-cut paper, 99 satisfied the detection criteria.  In the 32 cases where 
the target was not detected at the cutoff or the experimental limit of detection, 15 were 
attributed to low signal to blank ratios and 17 to ratio variability outside of the permitted 
tolerance.  When comparing the two methods, there were 22 instances where targets were 
detected manually but not when using the automated source and the laser-cut paper, and 
there were 7 instances where targets were detected with the automated source but not 
manually (See Figure 17). 
45
Of the 68 targets (etomidate excluded due to incorrect SRM channels being 
monitored) that were analyzed, using the die-cut paper, 87% were detected at cutoff or 
LOD.  Of the 8 targets that did not meet detection criteria using the die-cut paper, only 
two were due to low signal, while the rest were excluded due to ratio variability outside 
of the permitted ±30% window.  There were seven instances where targets were detected 
using die-cut paper that were not previously detected using the automated method on 
laser-cut paper. 
Figure 15  Number of analytical targets detected using three different methods.  Out of the 
133 targets analyzed using the manual method, 86% met detection criteria; for the 131 targets 
analyzed using the automatic method with laser-cut paper, 76% met detection criteria. Of the 
68 targets analyzed using the automatic method with die-cut paper, 87% met detection 
criteria 
n=133 n=131 n=68 
99 
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Table 7: A list of targets run at concentrations other than those proposed by AFT compared 
to normal, toxic, and fatal levels2  Normal levels are defined as the effective dose where no or 
minimal side effects occur.  Toxic levels are those at which side effects or negative symptoms 
arise, and fatal levels are the concentrations which result in either coma or death. 
Concentration in mg/L 
Target 
LOD found 
during 
project 
AFT 
proposed 
cutoff level 
Normal Toxic Fatal 
6-acetylmorphine 0.03 0.02 - - - 
7-aminoclonazepam 0.05 0.010 - - - 
Acetaminophen 10 20 10-25 100-150 200-300
Amphetamine 0.2 0.05 0.02-0.1 0.2 0.5-1 
Aripiprazole 0.1 0.05 0.15-0.5 1 - 
Benzylpiperazine 0.025 0.05 - - - 
Buspirone 0.025 0.01 0.001-0.004 .008 - 
Clonazepam 0.025 0.01 0.02-0.08 0.1 - 
Demoxepam 0.075 0.05 0.5-0.74 1 2.7 
Desmethylclomipramine 0.1 0.02 - - - 
Fentanyl 0.01 0.001 0.003-0.3 0.003-0.2 - 
Fluvoxamine 0.025 0.02 0.060-0.23 0.5-0.65 2.8 
Hydroxyzine 0.075 0.01 0.05-0.1 0.1 39 
MDA 0.1 0.05 - 1.5 1.8-2 
Mescaline 0.1 0.05 - - - 
Morphine 0.025 0.02 0.01-0.1 0.1 0.1-4 
Naproxen 3 30 20-50 200-400 - 
Norsertraline 2 0.1 - - - 
Nortramadol 1 0.1 - - - 
Oxycodone 0.1 0.02 0.005-0.1 0.2 0.6 
Oxymorphone 0.025 0.02 - - - 
Paroxetine 0.025 0.02 0.01-0.05 0.35-0.4 3.7-4 
Phenytoin 2.5 5 5-15 20-25 43 
Topiramate 1 2 2-10 16 - 
Tramadol 2 0.1 0.1-1 1 2 
Ziprasidone 0.1 0.01 0.05-0.2 0.4 - 
Zonisamide 7.5 10 10-40 40-70 100 
Zopiclone 0.025 0.01 0.01-0.05 0.15 0.6-1.8 
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Table 8: Summary of results for all 154 proposed analytical targets; "-" indicates not analyzed
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10-monohydroxyoxcarbazepine Not run - 
11-nor-9-Carboxy-THC Not run - 
6-acetylmorphine No Yes Yes G 
7-aminoclonazepam Yes No Yes G 
7-aminoflunitrazepam Yes Yes - J 
9-hydroxyrisperidone No Yes - K 
Acetaminophen Yes Yes - A 
Alfentanil Yes Yes Yes G 
Alpha-PVP Yes Yes Yes G 
Alprazolam No Yes - K 
Amitriptyline Yes Yes - L 
Amlodipine No No - J 
Amobarbital Negative ionizer - 
Amphetamine Yes Yes - C 
Aripiprazole Yes Yes Yes D 
Atenolol Yes Yes - L 
Baclofen Yes Yes - B 
Benzoylecgonine Yes No - L 
Benztropine Yes No - J 
Benzylpiperazine No Yes - C 
Brompheniramine Yes Yes Yes H 
Bupivacaine Yes Yes - C 
Buprenorphine Not run - 
Bupropion Yes Yes Yes G 
Buspirone Yes Yes Yes I 
Butabarbital Negative ionizer - 
Butalbital Negative ionizer - 
Carbamazepine Yes Yes - B 
Carbamazepine-10,11-epoxide Yes Yes - B 
Carisoprodol Yes Yes - A 
Chlordiazepoxide Yes Yes Yes G 
Chlorpheniramine Yes Yes Yes I 
Chlorpromazine Yes No No G 
Citalopram No No - M 
Clomipramine No Yes - J 
Clonazepam Yes No No I 
Clozapine Yes Yes Yes G 
Cocaethylene Yes Yes Yes G 
Cocaine Yes Yes - M 
Codeine Yes Yes - M 
Cyclobenzaprine Yes Yes - K 
delta9-THC Not run - 
Demoxepam No No Yes E 
Desalkylflurazepam Yes No No G 
Desipramine No No - J 
Desmethylclomipramine No No No D 
Dextromethorphan Yes Yes - K 
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Diazepam Yes Yes - L 
Diltiazem Yes Yes Yes G 
Diphenhydramine Yes Yes Yes H 
Donepezil Yes Yes Yes F 
Doxepin Yes Yes - M 
Doxylamine Yes Yes Yes H 
Duloxetine No Yes - J 
EDDP Yes Yes Yes H 
Ephedrine/ 
Pseudoephedrine 
Yes Yes Yes E 
Etomidate No - - D 
Felbamate Yes Yes - A 
Fentanyl Yes Yes - K 
Flecainide Yes Yes - C 
Flunitrazepam Yes No - J 
Fluoxetine No No - J 
Flurazepam Yes Yes Yes H 
Fluvoxamine Yes Yes Yes I 
Furosemide Negative ionizer - 
Gabapentin Yes No - C 
Haloperidol Yes Yes - K 
Hydrochlorothiazide Negative ionizer - 
Hydrocodone Yes No - L 
Hydromorphone Yes No - M 
Hydroxychloroquine Not Run - 
Hydroxyzine Yes Yes Yes E 
Ibuprofen Negative ionizer - 
Ketamine Yes Yes Yes D 
Labetalol Yes Yes Yes F 
Lamotrigine Yes Yes - B 
Levetiracetam Yes Yes - A 
Lidocaine Yes Yes - C 
Lorazepam Yes Yes Yes H 
mCPP Yes Yes - J 
MDA Yes Yes Yes D 
MDMA Yes Yes Yes F 
MDPV Yes Yes Yes F 
Meperidine Yes Yes Yes H 
Mephedrone Yes Yes Yes F 
Meprobamate Yes Yes - B 
Mescaline Yes No Yes D 
Metaxalone Yes Yes - B 
Methadone Yes Yes Yes I 
Methamphetamine Yes Yes Yes F 
Methocarbamol Yes Yes - B 
Methylone Yes Yes Yes F 
Methylphenidate Yes Yes - J 
Metoclopramide Yes Yes Yes D 
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 Table 8 Continued 
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Metoprolol Yes No Yes F 
Midazolam Yes Yes Yes F 
Mirtazapine Yes Yes Yes F 
Morphine Yes No Yes I 
Naproxen Yes Yes - A 
Norbuprenorphine Not run - 
Norclozapine Yes No No F 
Nordiazepam Yes Yes - M 
Nordoxepin Yes Yes - J 
Norfluoxetine no Yes - J 
Norketamine Yes Yes Yes D 
Normeperidine Yes Yes Yes H 
Norpropoxyphene Yes Yes Yes E 
Norsertraline No No - A 
Nortramadol Yes Yes - B 
Nortriptyline Yes Yes - L 
Norvenlafaxine No No Yes E 
Olanzapine Yes No No E 
Oxazepam No No - M 
Oxycodone Yes Yes Yes D 
Oxymorphone Yes No No I 
Papaverine Yes Yes - C 
Paroxetine Yes Yes Yes I 
PCP Yes Yes Yes H 
Pentazocine Yes Yes Yes E 
Pentobarbital Negative ionizer - 
Phenobarbital Negative ionizer - 
Phenytoin Yes Yes - A 
Pregabalin Yes Yes - C 
Primidone Yes No - A 
Promethazine Yes Yes Yes H 
Propoxyphene Yes Yes Yes E 
Propranolol Yes Yes Yes E 
Quetiapine Yes Yes Yes E 
Ranitidine Yes Yes - C 
Risperidone Yes Yes - K 
Ropinirole Yes No - K 
Salicylic Acid Negative ionizer - 
Secobarbital Negative ionizer - 
Sertraline Yes Yes Yes D 
Sildenafil Yes Yes Yes D 
Tadalafil Negative ionizer - 
Temazepam No No - M 
TFMPP Yes No No E 
Thiopental Negative ionizer - 
Topiramate - - - A 
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Tramadol Yes No - A 
Trazodone Yes Yes Yes D 
Triazolam Yes Yes - J 
Trimipramine Yes No - J 
Valproic 
Acid 
Negative ionizer - 
Vardenafil Yes Yes Yes D 
Venlafaxine Yes Yes Yes E 
Verapamil Yes Yes Yes E 
Warfarin Negative ionizer - 
Zaleplon Yes No Yes I 
Ziprasidone No Yes Yes D 
Zolpidem Yes Yes - K 
Zonisamide Yes Yes - B 
Zopiclone Yes Yes Yes I 
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Figure 17:  (A) Of the 68 targets run using all three methods, 16 were detected in at least
one method, but not in all three.  There was one instance (desmethylclomipramine ) where 
the target failed to be detected in any of the three methods. Venn diagram A depicts the 
methods where these 17 targets failed to meet detection criteria. (B) Of the 63 targets run 
using only the manual and laser-cut methods 23 total targets were not detected, 7 of which 
were detected in neither method. Venn diagram B specifies in which method these failures 
to meet detection criteria occurred. 
0 
7 
2
1 
Manual Laser-Cut 
7 
B. A. 
Figure 16. Stacked column graphs representing the reason that targets failed to meet detection 
criteria for each of the three methods.  When the manual method was used, 53% of failed 
detections were due to ratio deviations outside of the permitted ±30% window.  For the 
automatic method using laser-cut paper 53% of failures were due to ratio deviations, and for 
die-cut experiments, the failure due to ratio deviations reached 75%. 
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Table 9: Cocktail A-Manual experiments had 26 scans per target and experiments run on 
the automated ionization source on the laser-cut paper had 16 scans per target. Red 
shading indicates failure to meet detection criteria. 
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Acetaminophen 10000 152 
110 29 
28 -5%
139 
28 -6% 30 
65 25 55 
Levetiracetam 2000 171 
126 23 
26 6% 
48 
26 10% 24 
154 20 85 
Zonisamide 7500 213 
132 35 
48 5% 
671 
47 3% 46 
77 20 31 
Primidone 5000 219 
162 40 
72 3% 
292 
85 21% 70 
91 15 2 
Naproxen 3000 231 
170 21 
28 -9%
7 
30 -1% 30 
185 7 9 
Felbamate 10000 239 
117 14 
61 -5%
52 
64 -1% 64 
178 37 791 
Phenytoin 2500 253 
104 44 
66 7% 
6 
76 25% 61 
182 43 12 
Carisoprodol 2000 261 
55 4 
69 -17%
29 
78 -6% 83 
97 4 19 
Tramadol 2000 264 
264 10 
35 17% 
2 17
6 
120% 30 
58 39 5159 
Norsertraline 2000 275 
124 35 
7 -37%
57 
7 -36% 11 
159 29 66 
Topiramate 1000 362 
265 - 
- - 
- 
- - 52 
207 - - 
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Table 10: Cocktail B-Manual experiments had 35 scans per target and experiments run 
on the automated ionization source on the laser-cut paper had 16 scans per target. Red 
shading indicates failure to meet detection criteria. 
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Baclofen 1000 214 
151 94 
84 -4%
11 
89 2% 88 
115 78 35 
Meprobamate 2000 219 
158 208 
88 9% 
496 
87 8% 81 
97 25 24 
Metaxalone 1000 222 
105 24 
27 4% 
9 
28 10% 26 
161 118 113 
Carbamazepine 1000 237 
192 186 
22 -25%
208 
22 -25% 30 
194 181 888 
Methocarbamol 1000 242 
118 108 
21 -10%
109 
21 -11% 23 
199 65 94 
Nortramadol 1000 250 
232 5 
21 -17%
5 
23 -7% 25 
42 34 21 
Carbamazepine-
10,11-epoxide 
1000 253 
180 246 
39 8% 
291 
38 7% 36 
210 91 179 
Lamotrigine 1000 256 
145 77 
62 0% 
83 
64 1% 63 
211 84 181 
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Table 11: Cocktail C-Manual experiments had 32 scans per target and experiments run 
on the automated ionization source on the laser-cut paper had 16 scans per target. Red 
shading indicates failure to meet detection criteria. 
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u
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R
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R
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Amphetamine 200 136 
91 9 
23 -6%
6 
21 -15% 25 
119 22 47 
Pregabalin 500 160 
124 68 
467 0% 
12 
22 6% 21 
97 28 7 
Gabapentin 500 172 
119 103 
32 0% 
34 
814 2444% 32 
137 116 147 
Benzylpiperazine 25 177 
85 3 
21 70% 
41 
12 -1% 12 
91 16 34 
Lidocaine 500 235 
58 311 
10 -16%
59 
10 -16% 12 
86 410 7086 
Bupivacaine 500 289 
140 335 
17 -2%
13927 
17 -2% 17 
98 284 2130 
Ranitidine 500 315 
102 447 
51 4% 
10319 
51 4% 49 
176 225 713 
Papaverine 500 340 
324 347 
105 4% 
- 
- - 101 
202 342 - 
Flecainide 500 415 
301 310 
40 6% 
2025 
40 5% 38 
98 335 5159 
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Table 18: Cocktail J-Manual experiments had 19 scans per target and experiments run 
on the automated ionization source had 18 scans per target. Red shading indicates 
failure to meet detection criteria. 
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S
:B
 
R
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io
 
D
ev
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o
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T
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R
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mCPP 20 197 
154 6 
81 -9%
8 
90 1% 89 
118 13 4 
Methylphenidate 20 234 
84 12 
13 5% 
114 
13 4% 13 
56 6 5 
Nordoxepin 20 266 
107 8 
59 -1%
10 
56 -7% 60 
235 14 36 
Desipramine 20 267 
72 17 
37 79% 
249 
27 34% 20 
193 6 5 
7-aminoflunitrazepam 20 284 
135 11 
51 0% 
9 
55 8% 51 
227 13 8 
Trimipramine 20 295 
193 8 
78 10% 
25 
100 41% 71 
208 8 26 
Norfluoxetine 20 296 
134 3 
19 -25%
4 
19 -28% 26 
30 10 76 
Duloxetine 20 298 
44 2 
95 10% 
14 
88 1% 87 
154 2 3 
Benztropine 10 308 
167 13 
45 -1%
195 
1 -98% 45 
165 13 14 
Fluoxetine 20 310 
44 15 
16 30% 
219 
17 34% 13 
148 6 3 
Flunitrazepam 20 314 
268 3 
32 -16%
2 
23 -40% 38 
239 7 5 
Clomipramine 20 315 
227 4 
49 -33%
10 
67 -8% 73 
242 5 16 
Triazolam 20 343 
308 13 
85 11% 
336 
80 6% 76 
239 5 13 
Amlodipine 20 409 
238 2 
77 14% 
17 
79 18% 67 
294 2 2 
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Table 19: Cocktail K-Manual experiments had 30 scans per target and experiments run 
on the automated ionization source had 18 scans per target. Red shading indicates 
failure to meet detection criteria. 
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Ropinirole 10 261 
114 5 
22 3% 
8 
90 327% 21 
132 4 4 
Dextromethorphan 10 272 
215 5 
77 1% 
23 
81 7% 76 
147 5 11 
Cyclobenzaprine 10 276 
215 5 
39 -1%
150 
42 7% 39 
231 5 23 
Zolpidem 10 308 
92 4 
19 5% 
25 
20 11% 18 
235 5 23 
Alprazolam 5 309 
205 3 
87 0% 
6 
81 -7% 87 
281 3 4 
Fentanyl 10 337 
188 5 
76 9% 
13 
75 7% 70 
105 4 26 
Haloperidol 10 376 
123 4 
93 0% 
39 
91 -3% 93 
165 4 40 
Risperidone 10 411 
191 3 
8 3% 
141 
8 4% 8 
110 3 19 
9-hydroxyrisperidone 10 427 
207 3 
22 1% 
79 
24 9% 22 
110 3 16 
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Table 20: Cocktail L-Manual experiments had 14 scans per target and experiments run 
on the automated ionization source had 19 scans per target. Red shading indicates 
failure to meet detection criteria. 
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Nortriptyline 20 264 
233 31 
45 6% 
55 
44 4% 42 
117 12 23 
Atenolol 100 267 
145 6 
70 -10%
45 
77 -1% 78 
190 12 151 
Amitriptyline  20 278 
233 21 
62 1% 
37 
59 -4% 61 
117 14 46 
Diazepam 50 285 
154 18 
78 -3%
19 
81 0% 81 
222 22 34 
Benzoylecgonine 50 290 
168 11 
38 16% 
77 
51 55% 33 
77 4 4 
Hydrocodone 20 300 
199 19 
40 10% 
17 
56 54% 37 
171 10 5 
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Table 21: Cocktail M- Manual experiments had 13 scans per target and experiments run 
on the automated ionization source had 18 scans per target. Red shading indicates 
failure to meet detection criteria. 
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Nordiazepam 50 271 
140 44 
72 6% 
25 
72 -6% 68 
208 29 16 
Doxepin 20 280 
107 12 
48 -8%
28 
51 -2% 52 
165 15 28 
Hydromorphone  20 286 
185 6 
77 11% 
3 
105 53% 69 
157 4 3 
Oxazepam 50 287 
241 2 
89 511% 
2 
188 1151% 15 
77 1 2 
Codeine 20 300 
215 10 
74 23% 
4 
46 -25% 61 
199 4 5 
Temazepam 50 301 
177 2 
26 -17%
7 
47 48% 32 
239 3 3 
Cocaine 50 304 
182 46 
23 8% 
97 
22 2% 21 
82 14 49 
Citalopram 10 325 
262 16 
78 66% 
28 
68 44% 47 
234 6 12 
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6 INTERFERENCE STUDY 
In order for paper spray to be a viable approach to post-mortem toxicological 
screening it must be able to differentiate target analytes from endogenous substances that 
exist within a matrix, and it must also be able to differentiate target analytes from other 
exogenous compounds.  For example, PCP is one of the analytical targets of the 
developed screening method and is categorized as a schedule II controlled substance in 
the US, but it shares the same molecular weight as frovatriptan, a prescription migraine 
medication.  In this instance, the legal medication could affect the results for a controlled 
substance by producing a parent ion with the same mass to charge ratio.  It is therefore 
necessary to investigate the specificity of the developed method in producing accurate 
results in the presence of potentially interfering compounds.     
Interferences to the target analytes can arise from several different situations.  Both 
exogenous and endogenous isomers of an analyte may produce common daughter 
fragments with the target analyte, which would result in skewed fragmentation ratios and 
could create false negative results.  Compounds that do not share the same mass as the 
target could even interfere by producing adduct ions more complex than [M+H]+  that 
have the same mass to charge ratio as the protonated adduct of the target analyte.  
Isotopic interferences could also arise when molecules with moieties containing heavily 
abundant isotopes, such as chlorine or bromine, are present.  To a lesser extent, isotopic 
interferences in larger molecules could even arise due to the C-13 isotope if the 
interfering compound is found at a much higher concentration than the target analyte.  
Although this makes the list of potential interferences for the project’s 154 different 
analytical targets practically unquantifiable, investigating, to a reasonable extent, 
potentially interfering compounds will help inform data interpretation. 
To investigate compounds that could cause interferences with the developed drug 
screening method, potential interferences were sorted into two classifications: 
interferences that arise from exogenous substances potentially contained within blood, 
and intra-target interferences that arise from isomeric or isotopic parent ion overlap 
between the 154 analytical targets defined in the study.  
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6.1 Exogenous interferences 
While there are compounds that could produce isotopic interferences by generating 
the same parent ions as the target analytes in this project, these compounds would have to 
contain elements with relatively abundant isotopes (i.e. chlorine, bromine) and would 
have to be fairly concentrated within the matrix to become a true concern.  As the scope 
of identifying potentially interfering compounds is already wide, at this time the search 
has been limited to compounds that are biologically available to the matrix and have the 
same molecular weight as the target analytes.  To this end, two publically available 
databases were used to compile a list of potentially interfering compounds: the Human 
Metabolome Database63-65, a database of small molecule metabolites, and DrugBank, a 
searchable database that contains over 8232 drugs.66  Using these databases, 450 
potentially interfering exogenous compounds were identified that have the same 
molecular weight at the target analytes of this project.  These compounds are outlined in 
Appendix F. 
6.2 Intra-target interferences 
Out of the 154 analytical targets in this study, 43 positively ionizing analytes were 
identified that that have parent ions that share the same mass to charge ratio as another 
analyte, and could therefore be a source of interference.  These target analytes are 
presented in Table 22.  For an analyte to be a true interference to another target, it must 
produce at least one fragment as another target with the same parent ion, and it must 
produce this fragment in an abundance such that it alters the expected fragmentation ratio 
of the target analyte.  To this end, each of the 43 potentially interfering targets were 
spiked at 1ppm into 95:5:0.01 methanol:water:acetic acid and introduced into the mass 
spec via an ESI ionization source, where they were scanned for 60s for the daughter 
fragments of all the potentially interfering target analytes.  Each infusion was followed by 
a 60 second infusion of blank solvent to avoid carryover.  Topiramate was added to each 
solution at 100 ng/mL as an internal standard to monitor ionization.  The signal-to-blank
for topiramate never fell below 15:1 during all of the interference experiments, and the 
fragmentation ratio never deviated more than 8% from the established ratio.   
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During these preliminary experiments, 25 target analytes were identified that had 
a signal-to-blank greater than 3:1 when monitoring the SRM channels for a different 
analyte.  The results for the initial experiments using the ESI spray source are presented 
in Table 23.  These targets were investigated further, while the other 18 analytes were 
concluded to not be true interferences since they added no significant increase in signal at 
1000 ng/mL, a concentration much higher than the cutoff levels for most of the targets.
Table 22: Targets that share the same parent ion and could potentially interfere with 
one another. 
Name 
Cutoff 
in ng/mL MW 
Parent 
Ion 
Product 
Ion 1 
Product 
Ion 2 
Ion 
Ratio 
Primidone 5000 218 219.087 162.111 91.055 100:70 
Meprobamate 2000 218 219.096 158.134 97.105 100:101 
Amobarbital 500 226 225.116 182.139 42.066 100:47 
Pentobarbital 500 226 225.116 182.144 42.043 100:45 
Normeperidine 25 233 234.121 160.129 56.068 100:22 
Methylphenidate 20 233 234.122 84.086 56.072 100:12 
Phenytoin 5000 252 253.081 182.110 104.046 100:65 
Carbamazepine-10,11-
epoxide 
1000 252 253.088 180.092 210.110 100:36 
Lamotrigine 1000 255 256.010 210.993 144.949 100:65 
Diphenhydramine 25 255 256.129 167.098 165.073 100:48 
Carisoprodol 2000 260 261.144 97.097 55.065 100:81 
Ropinirole 10 260 261.145 114.128 86.099 100:25 
Nordoxepin 20 265 266.120 107.042 235.118 100:57 
Mirtazapine 50 265 266.133 195.104 194.091 100:41 
Norsertraline 100 291 275.030 158.974 123.990 100:26 
Chlorpheniramine 25 274 275.104 230.082 167.072 100:54 
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Table 22 Continued 
Name 
Cutoff 
in ng/mL MW
Parent 
Ion 
Product 
Ion 1 
Product 
Ion 2 
Ion 
Ratio 
MDPV 50 275 276.127 175.086 135.041 100:91 
Cyclobenzaprine 10 275 276.141 215.092 216.106 100:56 
EDDP 25 277 278.146 234.128 249.166 100:51 
Venlafaxine 50 277 278.154 58.083 121.063 100:26 
7-aminoclonazepam 10 285 286.057 222.134 121.109 100:85 
Morphine 20 285 286.107 152.057 165.062 100:70 
Pentazocine 50 285 286.162 218.155 69.068 100:29 
Desalkylflurazepam 50 288 289.035 140.015 226.092 100:66 
Bupivacaine 500 288 289.165 140.126 98.094 100:19 
Chlordiazepoxide 50 299 300.070 227.044 241.056 100:27 
Metoclopramide 100 299 300.125 227.057 184.026 100:51 
Sertraline 100 305 306.067 158.971 275.068 100:84 
Zaleplon 25 305 306.106 236.088 264.123 100:85 
Zolpidem 10 307 308.136 235.158 92.076 100:19 
Benztropine 10 307 308.149 167.074 165.069 100:68 
Norpropoxyphene 50 325 308.155 100.064 44.064 100:71 
Fluoxetine 20 309 310.106 44.069 148.105 100:6 
Methadone 25 309 310.156 265.166 105.027 100:34 
Norclozapine 50 312 313.096 192.062 270.081 100:70 
Olanzapine 50 312 313.124 256.070 198.025 100:49 
Clomipramine 20 314 315.120 86.087 58.072 100:37 
Ranitidine 500 314 315.124 176.061 102.026 100:53 
delta9-THC 10 314 315.167 193.130 123.032 100:65 
Clonazepam 10 315 316.000 270.156 214.002 100:36 
Oxycodone 20 315 316.115 241.094 256.128 100:82 
Brompheniramine 25 318 319.060 274.026 167.065 100:52 
Chlorpromazine 50 318 319.084 86.090 58.075 100:46 
Fluvoxamine 20 318 319.126 71.047 200.007 100:24 
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Table 23: Using an ESI spray source, targets were analyzed at 1000 ng/mL in solution
for the transitions used in the analysis of other targets which share the same parent ion. 
S:B less than 3:1 indicated that the target would not interfere with the channels scanned 
for the other target, while a greater signal routed targets through additional interference 
testing. The following 25 targets were found to have S:B greater than 3:1 for the 
transitions recorded below 
Table 23 Continued 
Target Present in 
Neat Solution 
Target whose 
fragments were 
scanned for 
SRM AUC S:B 
Methylphenidate Normeperdine 324 -> 56 
Blank 5.4E+03 
8586 
Interference 4.6E+07 
Lamotrigine Diphenhydramine 256 -> 165 
Blank 8.0E+03 
1201 
Interference 9.6E+06 
Ranitidine Clomipramine 
315 -> 86 
Blank 6.2E+04 
4 
Interference 2.5E+05 
315 -> 58 
Blank 2.6E+04 
90 
Interference 2.3E+06 
Methadone Fluoxetine 
310 -> 44 
Blank 6.0E+01 
64 
Interference 3.8E+03 
310 ->148 
Blank 3.0E+01 
6 
Interference 1.9E+02 
Normeperidine Methylphenidate 
234 -> 84 
Blank 5.6E+03 
5 
Interference 2.5E+04 
234 ->56 
Blank 3.4E+03 
7478 
Interference 2.5E+07 
Pentazocine 
7-Aminoclonazepam
286 -> 94 
Blank 1.8E+03 
63 
Interference 1.1E+05 
286 -> 121 
Blank 4.2E+03 
497 
Interference 2.1E+06 
Morphine 
286 -> 152 
Blank 1.0E+03 
3059 
Interference 3.2E+06 
286  -> 165 
Blank 1.7E+03 
77 
Interference 1.3E+05 
Normeperidine Methylphenidate 
234 -> 84 
Blank 5.4E+03 
5 
Interference 2.5E+04 
234 -> 56 
Blank 3.4E+03 
7478 
Interference 2.5E+07 
70
Table 23 Continued 
Target Present in 
Neat Solution 
Target whose 
fragments were 
scanned for 
SRM AUC S:B 
Benzotropine Zolpidem 
308 -> 92 
Blank 1.8E+03 
54 
Interference 9.6E+04 
308 -> 44 
Blank 1.5E+03 
38 
Interference 5.7E+04 
Morphine 7-Aminoclonazepam
286 -> 94 
Blank 9.0E+02 
140 
Interference 1.3E+05 
286 -> 121 
Blank 2.0E+03 
327 
Interference 6.7E+05 
Oxycodone Clonazepam 
316 -> 270 
Blank 1.4E+04 
74 
Interference 1.0E+06 
316 -> 214 
Blank 2.7E+03 
123 
Interference 3.3E+05 
Norpropoxyphene Benzotropine 308 -> 165 
Blank 6.6E+05 
5 
Interference 3.1E+06 
Bromopheniramine Fluvoxamine 
319 ->71 
Blank 2.8E+05 
3 
Interference 9.9E+05 
319 -> 200 
Blank 6.2E+04 
4 
Interference 2.2E+05 
Chlorpromazine 
Brompheniramine 
319 -> 274 
Blank 4.1E+05 
52 
Interference 2.1E+07 
319 -> 167 
Blank 2.2E+05 
23 
Interference 5.1E+06 
Fluvoxamine 
319 -> 71 
Blank 2.7E+05 
7 
Interference 1.9E+06 
319 -> 200 
Blank 6.0E+04 
5 
Interference 3.0E+05 
Norclozapine Olanzapine 
313 -> 256 
Blank 2.8E+02 
3978 
Interference 1.1E+06 
313 -> 198 
Blank 7.7E+01 
229 
Interference 1.8E+04 
7-Aminoclonazepam Morphine 
286 -> 152 
Blank 3.2E+04 
52 
Interference 1.7E+06 
286 -> 165 
Blank 2.5E+04 
6 
Interference 1.4E+05 
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Table 23 Continued 
Target Present in 
Neat Solution 
Target whose 
fragments were 
scanned for 
SRM AUC S:B 
Chlordiazepoxide Metoclopramide 300 -> 227 
Blank 5.7E+05 
300 
Interference 1.7E+08 
Clonazepam Oxycodone 
316 -> 241 
Blank 1.1E+03 
941 
Interference 1.1E+06 
316 -> 212 
Blank 1.1E+03 
13 
Interference 1.4E+04 
Desalkylflurazepam Bupivicaine 
289 -> 140 
Blank 1.5E+03 
11121 
Interference 1.7E+07 
289 -> 98 
Blank 1.4E+03 
3 
Interference 4.7E+03 
Cyclobenzapirine MDPV 
276 -> 175 
Blank 3.1E+03 
11 
Interference 3.4E+04 
276 -> 135 
Blank 3.5E+03 
3 
Interference 1.1E+04 
Cabamazepine, 
10-,11-epoxide 
Phenytoin 
253 -> 182 
Blank 3.5E+02 
25237 
Interference 8.9E+06 
253 -> 104 
Blank 3.8E+02 
119 
Interference 4.5E+04 
Clomipramine Ranitidine 
315 ->176 
Blank 3.6E+03 
8 
Interference 2.9E+04 
315 -> 102 
Blank 7.0E+02 
36 
Interference 2.5E+04 
Fluvoxamine 
Brompheniramine 
319 -> 274 
Blank 2.5E+03 
21 
Interference 5.2E+04 
319 -> 167 
Blank 5.2E+03 
7 
Interference 3.5E+04 
Chlorpromazine 319 -> 58 
Blank 7.3E+03 
5 
Interference 3.8E+04 
Mirtazapine Nordoxepin 
266 -> 107 
Blank 1.7E+03 
1196 
Interference 2.0E+06 
266 ->235 
Blank 3.0E+02 
47460 
Interference 1.4E+07 
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Table 23 Continued 
Target Present in 
Neat Solution 
Target whose 
fragments were 
scanned for 
SRM AUC S:B 
Nordoxepin Mirtazapine 
266 -> 195 
Blank 1.3E+06 
12 
Interference 1.5E+07 
266 -> 194 
Blank 7.0E+05 
14 
Interference 9.8E+06 
In the next round of testing, the 25 targets identified using the ESI spray source 
were tested using paper spray.  Targets sharing the same parent ion were combined at 
100ppb in the spray solvent (95:5:0.01 methanol:water:acetic acid) and sprayed over 
blank paper.  All of the fragment ions were scanned and targets ratios were monitored to 
see if the presence of the interfering compound caused the target’s ratio to vary more than 
the permitted ±30%.  The results of these experiments, found in Table 24, indicate that 
out of the 20 target pairs/groups, only 9 targets may produce false negatives in the 
presence of another target that shares a parent ion with it.  These targets are: phenytoin, 
norsertraline, desalkylflurazepam, chlordizepoxide, metoclopramide, zaleplon, 
benztropine, fluoxetine, and olanzapine. The transitions belonging to methadone were 
unintentionally left out of this series of tests, and no conclusion is made about the affect 
of the presence of fluoxetine on methadone at this time. 
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Table 24 Targets with the same parent ion were each added at 100 ng/mL to the
spray solvent and sprayed over blank paper.  The fragmentation ion for each target 
was monitored and those that differed from their established ratio by greater than 
the permissible deviation of ±30% were flagged, as shown in red.  The remaining 
targets were concluded to not interfere with one another 
Table 24 continued 
Name 
Parent 
Ion 
Product 
Ion 1 
Peak 
Area 
Product 
Ion 2 
Peak 
Area 
Ratio 
Ratio 
Deviation 
(%) 
Primidone 219 162 2.77E+06 91 1.99E+06 72 2.7 
Meprobamate 219 158 1.21E+06 97 1.24E+06 102 1.2 
Amobarbital 225 182 1.27E+08 42 6.12E+07 48 0.0 
Pentobarbital 225 182 1.27E+08 42 6.12E+07 48 0.1 
Normeperidine 234 160 4.80E+07 56 1.22E+07 25 15.3 
Methylphenidate 234 84 8.50E+07 56 1.22E+07 14 19.3 
Phenytoin 253 182 2.75E+06 104 5.44E+05 20 -69.6
Carbamazepine-10,11-
epoxide 
253 180 1.50E+07 210 5.69E+06 38 5.6 
Lamotrigine 256 211 1.48E+07 145 9.20E+06 62 -4.2
Diphenhydramine 256 167 8.80E+07 165 3.98E+07 45 -5.8
Carisoprodol 261 97 1.56E+06 55 1.31E+06 84 3.7 
Ropinirole 261 114 1.31E+08 86 3.03E+07 23 -7.4
Nordoxepin 266 107 6.79E+07 235 4.25E+07 63 9.8 
Mirtazapine 266 195 1.85E+08 194 7.06E+07 38 -6.8
Norsertraline 275 159 1.99E+07 124 1.41E+06 7 -72.7
Chlorpheniramine 275 230 1.40E+08 167 7.26E+07 52 -4.3
MDPV 276 175 7.22E+07 135 6.56E+07 91 -0.2
Cyclobenzaprine 276 215 1.83E+08 216 1.01E+08 55 -1.6
EDDP 278 234 2.90E+08 249 1.16E+08 40 -21.7
Venlafaxine 278 58 6.41E+07 121 1.65E+07 26 -1.3
7-aminoclonazepam 286 222 1.13E+07 121 9.02E+06 80 -5.8
Morphine 286 152 6.45E+06 165 3.92E+06 61 -13.1
Pentazocine 286 218 1.08E+10 69 2.46E+09 23 -21.7
Desalkylflurazepam 289 140 2.02E+08 226 4.84E+06 2 -96.4
Bupivacaine 289 140 2.02E+08 98 4.34E+07 21 12.8 
Chlordiazepoxide 300 227 2.88E+08 241 3.14E+07 11 -59.7
Metoclopramide 300 227 6.70E+10 184 8.86E+07 0 -99.7
Sertraline 306 159 5.43E+07 275 4.55E+07 84 -0.2
Zaleplon 306 236 9.78E+06 264 5.16E+06 53 -37.9
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Table 24 continued 
Name 
Parent 
Ion 
Product 
Ion 1 
Peak 
Area 
Product 
Ion 2 
Peak 
Area 
Ratio 
Ratio 
Deviation 
(%) 
Zolpidem 308 235 3.17E+08 92 5.71E+07 18 -5.4
Benztropine 308 167 3.92E+08 165 1.81E+08 46 -32.0
Norpropoxyphene 308 100 2.40E+07 44 1.61E+07 67 -5.1
Fluoxetine 310 44 1.83E+07 148 2.32E+06 13 111.8 
Methadone 310 265 - 105 7.04E+07 - - 
Norclozapine 313 192 1.24E+08 270 8.86E+07 72 2.4 
Olanzapine 313 256 1.99E+07 198 5.39E+06 27 -44.7
Clomipramine 315 86 1.06E+08 58 3.78E+07 36 -3.3
Ranitidine 315 176 4.24E+07 102 2.22E+07 52 -1.3
Clonazepam 316 270 1.19E+07 214 3.83E+06 32 -10.8
Oxycodone 316 241 1.53E+07 256 1.15E+07 75 -8.3
Brompheniramine 319 274 1.29E+08 167 6.25E+07 48 -7.1
Chlorpromazine 319 86 1.20E+08 58 5.35E+07 45 -2.9
Fluvoxamine 319 71 2.57E+07 200 5.51E+06 21 -10.6
6.3 Conclusions and Future Work 
Using database searches, 540 compounds were found who could potentially 
interfere with the target analytes of this study.  They would only be true interferences 
though, if they exist at detectable concentrations, ionize via protonation and produce a 
daughter fragment with the same mass to charge ratio as one that is monitored for one of 
the analytical targets.   
Nine targets were identified who could interfere with other targets and provide false 
negatives by skewing the fragmentation ratios outside of the permitted ±30% deviation. 
Carbamazepine-10,11-epoxide was identified as a potential interference for phenytoin,
and chlorphenirameine was identified as a potential interferences for norsertraline.  
Bupivacaine was identified as a potential interference to desalkylflurazepam, which is to 
be assumed to be a true interference since both analytes monitor the fragment with m/z 
140. Likewise, chlordiazepoxide and metoclopramide interfere with one another because
they both share the fragment with m/z 227.  Sertraline was identified as a potential 
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interference for zaleplon, and methadone was identified as a potential interference to 
fluoxetine.  Finally, norclozapine was identified as a potential interference to the 
detection of olanzapine. 
A final set of experiments needs to be run to confirm the effect of intra-target 
interferences.  The nine analytes that were identified as potential interferences in neat 
solution need to be analyzed in blood along with the targets that seem to cause their 
fragmentation ratios to skew.  The extraction efficiencies and the ionization suppression 
will likely be different for each target, so the targets should be run together with the 
interfering compound at a very high concentration to test for a “worst case scenario,” and 
they should also be run at the cutoff levels for a more realistic assessment of the extent to 
which they may interfere.  
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7 CONCLUSIONS 
Drug screening is a necessary tool in postmortem investigations that focuses 
analytical efforts, time, and resources.  Currently, drug screening itself can consume 
huge amounts of time and money in sample clean-up and analysis, and adding newly 
emerging compounds can be cumbersome.  Paper Spray Mass Spectrometry provides an 
alternative method for drug screening that drastically simplifies the screening process, 
allowing for rapid detection of a wide variety of drugs. While paper spray analysis has 
historically been applied to a small focused panel of targets, by adapting existing 
techniques, it has been found to be suitable to use in large-panel screening as well.   
7.1 Summary of Conclusions 
Two methods were developed during this project: the first was a manually run 
method that used hand-cut paper.  By detecting two daughter fragments and by
monitoring the ratio between their relative abundancies, this method was able to detect 
114 drugs and metabolites at toxicologically relevant concentrations in blood.  Using this 
method, screening the entire panel of drugs can be accomplished in three sixty second 
runs, requiring only 10.5 µL of blood.  Screening these 114 targets, this “manual” method 
would require approximately 9 minutes total analysis time.  In order to really make paper 
spray a viable alternative, a second, more automated and commercially available method 
was developed as well. 
The second method used commercially available disposable cartridges on an 
automated ionization source.  Under the same detection criteria used in the manually run 
experiments, this method was able to successfully detect a panel of 100 drugs and 
metabolites at toxicologically relevant concentrations in blood.  This method would also 
require 3 replicate dried blood spot samples due to the time needed for the mass 
spectrometer to scan through all of the SRM channels.  Because of the larger paper size, 
this method uses almost four times as much blood as the manual method, but the total 
volume of blood required is still less than 50 µL.  The automated method has the same 
analytical run time 
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as the manual method, however, there is very little down time between samples since the 
cartridges do not have to be cleaned, so the entire screening process can be accomplished 
in about 4 minutes. 
In addition to the successively developed methods, a list of potentially interfering 
compounds was compiled that can inform future data interpretation. Within the analytes 
on the panel tested, 9 were identified that could potentially interfere with one another and 
lead to false negatives if both a present in a sample.  
7.2 Discussion 
The target levels of detection used in developing these methods were based on the
lower limit of quantitation for methods used at a local toxicology laboratory.  While the 
level of detection for paper spray was found to be higher than the LLOQ presented by the 
toxicology laboratory in some instances, other times targets were run at lower 
concentrations than the reported LLOQ’s.    In the instances where PS-MS was not
sufficiently sensitive, it will be important to determine if the LOD is at a toxicologically 
relevant concentration; in the cases where it is more sensitive, paper spray could help 
properly route samples into confirmatory testing which could potentially be false 
negatives when analyzed using other methods. 
The concentrations, whether run at proposed cutoff levels or experimental LOD’s, 
used during analysis were established in method development using the manual method. 
The higher number of target analytes that were ultimately able to be detected in the 
manual method vs the automated method using the laser-cut paper suggest room for 
further method optimization and development for the automated method.  Although only 
about half as many targets were analyzed on die-cut paper as laser-cut paper, the percent 
of targets detected on the die-cut paper (87%) is much more congruent with the manual 
method (86%) than the laser-cut paper is (76%).  It is possible that the laser cutting 
approach used during manufacturing requires some refinement.  If this is the case, a new 
LOD may need to be established using the laser-cut paper, especially in the 11 cases 
where a target was detected using the manual method, but not using the automated 
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method with the laser-cut paper.  Revisiting blood spot placement and dilution could also 
prove advantageous for future experiments run on the laser-cut paper. 
In this project, 14 of the originally proposed analytical targets were not included 
because preliminary tests showed that they only ionized well in negative mode and would 
require further optimization in order to reach acceptable limits of detection.  This work 
was completed in a separate project, by McKenna et. al. where an optimized solvent of
90:10:0.01 MeOH:CCl4:NH4OH was used to successfully detect all 14 targets, 4 of 
which were determined to have LOD’s slightly higher than the purposed screening cutoff 
concentrations.67  This work was done on an exact mass instrument, but would be 
translated to a triple quadrupole instrument.  
7.3 Future work 
The next set of experiments that need to be run are establishing calibration curves 
for each of the analytes.  This will establish an experimental LOD and can help inform 
acceptance criteria.  One of the largest hurdles faced in this project was establishing a 
permissible ratio tolerance.  Ratio tolerances are always discussed in the context of 
chromatography, and usually at concentrations well above the LOD.  Since no intentional 
chromatography is performed during PS and this project deals with some analytes near or 
at their LOD, running calibration curves will help establish the robustness of fragment 
ion ratios in a context that has yet to be established.  This could lead to justifying either 
broadening or constricting the current ±30% permissible deviation, or even a ratio 
tolerance that is tied to signal to blank ratio.  To run a set of calibration curves, internal 
standards (IS) will need to be chosen.  Since it is impractical to use a stable-labeled 
internal standard for every target, work will need to be done to find a reasonable number 
of analogue standards that can act as internal standards for the entire panel of targets.  
Ideally, these IS’s could be cocktailed together and spiked directly into a sample.  
In addition to running calibration curves, a final blinded study of postmortem 
samples should be run to determine the effectiveness of the assay on true postmortem 
samples.  These will included blood in various degrees of decomposition and can be used 
to determine the false positive and false negative rate of the assay. 
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APPENDIX A 
Purposed Analytical Targets with Cutoff Values from AFT 
Target Drug Class 
Target Screening Cutoff 
(ng/mL) 
Chemical Structure 
Acetaminophen Analgesic 20000 
Alfentanil Narcotic 50 
Alpha-PVP Stimulant 50 
Alprazolam Benzodiazepine 5 
Amitriptyline Antidepressant 20 
Amlodipine Cardiovascular 20 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
Amobarbital Barbiturate 500 
Amphetamine Amphetamine 50 
Aripiprazole Antipsychotic 50 
Atenolol Cardiovascular 100 
Baclofen Analgesic 1000 
Benzoylecgonine Cocaine 50 
Benztropine Neurological 10 
Benzylpiperazine Miscellaneous 50 
Brompheniramine Antihistamine 25 
Bupivacaine Anesthetic 500 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
Buprenorphine Analgesic 1 
 
Bupropion Antidepressant 50 
 
Buspirone Antipsychotic 10 
 
Butabarbital Barbiturate 500 
 
Butalbital Barbiturate 500 
 
Carbamazepine Anticonvulsant 1000 
 
Carbamazepine-10,11-
epoxide 
Anticonvulsant 1000 
 
Carisoprodol Analgesic 2000 
 
Chlordiazepoxide Benzodiazepine 50 
 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
Chlorpheniramine Antihistamine 25 
Chlorpromazine Antipsychotic 50 
Citalopram Antidepressant 10 
Clomipramine Antidepressant 20 
Clonazepam Benzodiazepine 10 
Clozapine Antipsychotic 50 
Cocaethylene Cocaine 50 
Cocaine Cocaine 50 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
Codeine Opiate 20 
 
Cyclobenzaprine Analgesic 10 
 
delta9-THC Cannabinoid 10 
 
Demoxepam Benzodiazepine 50 
 
Desalkylflurazepam Benzodiazepine 50 
 
Desipramine Antidepressant 20 
 
Desmethylclomipramine Antidepressant 20 
 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
Dextromethorphan Narcotic 10 
Diazepam Benzodiazepine 50 
Diltiazem Cardiovascular 50 
Diphenhydramine Antihistamine 25 
Donepezil Neurological 50 
Doxepin Antidepressant 20 
Doxylamine Antihistamine 25 
Duloxetine Antidepressant 20 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
EDDP Methadone 25 
 
Ephedrine/Pseudoephedrine Amphetamine 50 
 
Etomidate Anesthetic 100 
 
Felbamate Anticonvulsant 10000 
 
Fentanyl Fentanyl 1 
 
Flecainide Cardiovascular 500 
 
Flunitrazepam Sedative/Hypnotic 20 
 
Fluoxetine Antidepressant 20 
 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
Flurazepam Benzodiazepine 25 
Fluvoxamine Antidepressant 20 
Furosemide Cardiovascular 1000 
Gabapentin Anticonvulsant 500 
Haloperidol Antipsychotic 10 
Hydrochlorothiazide Cardiovascular 100 
hydrocodone Opiate 20 
hydromorphone Opiate 20 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
Hydroxychloroquine Analgesic 2000 
 
Hydroxyzine Antihistamine 10 
 
Ibuprofen Analgesic 10000 
 
Ketamine Anesthetic 100 
 
Labetalol Cardiovascular 50 
 
Lamotrigine Anticonvulsant 1000 
 
Levetiracetam Anticonvulsant 2000 
 
Lidocaine Anesthetic 500 
 
Lorazepam Benzodiazepine 25 
 
mCPP Antidepressant 20 
 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
MDA Amphetamine 50 
 
MDMA Amphetamine 50 
 
MDPV Stimulant 50 
 
Meperidine Narcotic 25 
 
Mephedrone Stimulant 50 
 
Meprobamate Analgesic 2000 
 
Mescaline Miscellaneous 50 
 
Metaxalone Analgesic 1000 
 
Methadone Methadone 25 
 
Methamphetamine Amphetamine 50 
 
Methocarbamol Analgesic 1000 
 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
Methylone Stimulant 50 
 
Methylphenidate Stimulant 20 
 
Metoclopramide Gastrointestinal 100 
 
Metoprolol Cardiovascular 50 
 
Midazolam Anesthetic 50 
 
Mirtazapine Antidepressant 50 
 
Morphine Opiate 20 
 
Naproxen Analgesic 30000 
 
Norbuprenorphine Analgesic 1 
 
Norclozapine Antipsychotic 50 
 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
Nordiazepam Benzodiazepine 50 
 
Nordoxepin Antidepressant 20 
 
Norfluoxetine Antidepressant 20 
 
Norketamine Anesthetic 100 
 
Normeperidine Narcotic 25 
 
Norpropoxyphene Propoxyphene 50 
 
Norsertraline Antidepressant 100 
 
Nortramadol Analgesic 100 
 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
Nortriptyline Antidepressant 20 
 
Norvenlafaxine Antidepressant 50 
 
Olanzapine Antipsychotic 50 
 
Oxazepam Benzodiazepine 50 
 
Oxycodone Opiate 20 
 
Oxymorphone Opiate 20 
 
Papaverine Cardiovascular 500 
 
Paroxetine Antidepressant 20 
 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
PCP Phencyclidine 25 
Pentazocine Narcotics 50 
Pentobarbital Barbiturate 500 
Phenobarbital Barbiturate 2000 
Phenytoin Anticonvulsant 5000 
Pregabalin Anticonvulsant 500 
Primidone Anticonvulsant 5000 
Promethazine Sedative/Hypnotic 25 
Propoxyphene Propoxyphene 50 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
Propranolol Cardiovascular 50 
 
Quetiapine Antipsychotic 50 
 
Ranitidine Gastrointestinal 500 
 
Risperidone Antipsychotic 10 
 
Ropinirole Neurological 10 
 
Salicylic Acid Analgesic 9000 
 
Secobarbital Barbiturate 500 
 
Sertraline Antidepressant 100 
 
Sildenafil Urological 100 
 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
Tadalafil Urological 100 
 
Temazepam Benzodiazepine 50 
 
TFMPP Miscellaneous 50 
 
Thiopental Sedative/Hypnotic 2000 
  
Topiramate Anticonvulsant 2000 
 
Tramadol Analgesic 100 
 
Trazodone Antidepressant 100 
 
Triazolam Benzodiazepine 20 
 
Trimipramine Antidepressant 20 
 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
Valproic Acid Anticonvulsant 5000 
 
Vardenafil Urological 100 
 
Venlafaxine Antidepressant 50 
 
Verapamil Cardiovascular 50 
 
Warfarin Cardiovascular 500 
 
Zaleplon Sedative/Hypnotic 25 
 
Ziprasidone Antipsychotic 10 
 
Zolpidem Sedative/Hypnotic 10 
 
Zonisamide Anticonvulsant 10000 
 
Target Drug Class 
Target Screening 
Cutoff (ng/mL) 
Chemical Structure 
Zopiclone Sedative/Hypnotic 10 
10-
monohydroxyoxcarbazepine 
Anticonvulsant 1000 
11-nor-9-Carboxy-THC Cannabinoid 10 
6-acetylmorphine Opiate 20 
7-aminoclonazepam Benzodiazepine 10 
7-aminoflunitrazepam Sedative/Hypnotic 20 
9-hydroxyrisperidone Antipsychotic 10 
APPENDIX B 
Detailed results from loading capacity and blood dilution study for the five targets 
analyzed in Chapter 4. 
Morphine 
Whole 
Blood 
Diluted 
Blood 
Whole 
Blood 
Diluted 
Blood 
Whole 
Blood 
Diluted 
Blood 
Fragment 286 -> 152 286 -> 165 286 -> 201 
5
 u
L
 
Avg Blank 7.7E+03 5.6E+03 4.8E+03 4.7E+03 3.1E+05 3.7E+05 
Stdev 4.3E+03 1.0E+03 2.5E+03 5.3E+02 7.2E+04 4.4E+04 
Avg Drug 6.0E+04 7.5E+04 4.1E+04 5.3E+04 3.9E+05 4.1E+05 
Stdev 6.5E+03 7.6E+03 3.6E+03 4.8E+03 8.3E+04 1.5E+04 
S:B 7.8 14 8.4 11 1.3 1.1 
1
0
 u
L
 
Avg Blank 8.5E+03 4.1E+03 4.9E+03 2.4E+03 5.0E+05 2.5E+05 
Stdev 6.7E+03 2.6E+03 3.3E+03 1.3E+03 7.3E+04 1.7E+04 
Avg Drug 5.6E+04 6.5E+04 4.0E+04 4.7E+04 4.5E+05 3.5E+05 
Stdev 3.1E+03 2.1E+03 1.8E+03 1.7E+03 1.1E+05 5.7E+04 
S:B 6.6 16 8.1 20 0.90 1.4 
2
0
 u
L
 
Avg Blank 3.4E+03 8.7E+02 2.0E+03 6.3E+02 2.0E+03 1.2E+05 
Stdev 1.2E+03 4.3E+02 6.2E+02 3.4E+02 6.2E+02 4.6E+04 
Avg Drug 4.6E+04 5.3E+04 3.2E+04 3.7E+04 3.2E+04 2.6E+05 
Stdev 1.4E+04 1.0E+04 9.1E+03 7.2E+03 9.1E+03 7.4E+04 
S:B 13 61 16 9 16 2.3 
4
0
 u
L
 
Avg Blank 3.9E+03 8.8E+02 2.6E+03 6.8E+02 3.7E+05 9.8E+04 
Stdev 3.5E+03 1.3E+02 2.2E+03 2.3E+02 7.5E+04 3.3E+04 
Avg Drug 5.4E+04 3.7E+04 3.8E+04 2.6E+04 3.3E+05 2.1E+05 
Stdev 6.5E+03 6.2E+02 4.4E+03 3.2E+02 2.8E+04 5.9E+04 
S:B 14 42 15 38 0.89 2.2 
105
Zolpidem 
Whole 
Blood 
Diluted 
Blood 
Whole 
Blood 
Diluted 
Blood 
Fragment 308 -> 92 308 -> 235 
5
 u
L
 
Avg Blank 2.9E+04 1.7E+04 1.3E+05 7.2E+04 
Stdev 1.3E+04 5.8E+03 6.4E+04 2.9E+04 
Avg Drug 1.7E+05 1.3E+05 8.9E+05 6.7E+05 
Stdev 1.3E+04 1.9E+04 6.7E+04 9.3E+04 
S:B 6.0 8.0 6.7 9.3 
1
0
 u
L
 
Avg Blank 1.3E+04 8.0E+03 4.4E+04 3.2E+04 
Stdev 9.5E+03 3.6E+03 3.5E+04 1.6E+04 
Avg Drug 2.0E+05 1.4E+05 1.1E+06 7.3E+05 
Stdev 1.3E+04 1.3E+04 8.2E+04 8.1E+04 
S:B 15 17 24 23 
2
0
 u
L
 
Avg Blank 9.6E+03 2.9E+03 4.2E+04 1.2E+04 
Stdev 3.8E+03 1.2E+03 1.8E+04 5.3E+03 
Avg Drug 1.6E+05 1.0E+05 8.5E+05 5.5E+05 
Stdev 5.4E+04 1.4E+04 2.9E+05 7.3E+04 
S:B 17 36 20 44 
4
0
 u
L
 
Avg Blank 1.6E+04 4.0E+03 7.9E+04 2.0E+04 
Stdev 1.5E+04 3.7E+02 7.3E+04 4.5E+02 
Avg Drug 1.8E+05 6.7E+04 9.6E+05 3.5E+05 
Stdev 2.0E+04 2.7E+03 1.0E+05 1.3E+04 
S:B 11 17 12 18 
106
Fentanyl 
Whole 
Blood 
Diluted 
Blood 
Whole 
Blood 
Diluted 
Blood 
Whole 
Blood 
Diluted 
Blood 
Fragment 337 -> 79 337 -> 105 337 -> 188 
5
 u
L
 
Avg Blank 3.4E+04 2.6E+04 4.7E+04 3.4E+04 2.5E+04 1.3E+04 
Stdev 1.7E+04 2.8E+03 2.1E+04 3.0E+03 1.0E+04 5.1E+03 
Avg Drug 7.6E+04 8.1E+04 1.8E+05 1.5E+05 1.5E+05 1.0E+05 
Stdev 1.7E+04 1.5E+04 2.7E+04 1.2E+04 2.0E+04 1.8E+03 
S:B 2.3 3.1 3.9 4.5 6.0 7.8 
1
0
 u
L
 
Avg Blank 4.2E+04 1.9E+04 3.9E+04 1.9E+04 7.8E+03 5.2E+03 
Stdev 2.6E+04 7.1E+03 2.4E+04 7.5E+03 5.4E+03 2.3E+03 
Avg Drug 7.5E+04 5.9E+04 2.4E+05 1.4E+05 2.2E+05 1.1E+05 
Stdev 6.1E+03 8.6E+03 2.3E+04 7.0E+03 2.5E+04 1.6E+04 
S:B 1.8 3.2 6.2 7.6 28 22 
2
0
 u
L
 
Avg Blank 1.6E+04 4.6E+03 1.6E+04 5.8E+03 6.0E+03 2.8E+03 
Stdev 2.1E+03 2.7E+03 3.5E+03 2.8E+03 2.1E+03 1.3E+03 
Avg Drug 6.4E+04 4.4E+04 6.4E+04 1.3E+05 1.6E+05 1.1E+05 
Stdev 1.8E+04 6.7E+03 1.8E+04 1.3E+04 5.0E+04 1.1E+04 
S:B 4.0 9.4 3.9 22 27 38 
4
0
 u
L
 
Avg Blank 1.5E+04 3.6E+03 1.9E+04 6.6E+03 1.1E+04 5.0E+03 
Stdev 1.0E+04 4.8E+02 1.5E+04 5.6E+01 9.0E+03 5.0E+02 
Avg Drug 6.7E+04 2.9E+04 2.4E+05 9.4E+04 2.1E+05 8.7E+04 
Stdev 3.3E+03 2.9E+02 2.1E+04 3.8E+03 2.2E+04 2.2E+03 
S:B 4.6 8.0 12 14 19 17 
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APPENDIX C 
Mass spec parameters for purposed targets after tuning on triple quadrupole 
Target Q1 Q3 CE S lens Ion ratio 
Acetaminophen 152 110 16 59 100: 30 
65 30 
Alfentanil 417 268 17 95 100: 62 
197 26 
Alpha-PVP 232 91 24 69 100: 41 
77 43 
Alprazolam 309 205 41 111 100: 87 
281 25 
Amitriptyline 278 233 16 81 100: 61 
117 30 
Amlodipine 409 238 11 58 100: 67 
294 11 
Amphetamine 136 91 17 34 100: 25 
119 6 
Aripiprazole 448 285 25 146 100: 28 
176 31 
Atenolol 267 145 26 85 100: 78 
190 18 
Baclofen 214 151 18 52 100: 88 
115 45 
Benztropine 308 167 29 106 100: 45 
165 50 
Benzoylecgonine 290 168 19 85 100: 33 
77 48 
Benzylpiperazine 177 91 22 59 100: 12 
85 16 
Brompheniramine 319 274 19 62 100: 47 
167 41 
Bupivacaine 289 140 20 73 100: 17 
98 34 
110
Target Q1 Q3 CE S lens Ion ratio 
Bupropion 240 184 12 53 100: 55 
131 27 
Buspirone 386 122 31 127 100: 18 
95 50 
Carbamazepine 237 194 19 82 100: 30 
192 23 
Carbamazepine-10,11-epoxide 253 180 30 58 100: 36 
210 15 
Carisoprodol 261 97 16 42 100: 83 
55 29 
Chlordiazepoxide 300 227 25 75 100: 22 
255 20 
Chlorpheniramine 275 230 17 58 100: 53 
167 41 
Chlorpromazine 319 214 39 78 100: 26 
58 35 
Citalopram 325 262 19 95 100: 47 
234 28 
Clomipramine 315 227 40 75 100: 73 
242 26 
Clonazepam 316 270 24 136 100: 32 
214 36 
Clozapine 327 270 22 88 100: 64 
192 43 
Cocaethylene 318 196 19 78 100: 27 
82 32 
Cocaine 304 182 19 94 100: 21 
82 31 
Codeine 300 215 25 97 100: 61 
199 30 
Cyclobenzaprine 276 215 40 87 100: 39 
231 17 
Demoxepam 287 180 22 113 100: 65 
207 36 
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Target Q1 Q3 CE S lens Ion ratio 
Desalkylflurazepam 289 140 29 91 100: 66 
226 27 
Desipramine 267 72 16 68 100: 20 
193 38 
Desmethylclomipramine 301 72 17 73 100: 17 
227 37 
Dextromethorphan 272 215 23 107 100: 76 
147 30 
Diazepam 285 154 26 94 100: 81 
222 26 
Diltiazem 415 178 24 94 100: 44 
150 41 
Diphenhydramine 256 167 15 46 100: 43 
165 39 
Donepezil 380 91 36 112 100: 16 
243 26 
Doxepin 280 107 23 89 100: 52 
165 56 
Doxylamine 271 167 34 54 100: 88 
182 16 
Duloxetine 298 44 14 41 100: 87 
154 5 
EDDP 278 234 31 89 100: 42 
249 23 
Ephedrine/Pseudoephedrine 166 115 27 44 100: 86 
117 19 
Etomidate 245 141 10 45 100: 66 
95 24 
Felbamate 239 117 16 40 100: 64 
178 5 
Fentanyl 337 188 22 104 100: 70 
105 35 
Flecainide 415 301 32 127 100: 38 
98 29 
112
Target Q1 Q3 CE S lens Ion ratio 
Flunitrazepam 314 268 25 91 100: 38 
239 33 
Fluoxetine 310 44 14 56 100: 13 
148 6 
Flurazepam 388 315 22 90 100: 22 
317 18 
Fluvoxamine 319 71 16 67 100: 21 
200 21 
Gabapentin 172 137 15 51 100: 32 
119 17 
Haloperidol 376 123 37 101 100: 93 
165 23 
Hydrocodone 300 199 29 112 100: 37 
171 38 
Hydromorphone 286 185 30 97 100: 69 
157 40 
Hydroxyzine 375 201 19 71 100: 86 
165 61 
Ketamine 238 89 54 62 100: 24 
125 30 
Labetalol 329 162 25 71 100: 87 
91 36 
Lamotrigine 256 211 26 104 100: 63 
145 38 
Levetiracetam 171 126 15 33 100: 24 
154 5 
Lidocaine 235 86 18 66 100: 12 
58 35 
Lorazepam 321 276 18 65 100: 48 
167 41 
mCPP 197 154 19 71 100: 89 
118 34 
MDA 180 135 19 39 100: 91 
133 18 
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Target Q1 Q3 CE S lens Ion ratio 
MDMA 194 163 12 48 100: 35 
105 24 
MDPV 276 175 22 87 100: 89 
135 27 
Meperidine 248 220 21 81 100: 58 
174 20 
Mephedrone 178 145 20 54 100: 76 
144 31 
Meprobamate 219 158 5 39 100: 81 
97 14 
Mescaline 212 180 18 44 100: 81 
165 24 
Metaxalone 222 161 11 57 100: 26 
105 27 
Methadone 310 265 14 77 100: 32 
105 29 
Methamphetamine 150 91 19 50 100: 39 
119 11 
Methocarbamol 242 118 11 47 100: 23 
199 5 
Methylone 208 160 17 59 100: 52 
132 27 
Methylphenidate 234 84 20 69 100: 13 
56 41 
Metoclopramide 300 227 18 75 100: 39 
184 31 
Metoprolol 268 116 18 83 100: 68 
77 52 
Midazolam 326 291 26 98 100: 27 
249 37 
Mirtazapine 266 195 26 74 100: 41 
194 42 
Morphine 286 152 60 84 100: 71 
165 40 
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Target Q1 Q3 CE S lens Ion ratio 
Naproxen 231 185 14 63 100: 30 
170 26 
Norclozapine 313 192 41 90 100: 73 
270 24 
Nordiazepam 271 140 28 99 100: 68 
208 27 
Nordoxepin 266 107 22 76 100: 60 
235 15 
Norfluoxetine 296 134 5 43 100: 26 
30 13 
Norketamine 224 125 25 54 100: 44 
179 16 
Normeperidine 234 160 16 64 100: 22 
56 23 
Norpropoxyphene 308 44 20 60 100: 48 
128 43 
Norsertraline 275 159 18 77 100: 11 
124 41 
Nortramadol 250 232 5 48 100: 25 
42 53 
Nortriptyline 264 233 14 77 100: 42 
117 20 
Norvenlafaxine 264 58 19 69 100: 24 
107 34 
Olanzapine 313 256 22 96 100: 27 
198 41 
Oxazepam 287 241 22 88 100: 15 
77 51 
Oxycodone 316 241 28 86 100: 63 
212 41 
Oxymorphone 302 227 28 84 100: 73 
198 43 
Papaverine 340 324 30 114 100: 101 
202 26 
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Target Q1 Q3 CE S lens Ion ratio 
Paroxetine 330 192 20 88 100: 52 
70 30 
PCP 244 91 34 43 100: 56 
159 13 
Pentazocine 286 218 20 83 100: 22 
69 26 
Phenytoin 253 182 18 63 100: 61 
104 34 
Pregabalin 160 97 23 50 100: 21 
124 15 
Primidone 219 162 13 51 100: 70 
91 32 
Promethazine 285 86 17 60 100: 43 
198 27 
Propoxyphene 340 266 5 50 100: 20 
128 45 
Propranolol 260 116 18 76 100: 88 
183 18 
Quetiapine 384 253 22 97 100: 64 
221 36 
Ranitidine 315 176 17 77 100: 49 
102 34 
Risperidone 411 191 28 113 100: 8 
110 47 
Ropinirole 261 114 19 77 100: 21 
132 33 
Sertraline 306 159 29 50 100: 85 
275 12 
Sildenafil 475 100 29 158 100: 62 
283 38 
Temazepam 301 177 38 87 100: 32 
239 45 
TFMPP 231 188 22 76 100: 23 
118 39 
116
Target Q1 Q3 CE S lens Ion ratio 
Topiramate 362 265 18 93 100: 52 
  207 18   
Tramadol 264 264 15 60 100: 30 
   58 15     
Trazodone 372 176 23 101 100: 84 
  148 33   
Triazolam 343 308 26 146 100: 76 
   239 41     
Trimipramine 295 193 41 74 100: 71 
  208 25   
Vardenafil 489 151 47 152 100: 43 
   312 37     
Venlafaxine 278 58 18 61 100: 25 
  121 32   
Verapamil 455 165 28 115 100: 36 
   150 37     
Zaleplon 306 236 26 97 100: 88 
  264 22   
Ziprasidone 413 194 27 115 100: 37 
   159 40     
Zolpidem 308 92 51 103 100: 18 
  235 33   
Zonisamide 213 132 15 61 100: 46 
   77 33     
Zopiclone 389 245 16 59 100: 39 
  112 54   
6-acetylmorphine 328 165 38 100 100: 57 
   211 25     
7-aminoclonazepam 286 121 30 106 100: 36 
  94 40   
7-aminoflunitrazepam 284 135 27 100 100: 51 
   227 25     
9-hydroxyrisperidone 427 207 26 108 100: 22 
  110 40   
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APPENDIX D 
Spiking solutions A-C were made by combining stock solutions into 95:5:0.01 
methanol:water:acetic acid.  Spiking solutions D-J were made by combining stock 
solutions into 95:5 methanol:water at 200x cutoff and then diluting 1:10 with 95:5:0.01 
methanol:water:acetic acid.  Solution K was made by combining stock solutions into 95:5 
methanol:water at 2000x cutoff and then diluting 1:100 with 95:5:0.01 
methanol:water:acetic acid. 
Solution A Solution B 
Acetaminophen•† 
Carisoprodol 
Felbamate 
Levetiracetam• 
Naproxen† 
Norsertraline† 
Phenytoin† 
Primidone 
Topiramate† 
Tramadol† 
Zonisamide† 
Baclofen 
Carbamazepine• 
Carbamazepine-10,11-epoxide 
Lamotrigine 
Meprobamate 
Metaxalone 
Methocarbamol• 
Nortramadol† 
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Solution C Solution D 
Amphetamine† 
Benzylpiperazine† 
Bupivacaine• 
Flecainide 
Gabapentin 
Lidocaine 
Papaverine• 
Pregabalin 
Ranitidine• 
Aripiprazole•† 
Desmethylclomipramine† 
Etomidate• 
Ketamine 
MDA† 
Mescaline† 
Metoclopramide• 
Norketamine 
Oxycodone† 
Sertraline 
Sildenafil 
Trazodone 
Vardenafil 
Ziprasidone† 
Solution E Solution F 
Demoxepam† 
Ephedrine/Pseudoephedrine 
Hydroxyzine•† 
Norpropoxyphene 
Norvenlafaxine 
Olanzapine 
Pentazocine 
Propoxyphene 
Propranolol 
Quetiapine 
TFMPP 
Venlafaxine 
Verapamil 
Donepezil• 
Labetalol• 
MDMA 
MDPV 
Mephedrone 
Methamphetamine 
Methylone 
Metoprolol 
Midazolam 
Mirtazapine 
Norclozapine 
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Solution G Solution H 
6-acetylmorphine†
7-aminoclonazepam†
Alfentanil 
Alpha-PVP 
Bupropion 
Chlordiazepoxide 
Chlorpromazine 
Clozapine 
Cocaethylene 
Desalkylflurazepam 
Diltiazem 
Brompheniramine 
Diphenhydramine 
Doxylamine 
EDDP 
Flurazepam 
Lorazepam 
Meperidine 
Normeperidine 
PCP 
Promethazine 
Solution I Solution J 
Buspirone† 
Chlorpheniramine 
Clonazepam† 
Fluvoxamine•† 
Methadone 
Morphine† 
Oxymorphone† 
Paroxetine† 
Zaleplon 
Zopiclone† 
7-aminoflunitrazepam
Amlodipine• 
Benztropine• 
Clomipramine 
Desipramine 
Duloxetine 
Flunitrazepam 
Fluoxetine 
mCPP 
Methylphenidate 
Nordoxepin 
Norfluoxetine 
Triazolam 
Trimipramine 
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Solution K Solution L 
9-hydroxyrisperidone
Alprazolam 
Cyclobenzaprine 
Dextromethorphan 
Fentanyl† 
Haloperidol 
Risperidone 
Ropinirole• 
Zolpidem 
Amitriptyline   
Atenolol  
Benzoylecgonine 
Diazepam 
Hydrocodone 
Nortriptyline  
Solution M 
Citalopram 
Cocaine 
Codeine 
Doxepine 
Hydromorphone  
Nordiazepam 
Oxazepam  
Temazepam 
• Original solutions made
by dissolving powdered
Sigma reagents
†  Target run at a 
concentration other than 
that specified by AFT 
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APPENDIX E 
Detailed data by cocktail 
Acetaminophen 
Cocktail A 
m/z 110 m/z 65 n 
Manual 
Spiked Average 1.02E+07 2.87E+06 
4 
Spiked RSD 19% 19% 
Blank Average 3.49E+05 1.16E+05 
4 
Blank RSD 173% 144% 
Laser-cut 
Spiked Average 1.75E+07 4.96E+06 
4 
Spiked RSD 49% 51% 
Blank Average 1.26E+05 8.96E+04 
4 
Blank RSD 29% 27% 
Levetiracetam 
Cocktail A 
m/z 126 m/z 154 n 
Manual 
Spiked Average 9.37E+05 2.40E+05 
4 
Spiked RSD 10% 9% 
Blank Average 4.01E+04 1.21E+04 
4 
Blank RSD 167% 143% 
Laser-cut 
Spiked Average 3.78E+06 9.94E+05 
4 
Spiked RSD 43% 47% 
Blank Average 7.95E+04 1.17E+04 
4 
Blank RSD 42% 37% 
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Zonisamide 
Cocktail A 
m/z 132 m/z 77 n 
Manual 
Spiked Average 4.54E+06 2.19E+06 
4 
Spiked RSD 23% 23% 
Blank Average 1.30E+05 1.11E+05 
4 
Blank RSD 172% 110% 
Laser-cut 
Spiked Average 6.52E+06 3.08E+06 
4 
Spiked RSD 59% 59% 
Blank Average 9.71E+03 9.83E+04 
4 
Blank RSD 33% 22% 
Primidone 
Cocktail A 
m/z 162 m/z 91 n 
Manual 
Spiked Average 2.55E+06 1.83E+06 
4 
Spiked RSD 33% 32% 
Blank Average 6.32E+04 1.20E+05 
4 
Blank RSD 172% 86% 
Laser-cut 
Spiked Average 3.48E+06 4.09E+06 
4 
Spiked RSD 56% 44% 
Blank Average 1.19E+04 2.27E+06 
4 
Blank RSD 35% 19% 
Naproxen 
Cocktail A 
m/z 185 m/z 170 n 
Manual 
Spiked Average 1.12E+06 3.09E+05 
4 
Spiked RSD 15% 17% 
Blank Average 1.66E+05 1.50E+04 
4 
Blank RSD 58% 105% 
Laser-cut 
Spiked Average 3.48E+06 5.42E+05 
4 
Spiked RSD 56% 56% 
Blank Average 1.19E+04 7.32E+04 
4 
Blank RSD 35% 21% 
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Felbamate 
Cocktail A 
m/z 117 m/z 178 n 
Manual 
Spiked Average 7.17E+05 4.37E+05 
4 
Spiked RSD 22% 23% 
Blank Average 5.26E+04 1.17E+04 
4 
Blank RSD 76% 173% 
Laser-cut 
Spiked Average 1.68E+06 1.07E+06 
4 
Spiked RSD 48% 48% 
Blank Average 3.24E+04 1.35E+03 
4 
Blank RSD 18% 35% 
Phenytoin 
Cocktail A 
m/z 182 m/z 104 n 
Manual 
Spiked Average 5.49E+05 3.60E+05 
4 
Spiked RSD 80% 80% 
Blank Average 1.29E+04 8.19E+03 
4 
Blank RSD 121% 95% 
Laser-cut 
Spiked Average 2.75E+05 2.10E+05 
4 
Spiked RSD 67% 69% 
Blank Average 2.25E+04 3.61E+04 
4 
Blank RSD 28% 34% 
Carisoprodol 
Cocktail A 
m/z 97 m/z 55 n 
Manual 
Spiked Average 5.46E+05 3.75E+05 
4 
Spiked RSD 37% 29% 
Blank Average 1.42E+05 8.43E+04 
4 
Blank RSD 33% 45% 
Laser-cut 
Spiked Average 1.59E+06 1.25E+06 
4 
Spiked RSD 31% 34% 
Blank Average 8.38E+04 4.26E+04 
4 
Blank RSD 22% 22% 
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Tramadol 
Cocktail A 
  m/z 264 m/z 58 n 
Manual 
Spiked Average 1.58E+07 4.50E+07 
4 
Spiked RSD 46% 48% 
Blank Average 1.55E+06 1.16E+06 
4 
Blank RSD 52% 178% 
Laser-cut 
Spiked Average 7.75E+07 1.36E+08 
4 
Spiked RSD 18% 17% 
Blank Average 3.40E+07 2.64E+04 
4 
Blank RSD 21% 25% 
Norsertraline 
Cocktail A 
  m/z 158 m/z 123 n 
Manual 
Spiked Average 3.43E+06 2.40E+05 
4 
Spiked RSD 41% 43% 
Blank Average 1.17E+05 6.87E+03 
4 
Blank RSD 81% 93% 
Laser-cut 
Spiked Average 1.12E+07 7.89E+05 
4 
Spiked RSD 11% 12% 
Blank Average 1.68E+05 1.38E+04 
4 
Blank RSD 19% 37% 
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Meprobamate 
Cocktail B 
m/z 158 m/z 97 n 
Manual 
Spiked Average 5.77E+05 5.09E+05 
4 
Spiked RSD 20% 20% 
Blank Average 2.78E+03 2.05E+04 
4 
Blank RSD 51% 30% 
Laser-cut 
Spiked Average 9.12E+05 7.95E+05 
4 
Spiked RSD 21% 21% 
Blank Average 1.84E+03 3.28E+04 
4 
Blank RSD 31% 18% 
Metaxalone 
Cocktail B 
m/z 161 m/z 105 n 
Manual 
Spiked Average 1.42E+06 3.83E+05 
4 
Spiked RSD 21% 21% 
Blank Average 1.20E+04 1.58E+04 
4 
Blank RSD 29% 32% 
Laser-cut 
Spiked Average 1.77E+06 5.04E+05 
4 
Spiked RSD 19% 19% 
Blank Average 1.57E+04 5.78E+04 
4 
Blank RSD 27% 25% 
Carbamazepine 
Cocktail B 
m/z 194 m/z 192 n 
Manual 
Spiked Average 1.09E+07 2.45E+06 
4 
Spiked RSD 14% 14% 
Blank Average 6.04E+04 1.32E+04 
4 
Blank RSD 49% 47% 
Laser-cut 
Spiked Average 2.57E+07 5.76E+06 
4 
Spiked RSD 25% 24% 
Blank Average 2.90E+04 2.76E+04 
4 
Blank RSD 35% 38% 
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Methocarbamol 
Cocktail B 
  m/z 118 m/z 199 n 
Manual 
Spiked Average 3.49E+05 7.21E+04 
4 
Spiked RSD 23% 26% 
Blank Average 3.24E+03 1.12E+03 
4 
Blank RSD 30% 29% 
Laser-cut 
Spiked Average 6.46E+05 1.33E+05 
4 
Spiked RSD 24% 24% 
Blank Average 5.92E+03 1.41E+03 
4 
Blank RSD 27% 26% 
Nortramadol 
Cocktail B 
  m/z 232 m/z 42 n 
Manual 
Spiked Average 4.78E+05 9.98E+04 
4 
Spiked RSD 11% 20% 
Blank Average 9.97E+04 2.96E+03 
4 
Blank RSD 14% 23% 
Laser-cut 
Spiked Average 1.29E+06 2.98E+05 
4 
Spiked RSD 16% 16% 
Blank Average 2.59E+05 1.44E+04 
4 
Blank RSD 30% 32% 
Carbamazepine-10,11-epoxide 
Cocktail B 
  m/z 180 m/z 210 n 
Manual 
Spiked Average 3.58E+06 1.39E+06 
4 
Spiked RSD 17% 17% 
Blank Average 1.45E+04 1.53E+04 
4 
Blank RSD 51% 27% 
Laser-cut 
Spiked Average 1.01E+07 3.86E+06 
4 
Spiked RSD 26% 26% 
Blank Average 3.46E+04 2.15E+04 
4 
Blank RSD 20% 28% 
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Lamotrigine 
Cocktail B 
m/z 210 m/z 144 n 
Manual 
Spiked Average 2.97E+06 1.85E+06 
4 
Spiked RSD 16% 16% 
Blank Average 3.52E+04 2.39E+04 
4 
Blank RSD 66% 61% 
Laser-cut 
Spiked Average 4.53E+06 2.88E+06 
4 
Spiked RSD 16% 16% 
Blank Average 2.50E+04 3.47E+04 
4 
Blank RSD 24% 21% 
Baclofen 
Cocktail B 
m/z 151 m/z 115 n 
Manual 
Spiked Average 2.82E+06 2.37E+06 
4 
Spiked RSD 11% 10% 
Blank Average 2.99E+04 3.06E+04 
4 
Blank RSD 48% 34% 
Laser-cut 
Spiked Average 7.84E+05 7.02E+05 
4 
Spiked RSD 32% 31% 
Blank Average 2.24E+04 6.51E+04 
4 
Blank RSD 39% 20% 
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Amphetamine 
Cocktail C 
  m/z 91 m/z 119 n 
Manual 
Spiked Average 2.83E+06 6.61E+05 
4 
Spiked RSD 13% 16% 
Blank Average 3.17E+05 2.99E+04 
4 
Blank RSD 17% 23% 
Laser-cut 
Spiked Average 4.53E+06 9.61E+05 
4 
Spiked RSD 16% 14% 
Blank Average 7.48E+05 2.05E+04 
4 
Blank RSD 22% 31% 
Pregabalin 
Cocktail C 
  m/z 97 m/z 124 n 
Manual 
Spiked Average 1.26E+05 5.88E+05 
4 
Spiked RSD 9% 10% 
Blank Average 4.48E+03 8.69E+03 
4 
Blank RSD 24% 36% 
Laser-cut 
Spiked Average 1.11E+05 4.98E+05 
4 
Spiked RSD 27% 27% 
Blank Average 1.70E+04 4.26E+04 4 
Flecainide 
Cocktail C 
  m/z 301 m/z 98 n 
Manual 
Spiked Average 6.75E+06 2.73E+06 
4 
Spiked RSD 23% 24% 
Blank Average 2.17E+04 8.15E+03 
4 
Blank RSD 78% 86% 
Laser-cut 
Spiked Average 3.47E+07 1.39E+07 
4 
Spiked RSD 19% 18% 
Blank Average 1.71E+04 6.47E+03 
4 
Blank RSD 15% 15% 
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Gabapentin 
Cocktail C 
m/z 137 m/z 119 n 
Manual 
Spiked Average 1.80E+06 5.70E+05 
4 
Spiked RSD 9% 9% 
Blank Average 1.55E+04 5.54E+03 
4 
Blank RSD 36% 27% 
Laser-cut 
Spiked Average 1.78E+06 1.45E+07 
4 
Spiked RSD 30% 9% 
Blank Average 1.21E+04 4.30E+05 
4 
Blank RSD 44% 19% 
Benzylpiperazine 
Cocktail C 
m/z 91 m/z 85 n 
Manual 
Spiked Average 4.92E+06 1.03E+06 
4 
Spiked RSD 18% 9% 
Blank Average 3.16E+05 3.00E+05 
4 
Blank RSD 39% 19% 
Laser-cut 
Spiked Average 1.45E+07 1.73E+06 
4 
Spiked RSD 9% 9% 
Blank Average 4.30E+05 4.21E+04 
4 
Blank RSD 19% 42% 
Lidocaine 
Cocktail C 
m/z 86 m/z 58 n 
Manual 
Spiked Average 2.19E+07 2.22E+06 
4 
Spiked RSD 13% 13% 
Blank Average 5.35E+04 7.14E+03 
4 
Blank RSD 118% 101% 
Laser-cut 
Spiked Average 6.09E+07 6.14E+06 
4 
Spiked RSD 13% 14% 
Blank Average 8.59E+03 1.04E+05 
4 
Blank RSD 22% 25% 
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Bupivacaine 
Cocktail C 
  m/z 140 m/z 98 n 
Manual 
Spiked Average 4.26E+07 7.09E+06 
4 
Spiked RSD 24% 24% 
Blank Average 1.27E+05 2.50E+04 
4 
Blank RSD 101% 87% 
Laser-cut 
Spiked Average 1.48E+08 2.47E+07 
4 
Spiked RSD 17% 17% 
Blank Average 1.06E+04 1.16E+04 
4 
Blank RSD 25% 33% 
Ranitidine 
Cocktail C 
  m/z 176 m/z 102 n 
Manual 
Spiked Average 7.79E+06 3.96E+06 
4 
Spiked RSD 28% 28% 
Blank Average 3.46E+04 8.87E+03 
4 
Blank RSD 47% 97% 
Laser-cut 
Spiked Average 3.92E+07 1.99E+07 
4 
Spiked RSD 33% 35% 
Blank Average 5.50E+04 1.93E+03 
4 
Blank RSD 7% 55% 
Papaverine 
Cocktail C 
  m/z 324 m/z 202 n 
Manual 
Spiked Average 2.55E+07 2.67E+07 
4 
Spiked RSD 34% 33% 
Blank Average 7.35E+04 7.81E+04 
4 
Blank RSD 99% 98% 
Laser-cut 
Spiked Average   
4 
Spiked RSD   
Blank Average   
4 
Blank RSD   
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Mescaline 
Cocktail D 
m/z 180 m/z 165 n 
Manual 
Spiked Average 3.42E+05 2.19E+05 
4 
Spiked RSD 30% 43% 
Blank Average 5.28E+04 4.59E+03 
4 
Blank RSD 28% 51% 
Laser-cut 
Spiked Average 9.03E+05 2.74E+05 
3 
Spiked RSD 10% 8% 
Blank Average 5.71E+05 3.98E+04 
2 
Blank RSD 17% 32% 
Die-cut 
Spiked 3.70E+05 2.30E+05 
1 
Spiked RSD - - 
Blank Average 9.96E+04 4.18E+03 
3 
Blank RSD 32% 57% 
Norketamine 
Cocktail D 
m/z 125 m/z 179 n 
Manual 
Spiked Average 1.36E+06 6.12E+05 
4 
Spiked RSD 41% 40% 
Blank Average 1.27E+04 9.18E+03 
4 
Blank RSD 79% 56% 
Laser-cut 
Spiked Average 2.32E+06 1.07E+06 
3 
Spiked RSD 13% 15% 
Blank Average 1.97E+04 3.37E+04 
2 
Blank RSD 11% 5% 
Die-cut 
Spiked 2.96E+06 1.33E+06 
1 
Spiked RSD - - 
Blank Average 5.46E+03 8.34E+03 
3 
Blank RSD 47% 42% 
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Ketamine 
Cocktail D 
  m/z 89 m/z 125 n 
Manual 
Spiked Average 4.91E+05 1.99E+06 
4 
Spiked RSD 31% 30% 
Blank Average 5.42E+03 1.41E+04 
4 
Blank RSD 77% 104% 
Laser-cut 
Spiked Average 1.22E+06 4.72E+06 
3 
Spiked RSD 23% 21% 
Blank Average 3.89E+04 3.00E+04 
2 
Blank RSD 14% 15% 
Die-cut 
Spiked 1.84E+06 7.34E+06 
1 
Spiked RSD - - 
Blank Average 8.81E+03 4.75E+03 
3 
Blank RSD 71% 51% 
Etomidate 
Cocktail D 
  m/z 141 m/z 95 n 
Manual 
Spiked Average 2.15E+06 2.27E+06 
4 
Spiked RSD 29% 9% 
Blank Average 1.08E+05 4.46E+05 
4 
Blank RSD 49% 67% 
Laser-cut 
Spiked Average - 2.47E+06 
3 
Spiked RSD - 29% 
Blank Average - 7.45E+04 
2 
Blank RSD - 10% 
Die-cut 
Spiked Average - 2.52E+06 
1 
Spiked RSD - - 
Blank Average - 8.75E+04 
3 
Blank RSD - 47% 
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Metoclopramide 
Cocktail D 
m/z 227 m/z 184 n 
Manual 
Spiked Average 7.39E+06 2.75E+06 
4 
Spiked RSD 34% 34% 
Blank Average 6.70E+04 3.10E+04 
4 
Blank RSD 107% 77% 
Laser-cut 
Spiked Average 3.02E+07 1.14E+07 
3 
Spiked RSD 32% 31% 
Blank Average 1.90E+04 4.57E+04 
2 
Blank RSD 16% 6% 
Die-cut 
Spiked 7.51E+07 2.96E+07 
1 
Spiked RSD - - 
Blank Average 1.16E+04 2.04E+04 
3 
Blank RSD 60% 65% 
Desmethylclomipramine 
Cocktail D 
m/z 72 m/z 227 n 
Manual 
Spiked Average 3.77E+05 9.10E+04 
4 
Spiked RSD 36% 28% 
Blank Average 3.49E+03 8.18E+03 
4 
Blank RSD 68% 32% 
Laser-cut 
Spiked Average 1.52E+06 3.55E+05 
3 
Spiked RSD 6% 13% 
Blank Average 1.23E+03 2.77E+04 
2 
Blank RSD 6% 11% 
Die-cut 
Spiked 1.98E+06 5.09E+05 
1 
Spiked RSD - - 
Blank Average 1.15E+03 1.70E+04 
3 
Blank RSD 83% 78% 
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Sertraline 
Cocktail D 
  m/z 158 m/z 275 n 
Manual 
Spiked Average 2.66E+05 2.16E+05 
4 
Spiked RSD 33% 37% 
Blank Average 8.49E+03 2.66E+03 
4 
Blank RSD 44% 65% 
Laser-cut 
Spiked Average 8.95E+05 7.37E+05 
3 
Spiked RSD 6% 6% 
Blank Average 1.89E+04 2.11E+03 
2 
Blank RSD 4% 16% 
Die-cut 
Spiked 9.17E+05 7.68E+05 
1 
Spiked RSD - - 
Blank Average 1.27E+04 2.19E+03 3 
MDA 
Cocktail D 
  m/z 135 m/z 133 n 
Manual 
Spiked Average 2.86E+05 2.66E+05 
4 
Spiked RSD 33% 34% 
Blank Average 1.15E+04 1.54E+04 
4 
Blank RSD 38% 28% 
Laser-cut 
Spiked Average 4.48E+05 4.48E+05 
3 
Spiked RSD 5% 5% 
Blank Average 3.78E+04 3.78E+04 
2 
Blank RSD 22% 22% 
Die-cut 
Spiked 4.87E+05 4.87E+05 
1 
Spiked RSD - - 
Blank Average 2.08E+04 2.08E+04 
3 
Blank RSD 46% 46% 
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Oxycodone 
Cocktail D 
m/z 241 m/z 212 n 
Manual 
Spiked Average 2.84E+05 1.84E+05 
4 
Spiked RSD 36% 33% 
Blank Average 9.80E+03 9.51E+03 
4 
Blank RSD 36% 39% 
Laser-cut 
Spiked Average 4.93E+05 3.42E+05 
3 
Spiked RSD 17% 19% 
Blank Average 1.51E+04 3.31E+04 
2 
Blank RSD 19% 13% 
Die-cut 
Spiked 4.52E+05 3.06E+05 
1 
Spiked RSD - - 
Blank Average 7.39E+03 1.24E+04 
3 
Blank RSD 66% 70% 
Trazodone 
Cocktail D 
m/z 176 m/z 148 n 
Manual 
Spiked Average 2.52E+06 2.09E+06 
4 
Spiked RSD 36% 35% 
Blank Average 3.54E+04 2.76E+04 
4 
Blank RSD 52% 53% 
Laser-cut 
Spiked Average 9.91E+06 8.19E+06 
3 
Spiked RSD 23% 24% 
Blank Average 2.29E+04 4.90E+04 
2 
Blank RSD 6% 7% 
Die-cut 
Spiked 1.33E+07 1.10E+07 
1 
Spiked RSD - - 
Blank Average 4.19E+04 1.20E+04 
3 
Blank RSD 35% 62% 
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Ziprasidone 
Cocktail D 
  m/z 194 m/z 159 n 
Manual 
Spiked Average 7.30E+05 5.93E+05 
4 
Spiked RSD 49% 23% 
Blank Average 5.68E+03 9.76E+04 
4 
Blank RSD 69% 68% 
Laser-cut 
Spiked Average 1.32E+06 5.98E+05 
3 
Spiked RSD 16% 16% 
Blank Average 1.50E+04 9.83E+04 
2 
Blank RSD 6% 0% 
Die-cut 
Spiked 7.82E+05 3.43E+05 
1 
Spiked RSD - - 
Blank Average 6.23E+03 4.46E+04 
3 
Blank RSD 54% 34% 
Aripiprazole 
Cocktail D 
  m/z 285 m/z 176 n 
Manual 
Spiked Average 8.62E+05 2.46E+05 
4 
Spiked RSD 46% 43% 
Blank Average 1.16E+04 7.07E+03 
4 
Blank RSD 48% 27% 
Laser-cut 
Spiked Average 1.93E+06 5.46E+05 
3 
Spiked RSD 11% 11% 
Blank Average 8.94E+03 9.71E+03 
2 
Blank RSD 4% 20% 
Die-cut 
Spiked 1.50E+06 4.28E+05 
1 
Spiked RSD - - 
Blank Average 3.85E+03 9.49E+03 
3 
Blank RSD 50% 52% 
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Sildenafil 
Cocktail D 
m/z 100 m/z 283 n 
Manual 
Spiked Average 2.16E+05 1.50E+05 
4 
Spiked RSD 42% 35% 
Blank Average 1.51E+03 6.02E+03 
4 
Blank RSD 92% 36% 
Laser-cut 
Spiked Average 2.09E+05 1.41E+05 
3 
Spiked RSD 22% 24% 
Blank Average 4.20E+02 7.15E+03 
2 
Blank RSD 3% 3% 
Die-cut 
Spiked 1.63E+05 1.07E+05 
1 
Spiked RSD - - 
Blank Average 3.47E+02 2.29E+03 
3 
Blank RSD 97% 74% 
Vardenafil 
Cocktail D 
m/z 151 m/z 312 n 
Manual 
Spiked Average 5.39E+05 2.14E+05 
4 
Spiked RSD 40% 43% 
Blank Average 1.40E+04 2.17E+03 
4 
Blank RSD 36% 90% 
Laser-cut 
Spiked Average 1.20E+06 4.88E+05 
3 
Spiked RSD 28% 26% 
Blank Average 5.76E+03 2.08E+03 
2 
Blank RSD 4% 9% 
Die-cut 
Spiked Average 9.63E+05 4.05E+05 
1 
Spiked RSD - - 
Blank Average 3.59E+03 8.53E+02 
3 
Blank RSD 66% 70% 
138
Ephedrine/Pseudoephedrine 
Cocktail E 
  m/z 115 m/z 117 n 
Manual 
Spiked Average 1.85E+05 1.54E+05 
4 
Spiked RSD 4% 6% 
Blank Average 7.04E+03 5.66E+03 
4 
Blank RSD 112% 108% 
Laser-cut 
Spiked Average 3.55E+05 3.07E+05 
4 
Spiked RSD 36% 37% 
Blank Average 3.87E+03 9.06E+03 
2 
Blank RSD 1% 28% 
Die-cut 
Spiked Average 4.39E+05 3.62E+05 
4 
Spiked RSD 13% 13% 
Blank Average 9.95E+03 7.31E+03 
3 
Blank RSD 41% 56% 
TFMPP 
Cocktail E 
  m/z 188 m/z 118 n 
Manual 
Spiked Average 6.26E+05 1.50E+05 
4 
Spiked RSD 11% 10% 
Blank Average 1.49E+04 6.71E+03 
4 
Blank RSD 96% 66% 
Laser-cut 
Spiked Average 7.98E+05 2.45E+05 
4 
Spiked RSD 11% 25% 
Blank Average 3.16E+04 4.23E+04 
2 
Blank RSD 7% 10% 
Die-cut 
Spiked Average 1.20E+06 2.85E+05 
4 
Spiked RSD 15% 17% 
Blank Average 2.19E+04 1.42E+04 
3 
Blank RSD 63% 63% 
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Propranolol 
Cocktail E 
m/z 116 m/z 183 n 
Manual 
Spiked Average 3.13E+05 2.80E+05 
4 
Spiked RSD 8% 8% 
Blank Average 7.13E+03 1.23E+04 
4 
Blank RSD 125% 73% 
Laser-cut 
Spiked Average 8.76E+05 7.77E+05 
4 
Spiked RSD 21% 22% 
Blank Average 6.21E+03 1.49E+04 
2 
Blank RSD 15% 1% 
Die-cut 
Spiked Average 1.04E+06 9.41E+05 
4 
Spiked RSD 12% 11% 
Blank Average 1.86E+03 1.31E+04 
3 
Blank RSD 67% 36% 
Norvenlafaxine 
Cocktail E 
m/z 58 m/z 107 n 
Manual 
Spiked Average 5.46E+05 1.30E+05 
4 
Spiked RSD 12% 12% 
Blank Average 3.26E+04 1.04E+04 
4 
Blank RSD 123% 52% 
Laser-cut 
Spiked Average 1.95E+06 6.53E+05 
4 
Spiked RSD 53% 57% 
Blank Average 3.13E+04 1.94E+05 
2 
Blank RSD 41% 19% 
Die-cut 
Spiked Average 2.39E+06 6.22E+05 
4 
Spiked RSD 21% 22% 
Blank Average 4.90E+03 9.72E+04 
3 
Blank RSD 39% 68% 
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Venlafaxine 
Cocktail E 
  m/z 58 m/z 121 n 
Manual 
Spiked Average 9.77E+05 2.56E+05 
4 
Spiked RSD 17% 17% 
Blank Average 1.05E+04 1.26E+04 
4 
Blank RSD 150% 56% 
Laser-cut 
Spiked Average 3.70E+06 1.34E+06 
4 
Spiked RSD 47% 46% 
Blank Average 1.61E+04 1.74E+05 
2 
Blank RSD 21% 9% 
Die-cut 
Spiked Average 5.80E+06 1.52E+06 
4 
Spiked RSD 24% 24% 
Blank Average 6.48E+03 9.21E+04 
3 
Blank RSD 75% 68% 
Pentazocine 
Cocktail E 
  m/z 218 m/z 69 n 
Manual 
Spiked Average 1.58E+06 3.75E+05 
4 
Spiked RSD 15% 14% 
Blank Average 2.18E+04 3.47E+04 
4 
Blank RSD 132% 40% 
Laser-cut 
Spiked Average 6.86E+06 1.60E+06 
4 
Spiked RSD 40% 40% 
Blank Average 2.55E+04 1.06E+05 
2 
Blank RSD 7% 11% 
Die-cut 
Spiked Average 9.67E+06 2.17E+06 
4 
Spiked RSD 25% 25% 
Blank Average 1.25E+04 1.26E+05 
3 
Blank RSD 52% 70% 
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Demoxepam 
Cocktail E 
m/z 179 m/z 207 n 
Manual 
Spiked Average 1.91E+04 1.52E+04 
4 
Spiked RSD 21% 18% 
Blank Average 3.17E+03 5.62E+03 
4 
Blank RSD 76% 68% 
Laser-cut 
Spiked Average 4.53E+04 3.14E+04 
4 
Spiked RSD 56% 59% 
Blank Average 7.20E+03 6.92E+03 
2 
Blank RSD 16% 7% 
Die-cut 
Spiked Average 4.43E+04 2.95E+04 
4 
Spiked RSD 41% 45% 
Blank Average 2.40E+03 2.93E+03 
3 
Blank RSD 62% 64% 
Norpropoxyphene 
Cocktail E 
m/z 44 m/z 128 n 
Manual 
Spiked Average 2.62E+05 1.28E+05 
4 
Spiked RSD 20% 19% 
Blank Average 4.31E+03 6.32E+03 
4 
Blank RSD 115% 72% 
Laser-cut 
Spiked Average 1.39E+06 7.25E+05 
4 
Spiked RSD 27% 22% 
Blank Average 2.32E+03 2.94E+04 
2 
Blank RSD 17% 8% 
Die-cut 
Spiked Average 1.98E+06 9.67E+05 
4 
Spiked RSD 31% 32% 
Blank Average 2.32E+03 1.37E+04 
3 
Blank RSD 52% 55% 
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Olanzapine 
Cocktail E 
  m/z 256 m/z 198 n 
Manual 
Spiked Average 1.12E+05 3.07E+04 
4 
Spiked RSD 16% 14% 
Blank Average 4.02E+03 2.78E+03 
4 
Blank RSD 66% 52% 
Laser-cut 
Spiked Average 5.66E+05 1.74E+05 
4 
Spiked RSD 32% 41% 
Blank Average 8.51E+03 2.20E+04 
2 
Blank RSD 19% 3% 
Die-cut 
Spiked Average 4.10E+05 1.35E+05 
4 
Spiked RSD 22% 29% 
Blank Average 1.05E+04 7.75E+04 
3 
Blank RSD 57% 83% 
Propoxyphene 
Cocktail E 
  m/z 266 m/z 128 n 
Manual 
Spiked Average 3.23E+05 6.67E+04 
4 
Spiked RSD 14% 13% 
Blank Average 1.03E+04 6.59E+03 
4 
Blank RSD 64% 70% 
Laser-cut 
Spiked Average 1.26E+06 2.68E+05 
4 
Spiked RSD 48% 47% 
Blank Average 3.76E+03 1.89E+04 
2 
Blank RSD 5% 1% 
Die-cut 
Spiked Average 1.73E+06 3.43E+05 
4 
Spiked RSD 25% 25% 
Blank Average 4.07E+03 1.59E+04 
3 
Blank RSD 15% 75% 
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Hydroxyzine 
Cocktail E 
m/z 201 m/z 165 n 
Manual 
Spiked Average 2.20E+06 1.82E+06 
4 
Spiked RSD 10% 10% 
Blank Average 7.89E+04 3.24E+04 
4 
Blank RSD 63% 109% 
Laser-cut 
Spiked Average 8.73E+06 7.46E+06 
4 
Spiked RSD 40% 42% 
Blank Average 4.40E+04 7.12E+03 
2 
Blank RSD 14% 4% 
Die-cut 
Spiked Average 1.19E+07 1.00E+07 
4 
Spiked RSD 20% 20% 
Blank Average 9.63E+04 5.27E+03 
3 
Blank RSD 48% 65% 
Quetiapine 
Cocktail E 
m/z 253 m/z 221 n 
Manual 
Spiked Average 2.36E+06 1.51E+06 
4 
Spiked RSD 11% 10% 
Blank Average 3.58E+04 1.87E+04 
4 
Blank RSD 109% 128% 
Laser-cut 
Spiked Average 9.93E+06 6.44E+06 
4 
Spiked RSD 52% 53% 
Blank Average 9.03E+03 1.34E+04 
2 
Blank RSD 13% 5% 
Die-cut 
Spiked Average 1.08E+07 6.97E+06 
4 
Spiked RSD 25% 25% 
Blank Average 9.96E+03 8.58E+03 
3 
Blank RSD 83% 84% 
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Verapamil 
Cocktail E 
  m/z 165 m/z n 
Manual 
Spiked Average 1.57E+06 5.76E+05 
4 
Spiked RSD 10% 10% 
Blank Average 4.59E+04 7.21E+03 
4 
Blank RSD 72% 138% 
Laser-cut 
Spiked Average 8.45E+06 3.16E+06 
4 
Spiked RSD 14% 14% 
Blank Average 1.72E+04 8.86E+03 
2 
Blank RSD 6% 28% 
Die-cut 
Spiked Average 1.16E+07 4.30E+06 
4 
Spiked RSD 26% 26% 
Blank Average 1.80E+04 2.94E+03 
3 
Blank RSD 44% 54% 
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Mephedrone 
Cocktail F 
m/z 145 m/z 144 n 
Manual 
Spiked Average 1.09E+06 8.11E+05 
4 
Spiked RSD 8% 9% 
Blank Average 1.39E+04 7.25E+03 
4 
Blank RSD 42% 77% 
Laser-cut 
Spiked Average 1.85E+06 1.39E+06 
4 
Spiked RSD 20% 19% 
Blank Average 1.40E+04 1.22E+04 
2 
Blank RSD 25% 44% 
Die-cut 
Spiked Average 4.78E+06 3.58E+06 
4 
Spiked RSD 3% 4% 
Blank Average 2.08E+04 1.28E+04 
3 
Blank RSD 61% 34% 
MDMA 
Cocktail F 
m/z 163 m/z 105 n 
Manual 
Spiked Average 1.11E+06 4.03E+05 
4 
Spiked RSD 7% 7% 
Blank Average 9.74E+03 1.01E+04 
4 
Blank RSD 68% 42% 
Laser-cut 
Spiked Average 2.26E+06 8.64E+05 
4 
Spiked RSD 17% 19% 
Blank Average 5.76E+03 4.23E+04 
2 
Blank RSD 31% 30% 
Die-cut 
Spiked Average 3.58E+06 1.32E+06 
4 
Spiked RSD 10% 11% 
Blank Average 5.30E+03 5.83E+04 
3 
Blank RSD 95% 80% 
146
Methylone 
Cocktail F 
  m/z 160 m/z 132 n 
Manual 
Spiked Average 1.09E+06 5.76E+05 
4 
Spiked RSD 8% 9% 
Blank Average 1.88E+04 1.59E+04 
4 
Blank RSD 43% 18% 
Laser-cut 
Spiked Average 2.08E+06 1.13E+06 
4 
Spiked RSD 23% 26% 
Blank Average 6.75E+04 7.23E+04 
2 
Blank RSD 7% 13% 
Die-cut 
Spiked Average 4.00E+06 2.10E+06 
4 
Spiked RSD 13% 13% 
Blank Average 1.85E+04 4.70E+04 
3 
Blank RSD 112% 80% 
Mirtazapine 
Cocktail F 
  m/z 195 m/z 194 n 
Manual 
Spiked Average 1.60E+06 6.46E+05 
4 
Spiked RSD 9% 9% 
Blank Average 1.47E+04 6.39E+03 
4 
Blank RSD 57% 43% 
Laser-cut 
Spiked Average 3.77E+06 1.57E+06 
4 
Spiked RSD 26% 27% 
Blank Average 2.25E+04 6.16E+04 
2 
Blank RSD 1% 19% 
Die-cut 
Spiked Average 6.69E+06 2.73E+06 
4 
Spiked RSD 7% 7% 
Blank Average 2.03E+04 5.24E+04 
3 
Blank RSD 49% 46% 
 
147
Metoprolol 
Cocktail F 
m/z 116 m/z 77 n 
Manual 
Spiked Average 2.78E+05 2.08E+05 
4 
Spiked RSD 8% 7% 
Blank Average 4.00E+03 1.85E+04 
4 
Blank RSD 77% 33% 
Laser-cut 
Spiked Average 8.10E+05 7.23E+05 
4 
Spiked RSD 10% 20% 
Blank Average 2.22E+03 1.24E+05 
2 
Blank RSD 34% 18% 
Die-cut 
Spiked Average 1.14E+06 8.18E+05 
4 
Spiked RSD 11% 11% 
Blank Average 1.15E+03 4.61E+04 
3 
Blank RSD 110% 59% 
MDPV 
Cocktail F 
m/z 175 m/z 135 n 
Manual 
Spiked Average 1.26E+06 1.12E+06 
4 
Spiked RSD 18% 18% 
Blank Average 1.37E+04 1.33E+04 
4 
Blank RSD 40% 47% 
Laser-cut 
Spiked Average 2.83E+06 2.66E+06 
4 
Spiked RSD 38% 39% 
Blank Average 1.74E+04 8.56E+04 
2 
Blank RSD 28% 10% 
Die-cut 
Spiked Average 5.39E+06 4.82E+06 
4 
Spiked RSD 22% 23% 
Blank Average 1.74E+04 5.36E+04 
3 
Blank RSD 65% 40% 
148
Norclozapine 
Cocktail F 
  m/z 192 m/z 270 n 
Manual 
Spiked Average 3.97E+05 2.93E+05 
4 
Spiked RSD 10% 10% 
Blank Average 5.86E+03 4.94E+03 
4 
Blank RSD 53% 52% 
Laser-cut 
Spiked Average 6.90E+05 5.11E+05 
4 
Spiked RSD 21% 21% 
Blank Average 7.64E+03 1.12E+04 
2 
Blank RSD 16% 67% 
Die-cut 
Spiked Average 9.77E+05 7.15E+05 
4 
Spiked RSD 14% 15% 
Blank Average 5.41E+03 8.48E+03 
3 
Blank RSD 73% 45% 
Midazolam 
Cocktail F 
  m/z 291 m/z 249 n 
Manual 
Spiked Average 1.18E+06 3.33E+05 
4 
Spiked RSD 10% 10% 
Blank Average 2.63E+04 7.59E+03 
4 
Blank RSD 89% 83% 
Laser-cut 
Spiked Average 2.84E+06 7.99E+05 
4 
Spiked RSD 38% 37% 
Blank Average 8.05E+02 2.37E+03 
2 
Blank RSD 27% 21% 
Die-cut 
Spiked Average 5.40E+06 1.51E+06 
4 
Spiked RSD 14% 13% 
Blank Average 4.86E+02 1.01E+03 
3 
Blank RSD 80% 80% 
 
149
Labetalol 
Cocktail F 
m/z 162 m/z 91 n 
Manual 
Spiked Average 3.31E+05 3.16E+05 
4 
Spiked RSD 21% 18% 
Blank Average 8.10E+03 3.04E+04 
4 
Blank RSD 61% 40% 
Laser-cut 
Spiked Average 3.22E+05 3.06E+05 
4 
Spiked RSD 28% 30% 
Blank Average 1.34E+04 4.01E+04 
2 
Blank RSD 8% 19% 
Die-cut 
Spiked Average 3.84E+05 3.58E+05 
4 
Spiked RSD 16% 15% 
Blank Average 7.53E+03 3.84E+04 
3 
Blank RSD 63% 84% 
Donepezil 
Cocktail F 
m/z 91 m/z 243 n 
Manual 
Spiked Average 1.75E+06 2.81E+05 
4 
Spiked RSD 11% 12% 
Blank Average 2.35E+04 4.56E+03 
4 
Blank RSD 48% 44% 
Laser-cut 
Spiked Average 6.20E+06 1.01E+06 
4 
Spiked RSD 18% 18% 
Blank Average 2.28E+04 4.06E+03 
2 
Blank RSD 6% 11% 
Die-cut 
Spiked Average 1.19E+07 1.91E+06 
4 
Spiked RSD 12% 12% 
Blank Average 1.92E+04 2.73E+03 
3 
Blank RSD 39% 64% 
150
Methamphetamine 
Cocktail F 
  m/z 91 m/z 119 n 
Manual 
Spiked Average 1.14E+06 4.28E+05 
4 
Spiked RSD 8% 9% 
Blank Average 2.21E+04 4.37E+03 
4 
Blank RSD 44% 64% 
Laser-cut 
Spiked Average 2.28E+06 8.72E+05 
4 
Spiked RSD 15% 18% 
Blank Average 2.16E+04 2.64E+03 
2 
Blank RSD 11% 8% 
Die-cut 
Spiked Average 4.00E+06 1.53E+06 
4 
Spiked RSD 3% 3% 
Blank Average 5.82E+04 5.50E+03 
3 
Blank RSD 55% 98% 
 
151
Alpha-PVP 
Cocktail G 
m/z 91 m/z 77 n 
Manual 
Spiked Average 1.82E+06 7.53E+05 
4 
Spiked RSD 14% 14% 
Blank Average 3.34E+04 3.16E+04 
4 
Blank RSD 104% 61% 
Laser-cut 
Spiked Average 2.01E+04 1.08E+05 
4 
Spiked RSD 18% 26% 
Blank Average 2.52E+06 1.07E+06 
2 
Blank RSD 25% 23% 
Die-cut 
Spiked Average 2.14E+04 7.54E+04 
4 
Spiked RSD 51% 52% 
Blank Average 9.05E+06 3.72E+06 
3 
Blank RSD 31% 30% 
Bupropion 
Cocktail G 
m/z 184 m/z 131 n 
Manual 
Spiked Average 1.37E+06 7.63E+05 
4 
Spiked RSD 11% 10% 
Blank Average 2.89E+04 1.54E+04 
4 
Blank RSD 96% 93% 
Laser-cut 
Spiked Average 4.96E+04 2.16E+04 
4 
Spiked RSD 35% 20% 
Blank Average 1.75E+06 9.88E+05 
2 
Blank RSD 15% 14% 
Die-cut 
Spiked Average 4.66E+04 2.04E+04 
4 
Spiked RSD 56% 57% 
Blank Average 7.20E+06 4.04E+06 
3 
Blank RSD 33% 34% 
152
7-aminoclonazepam 
Cocktail G 
  m/z 121 m/z 94 n 
Manual 
Spiked Average 1.76E+05 6.92E+04 
4 
Spiked RSD 18% 18% 
Blank Average 9.32E+03 7.98E+03 
4 
Blank RSD 61% 53% 
Laser-cut 
Spiked Average 3.57E+04 5.48E+04 
4 
Spiked RSD 34% 22% 
Blank Average 7.70E+04 5.21E+04 
2 
Blank RSD 26% 31% 
Die-cut 
Spiked Average 1.92E+04 2.17E+04 
4 
Spiked RSD 51% 68% 
Blank Average 2.37E+05 1.03E+05 
3 
Blank RSD 40% 38% 
Desalkylflurazepam 
Cocktail G 
  m/z 140 m/z 226 n 
Manual 
Spiked Average 3.19E+05 1.54E+05 
4 
Spiked RSD 16% 33% 
Blank Average 5.43E+04 3.51E+03 
4 
Blank RSD 52% 125% 
Laser-cut 
Spiked Average 4.50E+03 8.07E+03 
4 
Spiked RSD 22% 12% 
Blank Average 3.69E+04 8.90E+04 
2 
Blank RSD 20% 19% 
Die-cut 
Spiked Average 1.06E+04 2.16E+03 
4 
Spiked RSD 85% 73% 
Blank Average 1.39E+05 2.08E+05 
3 
Blank RSD 21% 26% 
 
153
Chlordiazepoxide 
Cocktail G 
m/z 227 m/z 255 n 
Manual 
Spiked Average 6.81E+05 1.61E+05 
4 
Spiked RSD 11% 12% 
Blank Average 2.61E+04 9.06E+03 
4 
Blank RSD 74% 44% 
Laser-cut 
Spiked Average 1.28E+04 1.80E+04 
4 
Spiked RSD 24% 2% 
Blank Average 2.42E+05 6.41E+04 
2 
Blank RSD 22% 20% 
Die-cut 
Spiked Average 8.80E+03 1.31E+04 
4 
Spiked RSD 53% 57% 
Blank Average 5.17E+05 1.30E+05 
3 
Blank RSD 29% 28% 
Cocaethylene 
Cocktail G 
m/z 196 m/z 82 n 
Manual 
Spiked Average 3.53E+06 9.50E+05 
4 
Spiked RSD 10% 10% 
Blank Average 5.74E+04 2.28E+04 
4 
Blank RSD 103% 79% 
Laser-cut 
Spiked Average 1.73E+04 1.27E+04 
4 
Spiked RSD 2% 16% 
Blank Average 6.06E+06 1.62E+06 
2 
Blank RSD 19% 20% 
Die-cut 
Spiked Average 3.33E+04 8.27E+03 
4 
Spiked RSD 84% 57% 
Blank Average 2.66E+07 7.00E+06 
3 
Blank RSD 27% 27% 
154
Chlorpromazine 
Cocktail G 
  m/z 214 m/z 58 n 
Manual 
Spiked Average 3.65E+04 1.37E+05 
4 
Spiked RSD 10% 11% 
Blank Average 1.90E+03 6.27E+03 
4 
Blank RSD 62% 48% 
Laser-cut 
Spiked Average 8.04E+03 6.49E+03 
4 
Spiked RSD 12% 27% 
Blank Average 8.90E+04 3.25E+05 
2 
Blank RSD 19% 18% 
Die-cut 
Spiked Average 2.15E+03 7.47E+03 
4 
Spiked RSD 73% 56% 
Blank Average 2.08E+05 8.02E+05 
3 
Blank RSD 26% 26% 
Clozapine  
Cocktail G  
  m/z 270 m/z 192 n 
Manual 
Spiked Average 1.32E+06 8.41E+05 
4 
Spiked RSD 10% 10% 
Blank Average 1.72E+04 1.32E+04 
4 
Blank RSD 118% 104% 
Laser-cut 
Spiked Average 8.55E+03 7.83E+03 
4 
Spiked RSD 1% 24% 
Blank Average 2.61E+06 1.68E+06 
2 
Blank RSD 25% 25% 
Die-cut 
Spiked Average 3.76E+03 4.60E+03 
4 
Spiked RSD 57% 77% 
Blank Average 6.15E+06 3.97E+06 
3 
Blank RSD 36% 37% 
 
155
6-acetylmorphine
Cocktail G 
m/z 165 m/z 211 n 
Manual 
Spiked Average 8.69E+04 3.66E+04 
4 
Spiked RSD 11% 14% 
Blank Average 3.76E+04 1.64E+04 
4 
Blank RSD 36% 79% 
Laser-cut 
Spiked Average 9.03E+03 1.07E+04 
4 
Spiked RSD 14% 7% 
Blank Average 6.61E+04 3.93E+04 
2 
Blank RSD 24% 21% 
Die-cut 
Spiked Average 1.62E+04 9.08E+03 
4 
Spiked RSD 109% 70% 
Blank Average 9.86E+04 5.12E+04 
3 
Blank RSD 26% 25% 
Diltiazem 
Cocktail G 
m/z 178 m/z 150 n 
Manual 
Spiked Average 1.83E+06 7.92E+05 
4 
Spiked RSD 9% 9% 
Blank Average 2.40E+04 1.41E+04 
4 
Blank RSD 123% 100% 
Laser-cut 
Spiked Average 5.97E+03 8.12E+03 
4 
Spiked RSD 31% 18% 
Blank Average 4.91E+06 2.13E+06 
2 
Blank RSD 27% 27% 
Die-cut 
Spiked Average 2.17E+03 3.92E+03 
4 
Spiked RSD 94% 77% 
Blank Average 1.94E+07 8.48E+06 
3 
Blank RSD 31% 32% 
156
Alfentanil 
Cocktail G 
  m/z 268 m/z 197 n 
Manual 
Spiked Average 1.71E+05 1.17E+05 
4 
Spiked RSD 11% 10% 
Blank Average 6.35E+03 8.68E+03 
4 
Blank RSD 61% 39% 
Laser-cut 
Spiked Average 6.27E+02 2.05E+03 
4 
Spiked RSD 16% 14% 
Blank Average 1.99E+05 1.33E+05 
2 
Blank RSD 32% 30% 
Die-cut 
Spiked Average 3.07E+03 3.79E+03 
4 
Spiked RSD 100% 74% 
Blank Average 1.41E+06 8.76E+05 
3 
Blank RSD 42% 39% 
 
157
PCP 
Cocktail H 
m/z 91 m/z 159 n 
Manual 
Spiked Average 4.76E+05 2.60E+05 
4 
Spiked RSD 9% 9% 
Blank Average 5.58E+04 3.10E+04 
4 
Blank RSD 61% 58% 
Laser-cut 
Spiked Average 1.37E+06 6.51E+05 
4 
Spiked RSD 33% 37% 
Blank Average 7.27E+04 1.09E+04 
2 
Blank RSD 73% 32% 
Die-cut 
Spiked Average 1.34E+06 6.85E+05 
4 
Spiked RSD 30% 31% 
Blank Average 4.80E+04 7.39E+03 
3 
Blank RSD 39% 50% 
Meperidine 
Cocktail H 
m/z 220 m/z 174 n 
Manual 
Spiked Average 8.86E+05 5.04E+05 
4 
Spiked RSD 1% 2% 
Blank Average 5.66E+04 4.36E+04 
4 
Blank RSD 94% 73% 
Laser-cut 
Spiked Average 2.51E+06 1.55E+06 
4 
Spiked RSD 26% 27% 
Blank Average 8.62E+04 1.14E+05 
2 
Blank RSD 59% 67% 
Die-cut 
Spiked Average 2.61E+06 1.57E+06 
4 
Spiked RSD 28% 31% 
Blank Average 1.03E+04 1.58E+04 
3 
Blank RSD 55% 52% 
158
Diphenhydramine 
Cocktail H 
  m/z 167 m/z 165 n 
Manual 
Spiked Average 8.30E+05 3.63E+05 
4 
Spiked RSD 2% 1% 
Blank Average 6.65E+04 2.33E+04 
4 
Blank RSD 73% 92% 
Laser-cut 
Spiked Average 2.33E+06 1.04E+06 
4 
Spiked RSD 28% 30% 
Blank Average 2.11E+04 1.11E+04 
2 
Blank RSD 30% 52% 
Die-cut 
Spiked Average 2.49E+06 1.09E+06 
4 
Spiked RSD 26% 27% 
Blank Average 1.25E+04 4.73E+03 
3 
Blank RSD 43% 50% 
Doxylamine 
Cocktail H 
  m/z 167 m/z 182 n 
Manual 
Spiked Average 1.60E+06 1.41E+06 
4 
Spiked RSD 7% 8% 
Blank Average 9.87E+04 7.62E+04 
4 
Blank RSD 84% 96% 
Laser-cut 
Spiked Average 3.68E+06 3.22E+06 
4 
Spiked RSD 37% 34% 
Blank Average 5.48E+04 3.03E+04 
2 
Blank RSD 60% 5% 
Die-cut 
Spiked Average 4.15E+06 3.53E+06 
4 
Spiked RSD 32% 31% 
Blank Average 3.29E+04 1.15E+04 
3 
Blank RSD 43% 34% 
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EDDP 
Cocktail H 
m/z 234 m/z 249 n 
Manual 
Spiked Average 2.81E+06 1.15E+06 
4 
Spiked RSD 9% 10% 
Blank Average 2.26E+05 9.19E+04 
4 
Blank RSD 118% 118% 
Laser-cut 
Spiked Average 1.45E+07 5.95E+06 
4 
Spiked RSD 28% 28% 
Blank Average 2.96E+04 9.61E+03 
2 
Blank RSD 54% 54% 
Die-cut 
Spiked Average 1.46E+07 6.05E+06 
4 
Spiked RSD 30% 31% 
Blank Average 1.04E+04 2.21E+03 
3 
Blank RSD 36% 61% 
Promethazine 
Cocktail H 
m/z 86 m/z 198 n 
Manual 
Spiked Average 3.07E+05 1.31E+05 
4 
Spiked RSD 1% 1% 
Blank Average 5.14E+04 2.13E+04 
4 
Blank RSD 34% 39% 
Laser-cut 
Spiked Average 8.55E+05 3.82E+05 
4 
Spiked RSD 30% 32% 
Blank Average 5.14E+04 3.27E+04 
2 
Blank RSD 0% 16% 
Die-cut 
Spiked Average 7.36E+05 3.23E+05 
4 
Spiked RSD 28% 29% 
Blank Average 4.40E+04 1.98E+04 
3 
Blank RSD 26% 23% 
160
Brompheniramine 
Cocktail H 
  m/z 274 m/z 167 n 
Manual 
Spiked Average 7.88E+05 3.90E+05 
4 
Spiked RSD 5% 5% 
Blank Average 3.67E+04 4.20E+04 
4 
Blank RSD 93% 38% 
Laser-cut 
Spiked Average 2.64E+06 1.29E+06 
4 
Spiked RSD 32% 34% 
Blank Average 1.32E+04 1.31E+04 
2 
Blank RSD 69% 77% 
Die-cut 
Spiked Average 2.45E+06 1.17E+06 
4 
Spiked RSD 27% 28% 
Blank Average 3.41E+03 4.74E+03 
3 
Blank RSD 63% 63% 
Lorazepam 
Cocktail H 
  m/z 276 m/z 167 n 
Manual 
Spiked Average 7.82E+05 3.80E+05 
4 
Spiked RSD 5% 4% 
Blank Average 3.51E+04 3.46E+04 
4 
Blank RSD 95% 47% 
Laser-cut 
Spiked Average 2.54E+06 1.20E+06 
4 
Spiked RSD 29% 30% 
Blank Average 1.60E+04 1.08E+04 
2 
Blank RSD 43% 66% 
Die-cut 
Spiked Average 2.41E+06 1.14E+06 
4 
Spiked RSD 26% 26% 
Blank Average 8.18E+03 4.27E+03 
3 
Blank RSD 30% 65% 
 
161
Normeperidine 
Cocktail H 
m/z 160 m/z 56 n 
Manual 
Spiked Average 5.68E+05 1.30E+05 
4 
Spiked RSD 6% 6% 
Blank Average 5.18E+04 1.41E+04 
4 
Blank RSD 70% 76% 
Laser-cut 
Spiked Average 1.02E+06 2.08E+05 
4 
Spiked RSD 10% 10% 
Blank Average 1.41E+05 1.51E+04 
2 
Blank RSD 53% 64% 
Die-cut 
Spiked Average 1.15E+06 2.47E+05 
4 
Spiked RSD 17% 17% 
Blank Average 2.92E+04 3.06E+03 
3 
Blank RSD 29% 50% 
Flurazepam 
Cocktail H 
m/z 315 m/z 317 n 
Manual 
Spiked Average 9.48E+05 2.14E+05 
4 
Spiked RSD 2% 3% 
Blank Average 5.66E+04 1.79E+04 
4 
Blank RSD 106% 69% 
Laser-cut 
Spiked Average 4.32E+06 9.91E+05 
4 
Spiked RSD 34% 34% 
Blank Average 5.68E+03 2.06E+04 
2 
Blank RSD 68% 87% 
Die-cut 
Spiked Average 3.66E+06 8.32E+05 
4 
Spiked RSD 34% 32% 
Blank Average 1.85E+03 1.45E+03 
3 
Blank RSD 33% 38% 
162
Morphine 
Cocktail I 
  m/z 152 m/z 165 n 
Manual 
Spiked Average 1.53E+04 1.22E+04 
4 
Spiked RSD 18% 22% 
Blank Average 3.64E+03 3.80E+03 
4 
Blank RSD 70% 56% 
Laser-cut 
Spiked Average 3.70E+04 2.30E+04 
4 
Spiked RSD 15% 18% 
Blank Average 24154.03 10725.94 
2 
Blank RSD 62% 70% 
Die-cut 
Spiked Average 2.56E+04 1.60E+04 
1 
Spiked RSD - - 
Blank Average 6.67E+03 3.31E+03 
3 
Blank RSD 50% 67% 
Oxymorphone 
Cocktail I 
  m/z 227 m/z 198 n 
Manual 
Spiked Average 3.15E+04 2.43E+04 
4 
Spiked RSD 9% 11% 
Blank Average 3.76E+03 2.99E+03 
4 
Blank RSD 72% 71% 
Laser-cut 
Spiked Average 4.18E+04 4.68E+04 
4 
Spiked RSD 16% 19% 
Blank Average 13437.55 32548.87 
2 
Blank RSD 68% 72% 
Die-cut 
Spiked Average 3.74E+04 3.75E+04 
1 
Spiked RSD - - 
Blank Average 3.06E+03 5.25E+03 
3 
Blank RSD 58% 43% 
 
163
Zaleplon 
Cocktail I 
m/z 236 m/z 264 n 
Manual 
Spiked Average 5.80E+04 5.11E+04 
4 
Spiked RSD 41% 41% 
Blank Average 3.72E+03 3.41E+03 
4 
Blank RSD 91% 66% 
Laser-cut 
Spiked Average 5.74E+04 3.91E+04 
4 
Spiked RSD 31% 25% 
Blank Average 40471.3 13342.55 
2 
Blank RSD 64% 60% 
Die-cut 
Spiked Average 6.25E+04 6.21E+04 
1 
Spiked RSD - - 
Blank Average 3.55E+03 7.67E+03 
3 
Blank RSD 64% 88% 
Methadone 
Cocktail I 
m/z 265 m/z 105 n 
Manual 
Spiked Average 1.34E+06 4.41E+05 
4 
Spiked RSD 11% 10% 
Blank Average 3.69E+04 1.89E+04 
4 
Blank RSD 148% 111% 
Laser-cut 
Spiked Average 3.88E+06 1.26E+06 
4 
Spiked RSD 32% 33% 
Blank Average 15483.3 21467.25 
2 
Blank RSD 51% 74% 
Die-cut 
Spiked Average 1.11E+07 3.66E+06 
1 
Spiked RSD - - 
Blank Average 6.30E+03 1.20E+04 
3 
Blank RSD 64% 50% 
164
Clonazepam 
Cocktail I 
  m/z 270 m/z 214 n 
Manual 
Spiked Average 6.41E+04 1.88E+04 
4 
Spiked RSD 50% 51% 
Blank Average 1.17E+04 1.90E+03 
4 
Blank RSD 52% 70% 
Laser-cut 
Spiked Average 5.63E+04 2.50E+04 
4 
Spiked RSD 29% 31% 
Blank Average 71418.77 29487.67 
2 
Blank RSD 70% 74% 
Die-cut 
Spiked Average 5.33E+04 1.27E+04 
1 
Spiked RSD - - 
Blank Average 2.09E+04 3.07E+03 
3 
Blank RSD 48% 44% 
Fluvoxamine 
Cocktail I 
  m/z 71 m/z 200 n 
Manual 
Spiked Average 1.02E+05 2.55E+04 
4 
Spiked RSD 4% 9% 
Blank Average 1.00E+04 6.20E+03 
4 
Blank RSD 63% 44% 
Laser-cut 
Spiked Average 1.76E+05 4.06E+04 
4 
Spiked RSD 9% 8% 
Blank Average 16634.52 10218.4 
2 
Blank RSD 86% 6% 
Die-cut 
Spiked Average 3.50E+05 8.35E+04 
1 
Spiked RSD - - 
Blank Average 9.53E+03 6.28E+03 
3 
Blank RSD 42% 24% 
 
165
Paroxetine 
Cocktail I 
m/z 192 m/z 70 n 
Manual 
Spiked Average 7.46E+04 4.37E+04 
4 
Spiked RSD 5% 2% 
Blank Average 8.35E+03 6.79E+03 
4 
Blank RSD 61% 54% 
Laser-cut 
Spiked Average 1.29E+05 6.51E+04 
4 
Spiked RSD 11% 12% 
Blank Average 16409.67 7930.324 
2 
Blank RSD 39% 72% 
Die-cut 
Spiked Average 1.40E+05 7.93E+04 
1 
Spiked RSD - - 
Blank Average 5.33E+03 7.07E+03 
3 
Blank RSD 44% 69% 
Buspirone 
Cocktail I 
m/z 122 m/z 95 n 
Manual 
Spiked Average 7.62E+05 1.74E+05 
4 
Spiked RSD 12% 2% 
Blank Average 2.09E+04 3.20E+04 
4 
Blank RSD 131% 43% 
Laser-cut 
Spiked Average 3.14E+06 5.83E+05 
4 
Spiked RSD 24% 24% 
Blank Average 26690.31 38870.77 
2 
Blank RSD 68% 69% 
Die-cut 
Spiked Average 1.13E+07 2.05E+06 
1 
Spiked RSD - - 
Blank Average 5.71E+03 2.26E+04 
3 
Blank RSD 58% 48% 
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Chlorpheniramine 
Cocktail I 
  m/z 230 m/z 167 n 
Manual 
Spiked Average 9.67E+05 4.96E+05 
4 
Spiked RSD 11% 9% 
Blank Average 2.23E+04 1.77E+04 
4 
Blank RSD 149% 113% 
Laser-cut 
Spiked Average 2.48E+06 1.25E+06 
4 
Spiked RSD 26% 26% 
Blank Average 93527.49 13034.49 
2 
Blank RSD 83% 73% 
Die-cut 
Spiked Average 1.04E+07 5.25E+06 
1 
Spiked RSD - - 
Blank Average 8.75E+03 3.96E+03 
3 
Blank RSD 45% 63% 
Zopiclone 
Cocktail I 
  m/z 245 m/z 111 n 
Manual 
Spiked Average 1.40E+05 4.89E+04 
4 
Spiked RSD 5% 4% 
Blank Average 2.80E+04 2.72E+03 
4 
Blank RSD 29% 75% 
Laser-cut 
Spiked Average 1.25E+05 4.17E+04 
4 
Spiked RSD 17% 17% 
Blank Average 34498.15 3883.349 
2 
Blank RSD 34% 28% 
Die-cut 
Spiked Average 9.94E+04 3.65E+04 
1 
Spiked RSD - - 
Blank Average 1.45E+04 5.05E+03 
3 
Blank RSD 33% 80% 
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Methylphenidate 
Cocktail J 
m/z 84 m/z 56 n 
Manual 
Spiked Average 9.00E+05 1.18E+05 
4 
Spiked RSD 7% 7% 
Blank Average 7.69E+04 1.96E+04 
4 
Blank RSD 43% 36% 
Laser-cut 
Spiked Average 2.67E+06 3.60E+05 
4 
Spiked RSD 25% 20% 
Blank Average 2.34E+04 7.49E+04 
3 
Blank RSD 40% 38% 
Nordoxepin 
Cocktail J 
m/z 107 m/z 235 n 
Manual 
Spiked Average 1.06E+05 6.27E+04 
4 
Spiked RSD 4% 5% 
Blank Average 1.27E+04 4.58E+03 
4 
Blank RSD 55% 72% 
Laser-cut 
Spiked Average 2.73E+05 1.53E+05 
4 
Spiked RSD 6% 6% 
Blank Average 2.64E+04 4.20E+03 
3 
Blank RSD 50% 68% 
Desipramine 
Cocktail J 
m/z 72 m/z 193 n 
Manual 
Spiked Average 1.54E+05 5.64E+04 
4 
Spiked RSD 5% 6% 
Blank Average 8.80E+03 9.66E+03 
4 
Blank RSD 69% 32% 
Laser-cut 
Spiked Average 4.34E+05 1.16E+05 
4 
Spiked RSD 6% 5% 
Blank Average 1.74E+03 2.35E+04 
3 
Blank RSD 59% 53% 
168
7-aminoflunitrazepam 
Cocktail J 
  m/z 135 m/z 227 n 
Manual 
Spiked Average 1.17E+05 5.96E+04 
4 
Spiked RSD 11% 6% 
Blank Average 1.11E+04 4.76E+03 
4 
Blank RSD 38% 58% 
Laser-cut 
Spiked Average 2.42E+05 1.33E+05 
4 
Spiked RSD 24% 26% 
Blank Average 2.79E+04 1.60E+04 
3 
Blank RSD 52% 47% 
Trimipramine 
Cocktail J 
  m/z 193 m/z 208 n 
Manual 
Spiked Average 5.64E+04 4.11E+04 
4 
Spiked RSD 6% 7% 
Blank Average 6.94E+03 5.44E+03 
4 
Blank RSD 47% 31% 
Laser-cut 
Spiked Average 1.53E+05 1.53E+05 
4 
Spiked RSD 19% 19% 
Blank Average 6.00E+03 5.99E+03 
3 
Blank RSD 51% 51% 
Norfluoxetine 
Cocktail J 
  m/z 134 m/z 30 n 
Manual 
Spiked Average 1.47E+04 2.81E+03 
4 
Spiked RSD 10% 12% 
Blank Average 5.42E+03 2.70E+02 
4 
Blank RSD 28% 84% 
Laser-cut 
Spiked Average 1.41E+04 2.64E+03 
4 
Spiked RSD 7% 6% 
Blank Average 3.61E+03 3.47E+01 
3 
Blank RSD 44% 73% 
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Duloxetine 
Cocktail J 
m/z 44 m/z 154 n 
Manual 
Spiked Average 1.16E+04 1.11E+04 
4 
Spiked RSD 37% 31% 
Blank Average 5.94E+03 5.66E+03 
4 
Blank RSD 66% 66% 
Laser-cut 
Spiked Average 1.70E+04 1.49E+04 
4 
Spiked RSD 9% 4% 
Blank Average 1.21E+03 4.43E+03 3 
Blank RSD 82% 46% 
Benztropine 
Cocktail J 
m/z 167 m/z 165 n 
Manual 
Spiked Average 4.06E+05 1.82E+05 
4 
Spiked RSD 7% 8% 
Blank Average 3.03E+04 1.44E+04 
4 
Blank RSD 38% 41% 
Laser-cut 
Spiked Average 1.97E+06 8.94E+05 
4 
Spiked RSD 18% 19% 
Blank Average 1.01E+04 7.58E+03 
3 
Blank RSD 59% 64% 
Fluoxetine 
Cocktail J 
m/z 44 m/z 148 n 
Manual 
Spiked Average 4.47E+04 7.32E+03 
4 
Spiked RSD 4% 7% 
Blank Average 3.01E+03 1.26E+03 
4 
Blank RSD 70% 12% 
Laser-cut 
Spiked Average 1.03E+05 1.79E+04 
4 
Spiked RSD 4% 7% 
Blank Average 4.71E+02 6.06E+03 
3 
Blank RSD 61% 49% 
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Flunitrazepam 
Cocktail J 
  m/z 268 m/z 239 n 
Manual 
Spiked Average 8.77E+04 2.80E+04 
4 
Spiked RSD 14% 15% 
Blank Average 2.56E+04 3.91E+03 
4 
Blank RSD 47% 56% 
Laser-cut 
Spiked Average 1.38E+05 3.16E+04 
4 
Spiked RSD 18% 22% 
Blank Average 5.66E+04 6.22E+03 
3 
Blank RSD 56% 54% 
Clomipramine 
Cocktail J 
  m/z 227 m/z 242 n 
Manual 
Spiked Average 3.20E+04 2.05E+04 
4 
Spiked RSD 3% 5% 
Blank Average 8.74E+03 4.26E+03 
4 
Blank RSD 33% 37% 
Laser-cut 
Spiked Average 1.11E+05 7.42E+04 
4 
Spiked RSD 11% 10% 
Blank Average 1.09E+04 4.75E+03 
3 
Blank RSD 69% 57% 
Triazolam 
Cocktail J 
  m/z 308 m/z 239 n 
Manual 
Spiked Average 4.48E+04 3.81E+04 
4 
Spiked RSD 12% 12% 
Blank Average 3.35E+03 7.35E+03 
4 
Blank RSD 85% 42% 
Laser-cut 
Spiked Average 1.83E+05 1.47E+05 
4 
Spiked RSD 27% 24% 
Blank Average 5.43E+02 1.14E+04 
3 
Blank RSD 66% 60% 
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Amlodipine 
Cocktail J 
m/z 238 m/z 294 n 
Manual 
Spiked Average 4.44E+04 3.40E+04 
4 
Spiked RSD 3% 1% 
Blank Average 1.79E+04 1.58E+04 
4 
Blank RSD 13% 15% 
Laser-cut 
Spiked Average 4.00E+04 3.16E+04 
4 
Spiked RSD 8% 12% 
Blank Average 2.38E+03 1.41E+04 
3 
Blank RSD 27% 15% 
mCPP 
Cocktail J 
m/z 154 m/z 118 n 
Manual 
Spiked Average 1.27E+05 1.03E+05 
4 
Spiked RSD 5% 5% 
Blank Average 1.98E+04 7.94E+03 
4 
Blank RSD 56% 62% 
Laser-cut 
Spiked Average 1.53E+05 1.37E+05 
4 
Spiked RSD 8% 5% 
Blank Average 1.99E+04 3.15E+04 
3 
Blank RSD 44% 43% 
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Cyclobenzaprine 
Cocktail K 
  m/z 215 m/z 231 n 
Manual 
Spiked Average 1.32E+06 5.16E+05 
4 
Spiked RSD 121% 121% 
Blank Average 2.8E+05 1.1E+05 
3 
Blank RSD 53% 51% 
Laser-cut 
Spiked Average 6.30E+05 2.64E+05 
3 
Spiked RSD 31% 32% 
Blank Average 4.19E+03 1.13E+04 
3 
Blank RSD 65% 55% 
Zolpidem 
Cocktail K 
  m/z 92 m/z 235 n 
Manual 
Spiked Average 9.54E+05 5.07E+06 
4 
Spiked RSD 103% 104% 
Blank Average 2.1E+05 1.1E+06 
3 
Blank RSD 49% 51% 
Laser-cut 
Spiked Average 6.59E+05 3.34E+06 
3 
Spiked RSD 42% 41% 
Blank Average 2.69E+04 5.62E+03 
3 
Blank RSD 51% 54% 
Alprazolam 
Cocktail K 
  m/z 205 m/z 281 n 
Manual 
Spiked Average 4.81E+05 5.52E+05 
4 
Spiked RSD 78% 80% 
Blank Average 1.7E+05 1.9E+05 
3 
Blank RSD 13% 13% 
Laser-cut 
Spiked Average 5.68E+04 7.02E+04 
3 
Spiked RSD 64% 61% 
Blank Average 9.88E+03 1.91E+04 
3 
Blank RSD 51% 47% 
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Fentanyl 
Cocktail K 
  m/z 188 m/z 105 n 
Manual 
Spiked Average 2.23E+06 1.70E+06 
4 
Spiked RSD 114% 108% 
Blank Average 4.6E+05 4.0E+05 
3 
Blank RSD 54% 43% 
Laser-cut 
Spiked Average 1.46E+06 1.10E+06 
3 
Spiked RSD 37% 37% 
Blank Average 1.08E+05 4.19E+04 
3 
Blank RSD 19% 37% 
Haloperidol 
Cocktail K 
  m/z 122 m/z 165 n 
Manual 
Spiked Average 1.30E+06 1.20E+06 
4 
Spiked RSD 115% 117% 
Blank Average 3.1E+05 2.8E+05 
3 
Blank RSD 51% 52% 
Laser-cut 
Spiked Average 6.23E+05 5.64E+05 
3 
Spiked RSD 36% 36% 
Blank Average 1.60E+04 1.42E+04 
3 
Blank RSD 52% 39% 
Risperidone 
Cocktail K 
  m/z 191 m/z 110 n 
Manual 
Spiked Average 2.45E+06 1.96E+05 
4 
Spiked RSD 100% 96% 
Blank Average 7.3E+05 6.2E+04 
3 
Blank RSD 56% 48% 
Laser-cut 
Spiked Average 2.11E+06 1.75E+05 
3 
Spiked RSD 33% 35% 
Blank Average 1.50E+04 9.35E+03 
3 
Blank RSD 45% 62% 
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9-hydroxyrisperidone 
Cocktail K 
  m/z 207 m/z 110 n 
Manual 
Spiked Average 1.75E+06 3.88E+05 
4 
Spiked RSD 82% 84% 
Blank Average 5.8E+05 1.4E+05 
3 
Blank RSD 55% 54% 
Laser-cut 
Spiked Average 1.49E+06 3.58E+05 
3 
Spiked RSD 36% 38% 
Blank Average 1.90E+04 2.20E+04 
3 
Blank RSD 31% 48% 
Ropinirole 
Cocktail K 
  m/z 114 m/z 132 n 
Manual 
Spiked Average 1.31E+06 2.90E+05 
4 
Spiked RSD 112% 111% 
Blank Average 2.8E+05 6.5E+04 
3 
Blank RSD 53% 49% 
Laser-cut 
Spiked Average 5.49E+05 1.72E+05 
3 
Spiked RSD 33% 34% 
Blank Average 7.84E+03 4.82E+04 
3 
Blank RSD 35% 49% 
Dextromethorphan 
Cocktail K 
  m/z 215 m/z 147 n 
Manual 
Spiked Average 8.50E+05 6.58E+05 
4 
Spiked RSD 119% 118% 
Blank Average 1.9E+05 1.5E+05 
3 
Blank RSD 52% 52% 
Laser-cut 
Spiked Average 4.84E+05 3.93E+05 
3 
Spiked RSD 28% 29% 
Blank Average 2.06E+04 3.54E+04 
3 
Blank RSD 50% 50% 
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Benzoylecgonine 
Cocktail L 
m/z 168 m/z 77 n 
Manual 
Spiked Average 4.30E+05 1.65E+05 
4 
Spiked RSD 42% 37% 
Blank Average 4.05E+04 3.76E+04 
4 
Blank RSD 62% 92% 
Laser-cut 
Spiked Average 7.02E+05 3.58E+05 
4 
Spiked RSD 84% 75% 
Blank Average 9.14E+03 8.12E+04 
4 
Blank RSD 85% 85% 
Amitriptyline 
Cocktail L 
m/z 233 m/z 117 n 
Manual 
Spiked Average 2.30E+05 1.42E+05 
4 
Spiked RSD 17% 17% 
Blank Average 1.07E+04 1.01E+04 
4 
Blank RSD 67% 77% 
Laser-cut 
Spiked Average 7.67E+05 4.51E+05 
4 
Spiked RSD 43% 41% 
Blank Average 2.06E+04 9.81E+03 
4 
Blank RSD 53% 59% 
Nortriptyline 
Cocktail L 
m/z 233 m/z 117 n 
Manual 
Spiked Average 1.83E+05 8.16E+04 
4 
Spiked RSD 16% 12% 
Blank Average 5.82E+03 6.54E+03 
4 
Blank RSD 84% 66% 
Laser-cut 
Spiked Average 3.87E+05 1.70E+05 
4 
Spiked RSD 18% 14% 
Blank Average 7.10E+03 7.29E+03 
4 
Blank RSD 21% 69% 
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Atenolol 
Cocktail L 
  m/z 145 m/z 190 n 
Manual 
Spiked Average 9.32E+05 6.53E+05 
4 
Spiked RSD 18% 19% 
Blank Average 1.47E+05 5.46E+04 
4 
Blank RSD 84% 103% 
Laser-cut 
Spiked Average 9.65E+05 7.43E+05 
4 
Spiked RSD 3% 4% 
Blank Average 2.15E+04 4.91E+03 
4 
Blank RSD 66% 63% 
Hydrocodone 
Cocktail L 
  m/z 199 m/z 171 n 
Manual 
Spiked Average 1.87E+05 7.52E+04 
4 
Spiked RSD 18% 16% 
Blank Average 9.96E+03 7.35E+03 
4 
Blank RSD 67% 70% 
Laser-cut 
Spiked Average 1.57E+05 8.85E+04 
4 
Spiked RSD 10% 36% 
Blank Average 9.32E+03 1.68E+04 
4 
Blank RSD 89% 86% 
Diazepam 
Cocktail L 
  m/z 154 m/z 222 n 
Manual 
Spiked Average 2.53E+05 1.98E+05 
4 
Spiked RSD 26% 23% 
Blank Average 1.40E+04 8.84E+03 
4 
Blank RSD 91% 105% 
Laser-cut 
Spiked Average 1.67E+05 1.35E+05 
4 
Spiked RSD 25% 27% 
Blank Average 8.90E+03 4.00E+03 
4 
Blank RSD 83% 81% 
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Temazepam 
Cocktail M 
m/z 177 m/z 239 n 
Manual 
Spiked Average 5.10E+04 1.35E+04 
4 
Spiked RSD 14% 9% 
Blank Average 2.44E+04 4.00E+03 
4 
Blank RSD 70% 56% 
Laser-cut 
Spiked Average 4.33E+04 2.05E+04 
4 
Spiked RSD 27% 30% 
Blank Average 6.43E+03 5.90E+03 
4 
Blank RSD 93% 74% 
Doxepine 
Cocktail M 
m/z 107 m/z 165 n 
Manual 
Spiked Average 2.08E+05 9.94E+04 
4 
Spiked RSD 17% 18% 
Blank Average 1.76E+04 6.45E+03 
4 
Blank RSD 73% 79% 
Laser-cut 
Spiked Average 5.21E+05 2.65E+05 
4 
Spiked RSD 24% 24% 
Blank Average 1.83E+04 9.39E+03 
4 
Blank RSD 51% 75% 
Nordiazepam 
Cocktail M 
m/z 140 m/z 208 n 
Manual 
Spiked Average 2.05E+05 1.47E+05 
4 
Spiked RSD 25% 25% 
Blank Average 4.64E+03 5.02E+03 
4 
Blank RSD 29% 46% 
Laser-cut 
Spiked Average 8.33E+04 6.05E+04 
4 
Spiked RSD 33% 33% 
Blank Average 3.40E+03 3.71E+03 
4 
Blank RSD 99% 75% 
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Citalopram 
Cocktail M 
  m/z 262 m/z 234 n 
Manual 
Spiked Average 3.01E+04 2.35E+04 
4 
Spiked RSD 17% 11% 
Blank Average 1.83E+03 3.90E+03 
4 
Blank RSD 63% 58% 
Laser-cut 
Spiked Average 7.36E+04 4.99E+04 
4 
Spiked RSD 17% 16% 
Blank Average 2.62E+03 4.18E+03 
4 
Blank RSD 73% 49% 
Oxazepam 
Cocktail M 
  m/z 241 m/z 77 n 
Manual 
Spiked Average 1.49E+05 1.33E+05 
4 
Spiked RSD 20% 31% 
Blank Average 8.73E+04 9.94E+04 
4 
Blank RSD 65% 83% 
Laser-cut 
Spiked Average 1.24E+05 2.33E+05 
4 
Spiked RSD 30% 23% 
Blank Average 5.67E+04 1.23E+05 
4 
Blank RSD 64% 46% 
Hydromorphone 
Cocktail M 
  m/z 185 m/z 157 n 
Manual 
Spiked Average 4.71E+04 3.63E+04 
4 
Spiked RSD 10% 11% 
Blank Average 7.64E+03 8.64E+03 
4 
Blank RSD 42% 61% 
Laser-cut 
Spiked Average 7.12E+04 7.50E+04 
4 
Spiked RSD 16% 24% 
Blank Average 1.53E+04 2.84E+04 
4 
Blank RSD 67% 66% 
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Codeine 
Cocktail M 
m/z 215 m/z 199 n 
Manual 
Spiked Average 4.74E+04 3.53E+04 
4 
Spiked RSD 14% 20% 
Blank Average 4.67E+03 9.95E+03 
4 
Blank RSD 57% 67% 
Laser-cut 
Spiked Average 9.30E+04 4.25E+04 
4 
Spiked RSD 24% 21% 
Blank Average 2.54E+04 9.31E+03 
4 
Blank RSD 76% 88% 
Cocaine 
Cocktail M 
m/z 182 m/z 82 n 
Manual 
Spiked Average 2.40E+06 5.54E+05 
4 
Spiked RSD 18% 18% 
Blank Average 5.27E+04 3.97E+04 
4 
Blank RSD 12% 81% 
Laser-cut 
Spiked Average 5.73E+06 1.26E+06 
4 
Spiked RSD 40% 40% 
Blank Average 5.89E+04 2.55E+04 
4 
Blank RSD 183% 104% 
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APPENDIX F 
Exogenous interferences identified for each target analyte using the Human Metabolome 
Database and DrugBank 
Target Analyte Interference Compound Formula 
Molecular 
Weight 
Acetaminophen 
2-Amino-3-methylbenzoate C8H9NO2 151.1 
Dopamine quinone C8H9NO2 151.1 
Cathine C9H13NO 151.1 
Phenylpropanolamine C9H13NO 151.1 
4-Hydroxyamphetamine C9H13NO 151.1 
Amantadine C10H17N 151.1 
Alfentanil 
Trovafloxacin C20H15F3N4O3 416.1 
Ramipril C23H32N2O5 416.2 
Forasartan C23H28N8 416.2 
Alpha-PVP 
Paracetamol sulfate C8H9NO5S 231.0 
Isocarboxazid C12H13N3O2 231.1 
Fenfluramine C12H16F3N 231.1 
Dexfenfluramine C12H16F3N 231.1 
Aminophenazone C13H17N3O 231.1 
Alprazolam 
Pinazepam C18H13ClN2O 308.1 
Fluoxetine glucuronide C16H16N6O 308.1 
Phenylbutazone C19H20N2O2 308.2 
8-Hydroxycarteolol C16H24N2O4 308.2 
Indecainide C20H24N2O 308.2 
Oxybuprocaine C17H28N2O3 308.2 
Amitriptyline; Venlafaxine, 
EDDP 
DOPA sulfate C9H11NO7S 277.0 
Azathioprine C9H7N7O2S 277.0 
Ethylmethylthiambutene C15H19NS2 277.1 
Entecavir C12H15N5O3 277.1 
Maprotiline C20H23N 277.2 
N-Desmethylterbinafine C20H23N 277.2 
Perhexiline C19H35N 277.3 
Amlodipine 
Melatonin glucuronide C19H24N2O8 408.2 
Tamsulosin C20H28N2O5S 408.2 
Amphetamine 
Homocysteine C4H9NO2S 135.0 
Adenine C5H5N5 135.1 
Aripiprazole Hydromorphone-3-glucoside C23H29NO8 447.2 
Baclofen Chloroxine C9H5Cl2NO 213.0 
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Target Analyte Interference Compound Formula 
Molecular 
Weight 
Carmustine C5H9Cl2N3O2 213.0 
Droxidopa C9H11NO5 213.1 
Phenazopyridine C11H11N5 213.1 
Guanadrel Sulfate C10H19N3O2 213.1 
Benzoylecgonine 
Quinethazone C10H12ClN3O3S 289.0 
Chlophedianol C17H20ClNO 289.1 
Clofedanol C17H20ClNO 289.1 
Norcocaine C16H19NO4 289.1 
Chloropyramine C16H20ClN3 289.1 
Hydroxylated N-acetyl desmethyl 
frovatriptan 
C15H19N3O3 289.1 
Hyoscyamine C17H23NO3 289.2 
Donepezil metabolite M4 C17H23NO3 289.2 
Atropine C17H23NO3 289.2 
Dyclonine C18H27NO2 289.2 
Benztropine; Zolpidem 
2-oxobrimonidine C11H10BrN5O 307.0 
Nitazoxanide C12H9N3O5S 307.0 
Histamine Phosphate C5H15N3O8P2 307.0 
Glutathione C10H17N3O6S 307.1 
Tolnaftate C19H17NOS 307.1 
Alcaftadine C19H21N3O 307.2 
Ibopamine C17H25NO4 307.2 
Hydroxyterbinafine C21H25NO 307.2 
Betaxolol C18H29NO3 307.2 
Fingolimod C19H33NO2 307.3 
Benzylpiperazine 
Pemoline C9H8N2O2 176.1 
4-Methylaminorex C10H12N2O 176.1 
Cotinine C10H12N2O 176.1 
Brompheniramine; 
Chlorpromazine, Fluvoxamine 
Clotiazepam C16H15ClN2OS 318.1 
fluvoxamino acid C14H17F3N2O3 318.1 
5-Hydroxyemedastine C17H26N4O2 318.2 
Glycopyrrolate C19H28NO3 318.2 
Tridihexethyl C21H36NO 318.3 
Buprenorphine 
N-Desmethylrosuvastatin C21H26FN3O6S 467.2 
4-Hydroxytamoxifen sulfate C26H29NO5S 467.2 
Tobramycin C18H37N5O9 467.3 
Buprenorphine Tiropramide C28H41N3O3 467.3 
Bupropion 
9-Carboxymethoxymethylguanine C8H9N5O4 239.1 
Salbutamol C13H21NO3 239.2 
Moprolol C13H21NO3 239.2 
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Target Analyte Interference Compound Formula 
Molecular 
Weight 
Isoetharine C13H21NO3 239.2 
Benzphetamine C17H21N 239.2 
Buspirone 
5-hydroxylansoprazole C16H14F3N3O3S 385.1 
Hydroxylansoprazole C16H14F3N3O3S 385.1 
Lansoprazole sulfone C16H14F3N3O3S 385.1 
Phosphatidylserine C13H24NO10P 385.1 
Nilvadipine C19H19N3O6 385.1 
Carbamazepine 
Isosorbide Dinitrate C6H8N2O8 236.0 
Zileuton C11H12N2O2S 236.1 
Didanosine C10H12N4O3 236.1 
Hexobarbital C12H16N2O3 236.1 
O-Desmethyl-lacosamide C12H16N2O3 236.1 
Procaine C13H20N2O2 236.2 
Carbamazepine-10,11-epoxide; 
Phenytoin 
Hydroxyzileuton C11H12N2O3S 252.1 
Zileuton sulfoxide C11H12N2O3S 252.1 
Oxcarbazepine C15H12N2O2 252.1 
2-Hydroxycarbamazepine C15H12N2O2 252.1 
Epoxy-hexobarbital C12H16N2O4 252.1 
3'-Hydroxyhexobarbital C12H16N2O4 252.1 
Cimetidine C10H16N6S 252.1 
Talbutal C13H20N2O3 252.1 
Carisoprodol; Ropinirole 
Ifosfamide C7H15Cl2N2O2P 260.0 
Cyclophosphamide C7H15Cl2N2O2P 260.0 
Fenspiride C15H20N2O2 260.2 
Oxymetazoline C16H24N2O 260.2 
Chlordiazepoxide; 
Metoclopraminde; Codeine; 
Hydrocodone 
Imipenem C12H17N3O4S 299.1 
N-desalkylpropafenone C18H21NO3 299.2 
N-depropylpropafenone C18H21NO3 299.2 
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Target Analyte Interference Compound Formula 
Molecular 
Weight 
Chlorpheniramine 
4-Ketoifosfamide C7H13Cl2N2O3P 274.0 
4-Ketocyclophosphamide C7H13Cl2N2O3P 274.0 
5-Hydroxythalidomide C13H10N2O5 274.1 
Thalidomide arene oxide C13H10N2O5 274.1 
cis,trans-5'-Hydroxythalidomide C13H10N2O5 274.1 
N2-Succinoylarginine C10H18N4O5 274.1 
Ropivacaine C17H26N2O 274.2 
5-Methoxy-N,N-
diisopropyltryptamine 
C17H26N2O 274.2 
Citalopram 
Dorzolamide C10H16N2O4S3 324.0 
4-hydroxyalprazolam C17H13ClN4O 324.1 
Alpha-hydroxyalprazolam C17H13ClN4O 324.1 
Prazepam C19H17ClN2O 324.1 
Acetohexamide C15H20N2O4S 324.1 
Dolasetron C19H20N2O3 324.1 
Ditazole C19H20N2O3 324.1 
Valaciclovir C13H20N6O4 324.2 
Quinidine C20H24N2O2 324.2 
Quinine C20H24N2O2 324.2 
Diampromide C21H28N2O 324.2 
Clomipramine; Ranitidine; 
Delta-9-THC 
Clorazepate C16H11ClN2O3 314.0 
Dantrolene C14H10N4O5 314.1 
Sulfaphenazole C15H14N4O2S 314.1 
Pergolide C19H26N2S 314.2 
Clonazepam; Oxycodone 
Bromazepam C14H10BrN3O 315.0 
Efavirenz C14H9ClF3NO2 315.0 
Chlorprothixene C18H18ClNS 315.1 
Codeine N-oxide C18H21NO4 315.1 
Rotigotine C19H25NOS 315.2 
Alizapride C16H21N5O2 315.2 
Mitiglinide C19H25NO3 315.2 
Saxagliptin C18H25N3O2 315.2 
Clozapine 
Niclosamide C13H8Cl2N2O4 326.0 
5-Fluorodeoxyuridine
monophosphate
C9H12FN2O8P 326.0 
Hydroxyhexamide C15H22N2O4S 326.1 
Aceprometazine C19H22N2OS 326.1 
Acepromazine C19H22N2OS 326.1 
Ajmaline C20H26N2O2 326.2 
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Target Analyte Interference Compound Formula 
Molecular 
Weight 
Cocaethylene 
Nilutamide C12H10F3N3O4 317.1 
N2-Monodes-methylnizatidine C11H19N5O2S2 317.1 
Arbutamine C18H23NO4 317.2 
beta-oxycodol C18H23NO4 317.2 
Nateglinide C19H27NO3 317.2 
Tetrabenazine C19H27NO3 317.2 
Butenafine C23H27N 317.2 
Cocaine 
Clofarabine C10H11ClFN5O3 303.1 
Chlorambucil C14H19Cl2NO2 303.1 
Flumazenil C15H14FN3O3 303.1 
Pipemidic acid C14H17N5O3 303.1 
Cocaine 
Ezogabine C16H18FN3O2 303.1 
Phenoxybenzamine C18H22ClNO 303.1 
Fenoterol C17H21NO4 303.1 
7-Hydroxyetodolac C17H21NO4 303.1 
alpha-noroxycodol C17H21NO4 303.1 
Scopolamine C17H21NO4 303.1 
Hydromorphinol C17H21NO4 303.1 
Vildagliptin C17H25N3O2 303.2 
Cyclobenzaprine; MDPV 
Iobenguane C8H10IN3 275.0 
Lorcaserin sulfamate C11H14ClNO3S 275.0 
4'-hydroxypropanolol C16H21NO3 275.2 
Physostigmine C15H21N3O2 275.2 
Alphameprodine C17H25NO2 275.2 
Demoxepam; Oxazepam 
norclobazam C15H11ClN2O2 286.1 
nortemazepam C15H11ClN2O2 286.1 
3-Hydroxynordiazepam C15H11ClN2O2 286.1 
Phenytoin dihydrodiol C15H14N2O4 286.1 
4-Hydroxy tolbutamide C12H18N2O4S 286.1 
Abacavir C14H18N6O 286.2 
10-alpha-methoxy-9,10-
dihydrolysergol 
C17H22N2O2 286.2 
Desalkylflurazepam; 
Bupivacaine 
Tetrazepam C16H17ClN2O 288.1 
Sodium lauryl sulfate C12H25NaO4S 288.1 
Desipramine; Atenolol 
Carbamazepine-O-quinone C15H10N2O3 266.1 
Nevirapine C15H14N4O 266.1 
Practolol C14H22N2O3 266.2 
Cyclizine C18H22N2 266.2 
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Target Analyte Interference Compound Formula 
Molecular 
Weight 
Desmethylclomipramine; 
Temazepam 
Tazobactam C10H12N4O5S 300.1 
Clobazam C16H13ClN2O2 300.1 
Promazine 5-sulfoxide C17H20N2OS 300.1 
Chlorcyclizine C18H21ClN2 300.1 
Dextromethorphan 
6,7-Dichloro-3-hydroxy-1,5 dihydro-
imidazo[2,1-b]quinazolin-2-one 
C10H7Cl2N3O2 271.0 
4-hydroxy ketorolac C15H13NO4 271.1 
Norhydromorphone C16H17NO3 271.1 
Normorphine C16H17NO3 271.1 
Bupranolol C14H22ClNO2 271.1 
Desomorphine C17H21NO2 271.2 
4-Hydroxyatomoxetine C17H21NO2 271.2 
Diphenhydramine; Lamotrigine 
Gallium nitrate GaN3O9 254.9 
Anagrelide C10H7Cl2N3O 255.0 
Diphenhydramine; Lamotrigine 
Sulfathiazole C9H9N3O2S2 255.0 
Pranoprofen C15H13NO3 255.1 
Ketorolac C15H13NO3 255.1 
Ganciclovir C9H13N5O4 255.1 
Hydroxybupropion C13H18ClNO2 255.1 
Atomoxetine C17H21NO 255.2 
N-Demethyl orphenadrine C17H21NO 255.2 
Tripelennamine C16H21N3 255.2 
Donepezil 
Trichlormethiazide C8H8Cl3N3O4S2 378.9 
6-Thioguanosine monophosphate C10H14N5O7PS 379.0 
6-Thioguanylic acid C10H14N5O7PS 379.0 
Droperidol C22H22FN3O2 379.2 
Doxepin 
7-Hydroxyticlopidine C14H14ClNOS 279.0 
Ticlopidine S-oxide C14H14ClNOS 279.0 
2-Oxoticlopidine C14H14ClNOS 279.0 
Cidofovir C8H14N3O6P 279.1 
Oxamniquine C14H21N3O3 279.2 
E-10-Hydroxynortriptyline C19H21NO 279.2 
Etamiphylline C13H21N5O2 279.2 
Sibutramine C17H26ClN 279.2 
Duloxetine 
Cisplatin Cl2H4N2Pt 296.9 
2-Chloroticlopidine C14H13Cl2NS 297.0 
Albendazole sulfone C12H15N3O4S 297.1 
Nelarabine C11H15N5O5 297.1 
mono-isopropyl-disopyramide C18H23N3O 297.2 
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Molecular 
Weight 
Ephedrine; Pseudoephedrine 
Benzocaine C9H11NO2 165.1 
L-Phenylalanine C9H11NO2 165.1 
4-Methoxyamphetamine C10H15NO 165.1 
4-Hydroxymethamphetamine C10H15NO 165.1 
Hordenine C10H15NO 165.1 
Etomidate 
Apraclonidine C9H10Cl2N4 244.0 
Ribavirin C8H12N4O5 244.1 
Azacitidine C8H12N4O5 244.1 
Biotin C10H16N2O3S 244.1 
Carbidopa C10H16N2O5 244.1 
Felbamate Rufinamide C10H8F2N4O 238.1 
Fentanyl 
Captopril-cysteine disulfide C12H20N2O5S2 336.1 
Berberine C20H18NO4 336.1 
Acebutolol C18H28N2O4 336.2 
Acetyl-alpha-methylfentanyl C22H28N2O 336.2 
Flecainide; Diltiazem 
Miconazole C18H14Cl4N2O 414.0 
Nafcillin C21H22N2O5S 414.1 
N-desalkyl delavirdine C19H22N6O3S 414.1 
Fluoxetine; Methadone Lamivudine-monophosphate C8H12N3O6PS 309.0 
Fluoxetine; Methadone 
2,8-bis-Trifluoromethyl-4-quinoline 
carboxylic acid 
C12H5F6NO2 309.0 
3-oxobrimonidine C11H12BrN5O 309.0 
Hydroxylumiracoxib C15H13ClFNO3 309.1 
Glycodiazine C13H15N3O4S 309.1 
Ketotifen C19H19NOS 309.1 
Metixene C20H23NS 309.2 
Nadolol C17H27NO4 309.2 
Metipranolol C17H27NO4 309.2 
Diphenidol C21H27NO 309.2 
Dicyclomine C19H35NO2 309.3 
Flurazepam 
5'-Hydroxylornoxicam C13H10ClN3O5S2 387.0 
triazolopyridinone epoxide C19H22ClN5O2 387.1 
4'-hydroxytrazodone C19H22ClN5O2 387.1 
Terazosin C19H25N5O4 387.2 
Tamoxifen N-oxide C26H29NO2 387.2 
4-Hydroxytamoxifen C26H29NO2 387.2 
alpha-Hydroxytamoxifen C26H29NO2 387.2 
3-Hydroxytamoxifen (Droloxifene) C26H29NO2 387.2 
Gabapentin 
Metronidazole C6H9N3O3 171.1 
Rasagiline C12H13N 171.1 
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Molecular 
Weight 
Haloperidol 
Azidocillin C16H17N5O4S 375.1 
Tiagabine C20H25NO2S2 375.1 
Gatifloxacin C19H22FN3O4 375.2 
Benzylmorphine C24H25NO3 375.2 
Hydroxychloroquine 
Almotriptan C17H25N3O2S 335.2 
Naratriptan C17H25N3O2S 335.2 
Hydroxyzine 
Bromhexine C14H20Br2N2 374.0 
Etoricoxib 1'-N'-oxide C18H15ClN2O3S 374.0 
6-Hydroxymethyletoricoxib C18H15ClN2O3S 374.0 
N-Desmethylzopiclone C16H15ClN6O3 374.1 
omega-hydroxyfinasteride C22H34N2O3 374.3 
Ketamine 2-Amino-5-benzoylbenzimidazole C14H11N3O 237.1 
Labetalol 
7-hydroxyolanzapine C17H20N4OS 328.1 
2-hydroxymethylolanzapine C17H20N4OS 328.1 
Tiapride C15H24N2O4S 328.1 
Labetalol 
Methotrimeprazine C19H24N2OS 328.2 
7-hydroxygranisetron C18H24N4O2 328.2 
Stanozolol C21H32N2O 328.3 
Levetiracetam Propylthiouracil C7H10N2OS 170.1 
Lidocaine 
p-Chlorobenzene sulfonyl urea C7H7ClN2O3S 234.0 
4,4'-methanol-bisbenzonitrile C15H10N2O 234.1 
4'-hydroxymephenytoin C12H14N2O3 234.1 
S-4-Hydroxymephenytoin C12H14N2O3 234.1 
Epirizole C11H14N4O2 234.1 
Lorazepam Enoxacin C15H17FN4O3 320.1 
mCPP 
3,7-Dimethyluric acid C7H8N4O3 196.1 
1,9-Dimethyluric acid C7H8N4O3 196.1 
7,9-Dimethyluric acid C7H8N4O3 196.1 
1,3-Dimethyluric acid C7H8N4O3 196.1 
1,7-Dimethyluric acid C7H8N4O3 196.1 
MDA 
Hippuric acid C9H9NO3 179.1 
Acetylisoniazid C8H9N3O2 179.1 
Glucosamine C6H13NO5 179.1 
Mexiletine C11H17NO 179.1 
Methylephedrine C11H17NO 179.1 
Methoxyphenamine C11H17NO 179.1 
Rimantadine C12H21N 179.2 
Memantine C12H21N 179.2 
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Target Analyte Interference Compound Formula 
Molecular 
Weight 
MDMA 
3-Carbamoyl-2-
phenylpropionaldehyde 
C10H11NO3 193.1 
4-Anilino-4-oxobutanoic acid C10H11NO3 193.1 
4-Hydroxy-5-phenyltetrahydro-1,3-
oxazin-2-one 
C10H11NO3 193.1 
Meperidine 
Pethidine C15H21NO2 247.2 
desmethylprodine C15H21NO2 247.2 
Ketobemidone C15H21NO2 247.2 
Mephedrone 
Phenmetrazine C11H15NO 177.1 
Bethanidine C10H15N3 177.1 
N-Methylnicotinium C11H17N2 177.1 
Mescaline 
2,4-Dihydroxy-7-methoxy-2H-1,4-
benzoxazin-3(4H)-one 
C9H9NO5 211.0 
Milrinone; Milrinone Lactate C12H9N3O 211.1 
5-Hydroxylorcaserin C11H14ClNO 211.1 
1-Hydroxylorcaserin C11H14ClNO 211.1 
7-Hydroxylorcaserin C11H14ClNO 211.1 
4-(4-chlorophenyl)-4-
hydroxypiperidine 
C11H14ClNO 211.1 
Methyldopa C10H13NO4 211.1 
Mescaline 
3-O-Methyl-a-methyldopa C10H13NO4 211.1 
Zalcitabine C9H13N3O3 211.1 
Varenicline C13H13N3 211.1 
Pramipexole C10H17N3S 211.1 
Isoprenaline C11H17NO3 211.1 
Orciprenaline C11H17NO3 211.1 
Isoproterenol C11H17NO3 211.1 
Metaxalone 
N-Acetyl-D-glucosamine C8H15NO6 221.1 
N,N,O-Tridesmethyl-tramadol C13H19NO2 221.1 
Procarbazine C12H19N3O 221.2 
Tapentadol C14H23NO 221.2 
Methamphetamine 
NAPQI C8H7NO2 149.0 
Penicillamine C5H11NO2S 149.1 
L-Methionine C5H11NO2S 149.1 
Sevelamer C6H12ClNO 149.1 
Cathinone C9H11NO 149.1 
Phentermine C10H15N 149.1 
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Molecular 
Weight 
Methocarbamol 
Moxonidine C9H12ClN5O 241.1 
3'-Amino-3'-deoxythimidine C10H15N3O4 241.1 
Mefenamic acid C15H15NO2 241.1 
Tetrahydrobiopterin C9H15N5O3 241.1 
N,N-Didemethyl orphenadrine C16H19NO 241.1 
N-Desmethyldiphenhydramine C16H19NO 241.1 
Methylone 
triazolopropionic acid C9H9N3O3 207.1 
Isoniazid pyruvate C9H9N3O3 207.1 
Carbamazepine iminoquinone C14H9NO 207.1 
N-isopropylterephthalamic acid C11H13NO3 207.1 
4-(Methylnitrosamino)-1-(3-pyridyl)-
1-butanone
C10H13N3O2 207.1 
Ciclopirox C12H17NO2 207.1 
N-Desmethyl tapentadol C13H21NO 207.2 
Methylphenidate; 
Normeperidine 
Dopamine 3-O-sulfate C8H11NO5S 233.0 
Dopamine 4-sulfate C8H11NO5S 233.0 
Lomustine C9H16ClN3O2 233.1 
N,N-Didesmethyltramadol C15H23NO 233.2 
Metoprolol 
Sulfisoxazole C11H13N3O3S 267.1 
Sulfamoxole C11H13N3O3S 267.1 
Zidovudine C10H13N5O4 267.1 
Adenosine C10H13N5O4 267.1 
Vidarabine C10H13N5O4 267.1 
Metoprolol 
4-amino-MX C12H17N3O4 267.1 
Apomorphine C17H17NO2 267.1 
Voglibose C10H21NO7 267.1 
Mirtazapine; Nordoxepine Desacetyl-nitazoxanide C10H7N3O4S 265.0 
Mirtazapine; Nordoxepine 
Isoniazid alpha-ketoglutaric acid C11H11N3O5 265.1 
Albendazole C12H15N3O2S 265.1 
Streptozocin C8H15N3O7 265.1 
Thiamine C12H17N4OS 265.1 
E-10-Hydroxydesmethylnortriptyline C18H19NO 265.1 
Antazoline C17H19N3 265.2 
Oxprenolol C15H23NO3 265.2 
4-Hydroxy-alprenolol C15H23NO3 265.2 
Naproxen; TFMPP 
Diazoxide C8H7ClN2O2S 230.0 
Guanabenz C8H8Cl2N4 230.0 
Hydralazine pyruvate hydrazone C11H10N4O2 230.1 
cyclic Melatonin C13H14N2O2 230.1 
Ibudilast C14H18N2O 230.1 
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Target Analyte Interference Compound Formula 
Molecular 
Weight 
Norbuprenorphine 
Desacetylcefotaxime C14H15N5O6S2 413.0 
Dihydroetorphine C25H35NO4 413.3 
Norclozapine; Olanzapine 
Ethopropazine C19H24N2S 312.2 
Praziquantel C19H24N2O2 312.2 
Granisetron C18H24N4O 312.2 
Oseltamivir C16H28N2O4 312.2 
Nordiazepam; Doxylamine 
Sulfamethizole C9H10N4O2S2 270.0 
Leflunomide C12H9F3N2O2 270.1 
A771726 C12H9F3N2O2 270.1 
10,11-Dihydroxycarbamazepine C15H14N2O3 270.1 
Tolbutamide C12H18N2O3S 270.1 
Chloroprocaine C13H19ClN2O2 270.1 
N-Desmethylpromazine C16H18N2S 270.1 
Norfluoxetine 
Chlorothiazide C7H6ClN3O4S2 294.9 
Meclofenamic acid C14H11Cl2NO2 295.0 
Diclofenac C14H11Cl2NO2 295.0 
N4-Acetylsulfamethoxazole C12H13N3O4S 295.1 
Mebendazole C16H13N3O3 295.1 
Citalopram aldehyde C18H14FNO2 295.1 
Nor-ketotifen C18H17NOS 295.1 
Sumatriptan C14H21N3O2S 295.1 
(E)-2-hydroxydoxepin C19H21NO2 295.2 
Doxepin N-oxide C19H21NO2 295.2 
Norfluoxetine 
Tertatolol C16H25NO2S 295.2 
Esmolol C16H25NO4 295.2 
Norketamine 
Cerulenin C12H17NO3 223.1 
Neostigmine C12H19N2O2 223.1 
2,5-Dimethoxy-4-ethylamphetamine C13H21NO2 223.2 
Norpropoxyphene; Midazolam 
Amdinocillin C15H23N3O3S 325.1 
Ergonovine C19H23N3O2 325.2 
dinor-Levomethadyl acetate C21H27NO2 325.2 
Bisoprolol C18H31NO4 325.2 
Dapiprazole C19H27N5 325.2 
Tolterodine C22H31NO 325.2 
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Target Analyte Interference Compound Formula 
Molecular 
Weight 
Norsertraline 
Brimonidine C11H10BrN5 291.0 
Orciprenaline-3-O-sulfate C11H17NO6S 291.1 
Diethylthiambutene C16H21NS2 291.1 
Desethylchloroquine C16H22ClN3 291.2 
Cyclopentolate C17H25NO3 291.2 
Levobunolol C17H25NO3 291.2 
Terbinafine C21H25N 291.2 
Penbutolol C18H29NO2 291.2 
Nortramadol 
Alendronate C4H13NO7P2 249.0 
Norepinephrine sulfate C8H11NO6S 249.0 
Sulfapyridine C11H11N3O2S 249.1 
Epinastine C16H15N3 249.1 
Desmethylnortriptyline C18H19N 249.2 
Tenocyclidine C15H23NS 249.2 
Alprenolol C15H23NO2 249.2 
N,O-Didesmethylvenlafaxine C15H23NO2 249.2 
Norvenlafaxine; Nortrityline, 
Tramaol 
Amfecloral C11H12Cl3N 263.0 
Epinephrine sulfate C9H13NO6S 263.0 
Ticlopidine C14H14ClNS 263.1 
Gemcitabine C9H11F2N3O4 263.1 
Dimethylthiambutene C14H17NS2 263.1 
desethylzaleplon C15H13N5 263.1 
Protriptyline C19H21N 263.2 
demethylmaprotiline C19H21N 263.2 
2-Ethyl-5-methyl-3,3-diphenyl-1-
pyrroline 
C19H21N 263.2 
Protriptyline C19H21N 263.2 
Lisdexamfetamine C15H25N3O 263.2 
Oxymorphone Carboxybupranolol C14H20ClNO4 301.1 
Oxymorphone 
Noroxycodone C17H19NO4 301.1 
Dihydrocodeine C18H23NO3 301.2 
Dobutamine C18H23NO3 301.2 
Trihexyphenidyl C20H31NO 301.2 
Paroxetine 
Nitisinone C14H10F3NO5 329.1 
8-Hydroxyamoxapine C17H16ClN3O2 329.1 
Dopamine glucuronide C14H19NO8 329.1 
Cloperastine C20H24ClNO 329.2 
Trilostane C20H27NO3 329.2 
N-desethyloxybutynin C20H27NO3 329.2 
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Target Analyte Interference Compound Formula 
Molecular 
Weight 
PCP 
Cytarabine C9H13N3O5 243.1 
Agomelatine C15H17NO2 243.1 
Frovatriptan C14H17N3O 243.1 
Pregabalin Pargyline C11H13N 159.1 
Primidone; Meprobamate 
Mephenytoin C12H14N2O2 218.1 
N-Acetylserotonin C12H14N2O2 218.1 
N-despropyl ropinirole C13H18N2O 218.1 
Promethazine; Diazepam 
6-Thioinosinic acid C10H12N4O4S 284.1 
Mazindol C16H13ClN2O 284.1 
Phenytoin catechol C15H12N2O4 284.1 
arabinofuranosylguanine C10H14N5O5 284.1 
Etozoline C13H20N2O3S 284.1 
Articaine C13H20N2O3S 284.1 
Promazine C17H20N2S 284.1 
Tropicamide C17H20N2O2 284.2 
Propoxyphene; Papaverine; 
Topiramate 
Cefacetrile C13H13N3O6S 339.1 
Methylhydroxygliclazide C15H21N3O4S 339.1 
7-Hydroxygliclazide C15H21N3O4S 339.1 
Alogliptin C18H21N5O2 339.2 
Methylergonovine C20H25N3O2 339.2 
Methylergometrine C20H25N3O2 339.2 
noracymethadol C22H29NO2 339.2 
nor-Levomethadyl acetate C22H29NO2 339.2 
Disopyramide C21H29N3O 339.2 
Hexetidine C21H45N3 339.4 
Propranolol 
4-Bromo-2,5-
dimethoxyphenethylamine 
C10H14BrNO2 259.0 
Mizoribine C9H13N3O6 259.1 
Lenalidomide C13H13N3O3 259.1 
Clobenzorex C16H18ClN 259.1 
norzolmitripan C14H17N3O2 259.1 
Propranolol 
Ramelteon C16H21NO2 259.2 
Primaquine C15H21N3O 259.2 
Eperisone C17H25NO 259.2 
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Target Analyte Interference Compound Formula 
Molecular 
Weight 
Quetiapine 
clofarabind-5'-monophosphate C10H12ClFN5O6P 383.0 
Ceftizoxime C13H13N5O5S2 383.0 
Brinzolamide C12H21N3O5S3 383.1 
Felodipine C18H19Cl2NO4 383.1 
Pantoprazole C16H15F2N3O4S 383.1 
Meropenem C17H25N3O5S 383.2 
Prazosin C19H21N5O4 383.2 
Risperidone 
Butoconazole C19H17Cl3N2S 410.0 
Ceftibuten C15H14N4O6S2 410.0 
Sertraline; Zaleplon 
Fenoldopam C16H16ClNO3 305.1 
Entacapone C14H15N3O5 305.1 
Sildenafil Vandetanib C22H24BrFN4O2 474.1 
Trazodone 
Lornoxicam C13H10ClN3O4S2 371.0 
Carboplatin C6H12N2O4Pt 371.0 
Berberine chloride C20H18ClNO4 371.1 
Camazepam C19H18ClN3O3 371.1 
Isradipine C19H21N3O5 371.1 
Tamoxifen C26H29NO 371.2 
Triazolam 
5-Fluorouridine monophosphate C9H12FN2O9P 342.0 
Etizolam C17H15ClN4S 342.1 
Clozapine N-oxide C18H19ClN4O 342.1 
Trimipramine 
Estazolam C16H11ClN4 294.1 
Sulfacytine C12H14N4O3S 294.1 
Rosoxacin C17H14N2O3 294.1 
Aspartame C14H18N2O5 294.1 
Alosetron C17H18N4O 294.1 
Proparacaine C16H26N2O3 294.2 
Dimetacrine C20H26N2 294.2 
Verapamil 
Sitaxentan C18H15ClN2O6S2 454.0 
Cefazolin C14H14N8O4S3 454.0 
Methotrexate C20H22N8O5 454.2 
Ziprasidone 
Zileuton O-glucuronide C17H20N2O8S 412.1 
O-Deethylated candesartan C22H16N6O3 412.1 
Cinalukast C23H28N2O3S 412.2 
Trandolapril-d5 Diketopiperazine C24H32N2O4 412.2 
Zopiclone 
Sulfinpyrazone sulfide C23H20N2O2S 388.1 
Bepotastine C21H25ClN2O3 388.2 
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Target Analyte Interference Compound Formula 
Molecular 
Weight 
Zopiclone 
Cetirizine C21H25ClN2O3 388.2 
Bepotastine C21H25ClN2O3 388.2 
Nisoldipine C20H24N2O6 388.2 
Trimethobenzamide C21H28N2O5 388.2 
Ramiprilat C21H28N2O5 388.2 
10-monohydroxyoxcarbazepine
N-acetyl zonisamide C10H10N2O4S 254.0 
Acetaminophen cystein C11H14N2O3S 254.1 
2-Hydroxyfelbamate C11H14N2O5 254.1 
Dyphylline C10H14N4O4 254.1 
Nepafenac C15H14N2O2 254.1 
Thiamylal C12H18N2O2S 254.1 
Midodrine C12H18N2O4 254.1 
6-acetylmorphine
Diloxanide C14H11Cl2NO4 327.0 
Acetaminophen glucuronide C14H17NO8 327.1 
Desethylamodiaquine C18H18ClN3O 327.1 
Naloxone C19H21NO4 327.1 
Dimenoxadol C20H25NO3 327.2 
Butorphanol C21H29NO2 327.2 
Norelgestromin C21H29NO2 327.2 
Butorphanol C21H29NO2 327.2 
7-aminoclonazepam;
Hydromorphone, Morphine 
Cladribine C10H12ClN5O3 285.1 
Faropenem C12H15NO5S 285.1 
Letrozole C17H11N5 285.1 
Probenecid C13H19NO4S 285.1 
Isothipendyl C16H19N3S 285.1 
Norcodeine C17H19NO3 285.1 
Norhydrocodone C17H19NO3 285.1 
N-Monodesmethyl-rizatriptan C15H19N5O 285.2 
Mepyramine; Pyrilamine C17H23N3O 285.2 
7-aminoflunitrazepam
Risedronate C7H11NO7P2 283.0 
Oxtriphylline; Choline theophylline C12H21N5O3 283.2 
Cadralazine C12H21N5O3 283.2 
alpha-Hydroxymetoprolol C15H25NO4 283.2 
Levallorphan C19H25NO 283.2 
N-Dealkylated tolterodine C19H25NO 283.2 
9-hydroxyrisperidone
Iloperidone C24H27FN2O4 426.2 
Darifenacin C28H30N2O2 426.2 
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